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ABSTRACT 
    
 One of the hallmarks of an infection with pathogenic HIV-1 is the elevated level 
of immune activation that leads to rapid progression to AIDS. Surprisingly, nonhuman 
primates naturally infected with SIV do not exhibit an augmented activation phenotype 
nor severe immunodeficiency. One of the viral components implicated in determining the 
state of immune activation is the accessory protein Nef which has been demonstrated to 
affect T cell signaling pathways from within the intracellular compartment and for Nef 
from SIV, to downregulate TCR surface expression. Recently, Nef from HIV-1 and SIV 
have been demonstrated to bind the ζ chain of the TCR which functions as the primary 
signaling subunit of the receptor. However, the molecular details of the Nef-TCRζ 
interaction as well as the role of complex formation in modulation of immune activation 
remain largely unknown. 
 This thesis describes work directed at elucidating the biochemical and structural 
features of the Nef-TCRζ interaction and the functional consequences of complex 
formation relevant to T cell activation. Chapter I provides a brief introduction on 
HIV/SIV classification and pathogenesis with an emphasis on Nef and its pleiotropic 
function in T cells.  
 Chapter II describes the biochemical characterization of the interaction of the 
conserved core domain of Nef proteins from HIV-1, HIV-2 and SIV with the cytoplasmic 
domain of TCRζ. The core domains of HIV-2 ST and SIVmac239 are demonstrated to 
bind the cytoplasmic domain of TCRζ at two distinct regions and with different affinities. 
In contrast, the core domain of HIV-1 isolate ELI Nef only binds to one region and with 
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the weakest calculated affinity among the HIV-1, HIV-2 and SIV Nef proteins studied. In 
addition, both the N-terminal domain and the strong TCRζ-binding core domain of 
SIVmac239 Nef each are demonstrated to be necessary but not sufficient for 
downregulation of TCR surface expression. 
 Chapter III describes the crystallization and structure determination methods used 
to solve the crystal structures of the core domain of SIVmac239 Nef in complex with two 
overlapping TCRζ polypeptides. Crystals of Nef in complex with the longer TCRζDP1 
(L51-D93) polypeptide grew in a tetragonal space group but only diffracted to low 
resolution. In contrast, crystals of the Nefcore-TCRζA63-R80 complex grew in an 
orthorhombic space group and diffracted to high resolution but were nearly perfectly 
pseudo-merohedrally twinned thus complicating structure determination. Following 
identification of the twin law relating the twin domains, the structure of the Nefcore-
TCRζA63-R80 complex was determined using refinement procedures that accounted for 
crystal twinning to 2.05 Å. The structure of the Nefcore-TCRζDP1 complex was solved to 
3.7 Å from a single non-twinned crystal. The altered crystal packing induced by the 
shorter TCRζ A63-R80 polypeptide is postulated to have led to a reduction in crystal 
symmetry and increase in proneness to crystal twinning. 
Chapter IV provides a detailed analysis of the structure of the Nefcore-TCRζA63-R80 
complex and demonstrates its effect on modulation of Src family kinase activity. The 
TCRζ polypeptide adopts an alpha helical conformation and occupies a hydrophobic 
crevice on Nef not shared by any of Nef’s reported interaction partners. The interaction 
of Nefcore with TCRζ is mediated primarily by the burial of hydrophobic residues on 
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TCRζ (L75, L77) in a hydrophobic pocket on Nef and a salt bridge between a glutamic 
acid (E74) on TCRζ and a basic patch on Nef consisting of two conserved arginines 
(R105, R106). The TCRζ polypeptide additionally orders the N-terminus of Nefcore into a 
polyproline type II helix that has been described to bind the SH3 domain of Src family 
kinases. We demonstrate that in vitro phosphorylation of TCRζcyt by Fyn and Src is 
specifically augmented by HIV-1 and SIV Nefcore and suggest that Nef-TCRζ complex 
formation cooperatively enhances kinase activity. 
Chapter V contains overall conclusions, future directions and a model illustrating 
the proposed role of the Nef-TCRζ interaction in immune activation modulation. The 
Appendices contain sequences of the proteins, gene constructs and primers used in this 
work.
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CHAPTER I: Introduction 
 
 The causative agent of acquired immunodeficiency syndrome (AIDS) in humans 
was first identified in 1983 by two groups who named the retrovirus lymphadenopathy-
associated virus (LAV) (Barre-Sinoussi et al., 1983) and human T-cell leukemia virus III 
(HTLV-III) (Gallo et al., 1983). A simian virus that exhibited similar growth 
characteristics and antigenic properties to LAV and HTLV-III was described two years 
later in rhesus macaques (Daniel et al., 1985) and was aptly named simian T- cell 
leukemia virus III (STLV-III). The identification of an additional AIDS-associated 
retrovirus (ARV) prompted the classification of LAV, HTLV-III and ARV as human 
immunodeficiency viruses (Coffin et al., 1986), thus burgeoning an expansive research 
effort targeted at understanding the mechanism of HIV disease and developing anti-viral 
therapeutics and vaccines. STLV-III, later referred to as simian immunodeficiency virus 
(SIV), provided a unique opportunity to study HIV pathogenesis in an animal model 
[reviewed in (Desrosiers et al., 1989)]. 
 Despite significant advances in the investigation of HIV pathogenesis, the 
development of curative therapies and vaccines has remained elusive. This is in large part 
due to the immense sequence variability found among different clinical HIV isolates as 
well as a lack of detailed understanding of the numerous HIV-host interactions that 
contribute to disease progression. In addition, the viral components of HIV perform a 
multitude of functions that collectively determine the pathogenicity of the infecting virus. 
Therefore, detailed investigation of HIV-host interactions as well as the correlative 
analysis of viral function and disease outcome will need to be performed to further 
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advance our knowledge of HIV disease and to develop novel strategies of therapeutic 
intervention.  
 
 
I.A. Human immunodeficiency virus and simian immunodeficiency virus 
I.A.1. Classification 
 HIV and its orthologous simian SIV partner comprise the primate lentiviral group 
of viruses in the Retroviridae family. HIV is divided into two types, HIV-1 and HIV-2, 
based on differences in viral genome architecture and serological properties of infected 
individuals. HIV-1 is further divided into three groups: the “main” group M, the “outlier” 
group O and the extremely rare “non-M, non-O” group N. Over 90% of the sequenced 
HIV-1 isolates belong to M group and are classified into eleven subtypes or clades (A1, 
A2, B, C, D, F1, F2, G, H, J, K) based on their env and gag gene sequences. Each clade 
differs by over 20% and 15% in their env and gag sequences, respectively, and some 
clades are reclassified subtypes of precursor clades such as clades A1 and A2 from clade 
A. Hybrid HIV-1 viruses that develop during co-infection with HIV from different clades 
form a separate subtype designated as the circulating recombinant form (CRF). To date, 
43 CRF subtypes have been classified and are deposited in the HIV sequence 
compendium (HIV Sequence Compendium 2009). The less investigated HIV-2 viruses 
are organized into eight distinct sequence clusters and form groups A-H, with group A 
being the most prevalent HIV-2 group (>10%). 
According to the 2009 edition of the HIV Sequence Compendium, over 25 unique 
nonhuman primate lentiviruses have been classified. SIV classification is species-based 
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and categorizes genetically distinct viral isolates according to their infected hosts. For 
example, SIV isolates found in sooty mangabeys and chimpanzees are designated as 
SIVSMM and SIVCPZ viruses, respectively. Analysis of genomic architecture and sequence 
homology reveals that SIVCPZ is closely related to HIV-1 whereas SIVSMM is more 
closely linked to HIV-2 (Hahn et al., 2000). SIVMAC presents an interesting classification 
dilemma as the highly pathogenic virus found in macaques is highly homologous to 
SIVSMM and has been suggested to have been acquired during captivity from infected 
sooty mangabey monkeys (Desrosiers et al., 1989; Hirsch et al., 1989) . Therefore, 
SIVMAC may not be a naturally infecting virus but an experimental cross-species virus 
that is not native to its host species [reviewed in (Desrosiers, 1990)]. 
In total, 229,451 sequences of HIV-1, HIV-2 and SIV isolates have been 
deposited in the HIV sequence database and continuous re-evaluation of the classification 
methods is ongoing. Owing to the high sequence variability nature of primate 
lentiviruses, classification of the numerous viral isolates based on sequence homology is 
a difficult challenge that complicates HIV research, predictions of disease outcome as 
well as the development of subtype or clade-specific antiviral therapies or vaccines. 
 
I.A.2. Genome architecture 
 The HIV and SIV genomes are compact (~9.2-9.7kb) and exist either as single 
stranded RNA or double stranded DNA depending on their location (Muesing et al., 
1985). In mature viral particles, the viral genome exists as single stranded RNA and in 
the intracellular compartment it is found in proviral double-stranded DNA form. Two 
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similar but distinct genomic organizations are found among the primate lentiviruses for 
HIV-1 and HIV-2 with the heavily investigated SIVMAC strains corresponding to the 
HIV-2 genomic architecture (Figure I-1). The genome is flanked at both ends by a repeat 
sequence known as the long terminal repeat (LTR). Between the 5’ and 3’ LTRs are 
overlapping open reading frames that encode one enzymatic (Pol) and two structural 
(Gag, Env) precursor polypeptides as well several essential (Tat, Rev) and non-essential 
(Vpu, Vpr, Vpx, Vif, Nef) viral accessory proteins. HIV-1 differs from HIV-2/SIVMAC in 
its expression of the viral accessory protein Vpu which is substituted with Vpx in HIV-
2/SIVMAC. The open reading frame for the nef gene is also variable among the two viral 
types. In HIV-2/SIVMAC, the nef gene overlaps with the 3’ end of the env open reading 
frame where in HIV-1 it is distal to the env 3’ termination site. Consequently, the N-
terminus of the expressed Nef protein is highly variable among HIV-1 and HIV-
2/SIVMAC isolates. 
 
I.A.4. Viral pathogenesis and disease outcome 
Pathogenic HIV-1 infection results in the development of HIV disease that is 
characterized by profound viremia, chronic elevation in immune activation and depletion 
of CD4+ T cells. As the disease progresses, the infected individual develops acquired 
immunodeficiency syndrome (AIDS), resulting in increased susceptibility to 
opportunistic infection, neoplastic growth and fatal disease. Current Center for Disease 
Control guidelines consider CD4+ T lymphocyte counts below 200 cells/μl to be the 
diagnostic threshold for AIDS. In contrast, HIV-2 is far less aggressive and  
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Figure I-1. Lentiviral genome structure. The genome organization of HIV-1 and HIV-
2/SIVMAC proviral DNA is shown. The structural genes (gag, pol and env) are shaded in 
red. The essential regulatory genes (tat, rev) and non-essential accessory genes (vif, vpr, 
vpx, vpu, nef) are boxed. (Adapted from (Fields et al, ed)) 
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is out-replicated in the presence of HIV-1 (Koblavi-Deme et al., 2004; Sousa et al., 
2002). Although capable of progressing to AIDS, HIV-2 infection more closely 
resembles the features of a natural infection of nonhuman primates with simian 
immunodeficiency virus (SIV) which is largely non-pathogenic. With the exception of 
experimentally-inoculated macaques with SIVMAC strains, infected nonhuman primates 
predominately exhibit suppressive activation phenotypes despite high viremia throughout 
the course of infection without developing extensive symptoms of AIDS (Rey-Cuille et 
al., 1998; Silvestri et al., 2003). 
The majority of HIV-1 transmission occurs through the anorectal and vaginal 
mucosa where CCR5+CD4+ T lymphocytes prone to HIV infection reside in the lamina 
propria (Royce et al., 1997; Schacker et al., 1996). Transmission of HIV into the blood 
circulation (i.e. blood transfusion, sharing of contaminated needles, trauma during sexual 
intercourse) requires clearance to regional lymph nodes and the spleen for viral 
propagation; circulating T lymphocytes only comprise ~2-5% of the total T cell 
population. Dendritic cells, through their surface lectin DC-SIGN, have been suggested to 
serve as critical viral transporters by binding surface gp120 molecules on circulating HIV 
particles and delivering them to CD4+ T cells present in lymph nodes (Granelli-Piperno et 
al., 1999). Propagated virus then disseminates from the primary site of infection to other 
regions of the body, including the mucosa-associated lymphoid tissue (MALT) and gut-
associated lymphoid tissue (GALT), and develops into a persistent and chronic infection 
that can lead to the development of AIDS.  
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The MALT and GALT represent the largest pools of lymphocytes in the body 
(Guy-Grand and Vassalli, 1993) and have therefore been widely considered as major 
targets of HIV during infection (Brenchley et al., 2004; Veazey et al., 1998). Destruction 
of the mucosal immune system has been postulated extensively to result in the 
development of AIDS (Grossman et al., 2006; Haase, 2005; Picker and Watkins, 2005; 
Veazey and Lackner, 2005). However, depletion of the mucosal and intestinal 
CCR5+CD4+ T cell population is only a precursor in the development of AIDS and is not 
a valid predictor of pathogenicity. In HIV-1 infected individuals (Brenchley et al., 2004; 
Guadalupe et al., 2003; Mehandru et al., 2004) and SIV-infected macaques (Li et al., 
2005b; Mattapallil et al., 2005; Picker et al., 2004; Veazey et al., 2000a; Veazey et al., 
2000b), extensive depletion of the MALT and GALT-associated CD4+ T cells occurs 
within weeks of infection whereas progression to AIDS can take several years. Recent 
studies in rhesus macaques with pathogenic SIV strains demonstrated that infection of 
intestinal CD4+ T cells occurred within days of infection with > 60% of CD4+ T cells 
depleted by day 14 (Mattapallil et al., 2005). This was suggested to occur in part due to 
virus-triggered, Fas-Fas ligand–mediated apoptosis (Li et al., 2008) in addition to the 
host’s cytotoxic T lymphocyte (CTL) and natural killer (NK) cell response. In follow-up 
studies of nonhuman primates infected with pathogenic (SIVSMM in rhesus macaques), 
non-pathogenic (SIVAGM in African green monkeys) and controlled (SIVAGM infection in 
rhesus macaques) SIV, all of the infected hosts exhibited similar extensive and rapid 
GALT destruction and mucosal damage despite presenting with varying levels of disease, 
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suggesting that viral pathogenicity could not be forecast by the time course nor the extent 
of CD4+ T cell depletion (Pandrea et al., 2007) 
In both humans and rhesus macaques, pathogenic HIV and SIV-induced 
destruction of the mucosal architecture is followed by elevated chronic immune 
activation that continues to increase during progression to AIDS (Deeks et al., 2004; 
Giorgi et al., 1999; Grossman et al., 2006). The augmented immune activation profile 
includes several components of the immune system, including both the humoral and 
adaptive immune system where B cell, CD4+ T cell and CD8+ T cell proliferation is 
observed [reviewed in (Lawn et al., 2001)]. Prominent among HIV’s effects on immune 
activation is the augmentation of T cell activation that promotes active viral replication 
[reviewed in (Jerome, 2008)]. Additional features, including increased activation of TNF-
α signaling pathways and increased cytokine release also have been demonstrated to 
contribute to disease progression [reviewed in (Lawn et al., 2001; Matsuyama et al., 
1991)]. However, due to the generalized nature of the immune activation, detailed 
investigation of the mechanisms by which HIV modulated immune function has proven 
to be difficult [reviewed in (Douek et al., 2009)] and will require careful dissection of 
HIV-1 numerous effects on the immune system. 
 
I.B. Nef 
Expressed in abundance during the early stages of HIV/SIV replication, the viral 
accessory protein negative factor (Nef) has been demonstrated to enhance viral 
infectivity, downregulate surface receptor molecules and importantly, modulate immune 
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activation in infected CD4+ T cells. Nef has therefore been suggested to play a vital role 
in HIV pathogenesis and progression to AIDS (Kestler et al., 1991). In both rhesus 
monkeys (Kestler et al., 1991) and isolated human cases (Kirchhoff et al., 1995), nef-
deleted variants of SIV and HIV-1 respectively failed to exhibit disease progression and 
instead displayed low viral loads and stable CD4+ lymphocyte counts in the affected 
individual, similar to HIV-2 infected patients. Furthermore, nef-transgenic mice have 
been observed to display AIDS-like phenotypes (Hanna et al., 1998a; Hanna et al., 
1998b; Hanna et al., 2006), further highlighting the importance of Nef in determining 
viral pathogenicity. 
 
I.B.1 Structure 
Nef is the largest of the non-essential viral accessory proteins encoded by HIV-1 
(206 residues, ~27kDa) and HIV-2/SIV (250-263 residues, ~35kDa). The full length 
protein consists of a highly variable N-terminal anchor domain and a structured C-
terminal core domain that is well-conserved among HIV-1 and HIV-2/SIV strains (Figure 
I-2). In HIV-1 Nef, the N-terminal domain and core domain are separated by a cleavage 
sequence (ACAW ↓ LEAQ) that is sensitive to proteolysis by HIV-1 protease during viral 
assembly. As a result, the Nef protein present in the mature viral particle is comprised 
only of the core domain whereas the Nef protein that is found in the intracellular 
cytoplasmic space of the host cell exists in its full length form. HIV-2 and SIV Nef do not 
contain a cleavage sequence and are thus resistant to post-translation proteolysis by their 
respective proteases. 
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The N-terminal domain (HIV-1: M1-W57; SIV: M1-S95) contains a consensus 
myristylation sequence (MGxxxS/T) that results in the covalent linkage of a myristate to 
residue G2 by N-myristyl transferase (Resh, 1994; Resh, 1999). The myristyl 
modification directs Nef to the inner leaflet of the plasma membrane where it performs 
the majority of its functions [reviewed in (Kirchhoff et al., 2008)]. In the NMR solution 
structure (pdb code IQA4) of its unmyristylated form, the N-terminal domain of HIV-1 
clone 12 Nef (G2-W57) is largely disordered with the exception of a short alpha helix 
(A33-G41) near the C-terminus. In its myristylated form (pdb code 1QA5) (Figure I-2A), 
the N-terminal domain contains a well-defined second alpha helix (P14-R22) that is 
stabilized by the myristyl modification (Geyer et al., 1999). Overall, the N-terminal 
domain is largely flexible and devoid of compact globular structure allowing it to adopt 
multiple conformations (Barnham et al., 1997; Geyer et al., 1999). The N-terminal 
domain of HIV-2/SIV Nef is significantly longer in sequence and no structural 
information for that region has been reported. 
In contrast to the N-terminal domain, the core domain of Nef (Nefcore) represents 
the structured globular domain of the protein (Figure I-2B) that is responsible for the 
majority of its interactions with host proteins (reviewed in (Geyer et al., 2001). As 
observed in the crystal structure of HIV-1 isolate LAI Nefcore (pdb code 1AVV) (Arold et 
al., 1997) and the NMR solution structure of HIV-1 isolate BH10 Nefcore (pdb code 
2NEF) (Grzesiek et al., 1997), Nefcore contains two pairs of alpha helices (α1- α2, α3-
 α4) that flank a four stranded anti-parallel β-sheet. The longer alpha helices α1 and α2  
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Figure I-2. Nef structure. A. The NMR solution structure of the myristylated N-terminal 
domain (G2-W57) of HIV-1 clone 12 Nef (pdb code 1QA5) is shown in ribbon diagram. 
Secondary structure elements are labeled and the myristyl group is depicted in stick 
model. B. The crystal structure of the core domain (L58-C206) of HIV-1 isolate LAI Nef 
is shown in ribbon diagram with secondary structure elements labeled. 
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along with the α1-α2 connecting loop form a solvent-accessible crevice thought to 
potentially serve as a binding site for a binding partner (Lee et al., 1996), however none 
has been identified. The structure of the four stranded β-sheet is irregular due to the 
presence of conserved proline residues (P136, P147) that introduce kinks into the β-sheet 
structure. This results in the presence of two distinct pairs of anti-parallel β-strands that 
contain elements of the hydrophobic core of the protein. Between β-strands β3 and β4 is 
a long disordered loop (E159-E173) that is not visualized in the crystal structure of HIV-
1 Nefcore and had to be removed from the protein in order to determine the NMR solution 
structure. 
In the crystal structures of HIV-1 Nefcore in complex with the SH3 domain of 
wildtype Fyn (pdb code 1AVZ) (Arold et al., 1997) and mutant (F96I) Fyn (pdb code 
1EFN) (Lee et al., 1996), an N-terminal region of the Nef core domain (70-77) is ordered 
in a polyproline type II helix at the Nef-Fyn interface. The PxxP structural motif 
responsible for binding the SH3 domain is conserved among HIV-1, HIV-2 and SIV Nef 
variants and has been suggested to modulate activity of Src family kinases including Lck, 
Fyn and Hck in vitro (Arold et al., 1997; Lee et al., 1996) 
 
I.B.2. Function 
Although Nef’s influence on HIV/SIV pathogenesis is well-documented, the 
precise mechanisms by which Nef acts and more importantly, how they collectively 
affect disease progression are not well understood. Nef does not possess any enzymatic 
activity and therefore exerts its function through protein-protein interactions. Recent 
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studies have identified a series of host cellular binding partners including type I 
membrane proteins, cellular kinases involved in T-cell signaling pathways and members 
of the endocytotic machinery (reviewed in (Baur, 2004; Greenway et al., 1996; Piguet 
and Trono, 1999); summarized in Table I-1). The majority of the binding motifs and the 
structural features required for Nef function localize to the core domain (Figure I-2) that 
is well conserved among HIV-1, HIV-2 and SIV. Nef’s activities in the intracellular 
compartment can be reduced to two major activities that collectively enhance viral 
fitness: downregulation of surface receptors and modulation of T cell activation. 
 
I.B.2.a. Downregulation of surface receptors 
HIV-1 and SIV Nef downregulate a number of cell surface receptors that 
participate in the immunological synapse, including MHC Class I molecules (Collins et 
al., 1998; Le Gall et al., 1997; Schindler et al., 2006; Schwartz et al., 1996), CD4 (Aiken 
et al., 1994; Anderson et al., 1993; Benson et al., 1993; Garcia and Miller, 1991; Mariani 
and Skowronski, 1993; Schindler et al., 2006) and CD28 (Bell et al., 2001; Schindler et 
al., 2006; Swigut et al., 2001). Nef also downregulates surface TCR expression but only 
in the context of HIV-2 and SIV and not HIV-1 (Schindler et al., 2006). 
 Downregulation of MHC Class I molecules by Nef is a conserved function among 
HIV-1 and SIV strains (DeGottardi et al., 2008; Specht et al., 2008). Interestingly, Nef-
mediated MHC downregulation is restricted to HLA-A and -B alleles and is not observed 
for HLA-C and -E. The selective allelic downregulation results in the clever protection of 
the infected cell from lysis by cytotoxic T lymphocytes (CTL) and killing by surveilling  
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Table I-1. Interaction of Nef with cellular proteins 
 
Region on Nef important for 
binding and/or function1 Interaction partner 
Region on partner 
important for binding 
and/or function 
Requirement for 
pathogenicity2 
Protein modification    
 MGxxS1 N-myristoyl transferase n.d.3 + 
 CAW↓LEA55 HIV-1 protease n.d. -4 
 
    
Cell surface receptors    
 MGxxS1, WL57,L110, 
FPD121, D/ExxLL160, 
EE154, DD174 
CD4 407-418 + 
 MGxxS1 CD28 cytoplasmic tail + 
 MGxxS1, M20, EEEE62, 
PxxPxR72, FPD121, EE154 
MHC class I cytoplasmic tail + (EEE62) 
 MGxxS1, D/ExxLL160, 
EEEE62, PxxPxR72 
MHC class II cytoplasmic tail + (EEE62) 
 
    
Signalling    
 PxxPxR72 Fyn 
Hck 
Lck 
Lyn 
MAPK 
Src 
Vav 
TCRζ5 
SH3 domain 
SH3 domain 
SH3 domain 
SH3 domain 
SH3 domain 
SH3 domain 
SH3 domain 
n.d. 
+/- 
 n.d.6 TCRζ7 YENLNL(x), 
YSEIMGRR(x) 
n.d. 
 MGxxS1, PxxPxR72, RR105 PAK1/2 (NAK) n.d. + 
 DDPxxE174 c-Raf1 kinase n.d. n.d. 
 N-, C-terminus PI-3 kinase p85 subunit n.d. 
 n.d. Ask1 n.d. n.d. 
 M1-W57 p53 n.d. + 
 
    
Trafficking    
 EEEE62 PACS-1 n.d. + 
 FPD121 Human thioesterase (p35) n.d. n.d. 
 EE154 β-COP n.d. n.d. 
 D/ExxLL160 Adaptor proteins AP-1/2/3 
β1 of AP-1 
μ subunit of AP-1/2/3 
β1 of AP-1 
n.d. 
 DD174 V1H n.d. + 
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1 Residue numbering is shown for HIV-1 laboratory strain NL4-3 Nef 
2 Requirement of the binding motif on Nef for pathogenicity 
3 Intact full length protein is required for pathogenicity 
4 n.d., not determined 
5 As described for HIV-1 Nef (Fackler et al., 2001; Xu et al., 1999) 
6 To be described in this thesis 
7 As described for HIV-2 and SIVmac239 Nef (Schaefer et al., 2000) 
 
Modified from (Das and Jameel, 2005; Geyer et al., 2001; Kirchhoff et al., 2008) 
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Figure I-3. Structural motifs on Nef important for binding and function. The NMR 
solution structure of HIV-1 isolate BRU Nef  (H40-A206, Δ159-173, C206A; pdb code 
2NEF) is shown in ribbon diagram The residues involved in the interaction of Nef with 
its host cellular partners or are important for functional activity are depicted in stick 
models. 
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natural killer (NK) cells (Collins et al., 1998; Specht et al., 2008). Nef mediates the 
downregulation of surface MHC expression through two unique sorting pathways. The 
first reported mechanism described Nef linking phosphofurin acidic cluster sorting 
protein-1 (PACS-1) with the short MHC cytoplasmic tail and directing the complex to the 
trans-Golgi network (TGN) (Crump et al., 2001; Piguet et al., 2000; Wan et al., 1998). 
Although the binding site on Nef specific for MHC is unknown, a highly acidic cluster of 
residues near the N-terminus of Nef (E62, E63, E64, E65) was found to be crucial in 
binding PACS-1 (Crump et al., 2001; Piguet et al., 2000). Subsequent studies 
demonstrated that Nef is also capable of downregulating surface MHC HLA-A2 
expression in a PACS-1-independent manner that instead uses AP-1 and clathrin to direct 
MHC molecules to endosomes and lysosomes (Lubben et al., 2007). 
 The interaction of Nef with CD4 and its subsequent downregulation are among 
the most heavily investigated functions of Nef. Nef reduces surface expression of CD4 by 
directly coupling the cytoplasmic tail of CD4 to components of the endocytotic 
machinery, including clathrin, dynamin and the clathrin adaptor proteins AP-1 and AP-2; 
complex formation results in the direction of CD4 to the lysosomal compartment for 
eventual degredation. The interaction of HIV-1 Nef with CD4 is determined by the 
presence of an alpha helix in the cytoplasmic tail of CD4 (403-433) that allows for high 
affinity binding (KD = 0.5 – 1.4 μM) of Nef (Grzesiek et al., 1996b; Preusser et al., 
2002). In addition, the specificity of Nef with the clathrin adaptor protein AP-2 is 
conferred by a dileucine motif that has been demonstrated to be unique to CD4 
downregulation and essential for proper sorting of the receptor  (Aiken et al., 1994; 
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Bresnahan et al., 1998; Chaudhuri et al., 2007; Lindwasser et al., 2008; Mangasarian et 
al., 1997). Downregulation of CD4 has been postulated to serve a role in immune evasion 
by disrupting the antigen presenting cell-T cell interface and allowing for the infected T 
cell to circulate and engage in viral spread. In addition, because CD4 serves as the 
receptor for Env, CD4 downregulation may help to enhance release of HIV progreny 
during viral budding (reviewed in (Li et al., 2005a)). 
 In contrast to the downregulation of CD4 and MHC class I proteins, 
downregulation of surface TCR expression is only observed for HIV-2 and SIV Nef and 
represents one of the few functions of Nef that is lentiviral type-dependent. The inability 
of HIV-1 Nef to downregulate TCR expression has been suggested to be a consequence 
of cross-species evolution resulting in the loss of T cell activation suppression activity 
(Schindler et al., 2006). SIV Nef binds the ζ chain of the TCR at two unique sites (Howe 
et al., 1998; Schaefer et al., 2000) and mediates TCR downregulation binding of the 
clathrin-associated protein AP-2 through a unique cooperative mechanism (Swigut et al., 
2003). Interestingly, HIV-1 Nef has also been demonstrated to interact with TCRζ in 
vitro (Fackler et al., 2001; Xu et al., 1999) suggesting that TCR-binding and TCR 
downregulation are separable functions and differentially conserved among HIV-1, HIV-
2 and SIV Nef. 
 
I.B.2.b. Modulation of T cell activation 
As shown in Table I-1, Nef has been reported to bind multiple proteins involved 
in T cell signaling, including the Src family of protein tyrosine kinases (i.e. Fyn, Lck, 
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Src), PI-3 kinase and the signaling ζ chain of the T cell receptor. However, the functional 
consequences of those interactions are poorly understood. Furthermore, the reported 
effects of HIV-1 Nef on T cell activation has been inconsistent with some reports 
suggesting that Nef plays a positive enhancing role where other reports argue that Nef 
suppresses T cell activation in the presence of external stimuli (summarized in Table I-2). 
HIV-1 Nef has also been reported to induce a T-cell transcriptional program that closely 
resembles activation by anti-CD3 stimulation (Simmons et al., 2001). The discrepancy in 
the observed immunomodulatory effects suggests that Nef plays a significant role in 
modulating T cell signaling pathways but that its effect is pleiotropic. Each experimental 
condition may therefore highlight certain features of Nef’s overall effect on T cell 
activation and result in aberrant functional outcomes.  
Despite the controversy in Nef’s immunomodulatory effect, one structural feature 
on Nef has consistently been demonstrated to be crucial for Nef’s function in T cells: 
myristylation of the N-terminus. The myristylation modification directs Nef to the plasma 
membrane where it participates in the downregulation of surface molecules but 
additionally affects T cell signaling mechanisms, including the formation of the 
immunological synapse (IS) (Fenard et al., 2005; Thoulouze et al., 2006). Nef’s 
recruitment to the IS has been demonstrated to potentiate TCR-mediated signaling events 
and reduce the stimulus threshold required for NFAT and NFkB (Fenard et al., 2005). 
Other studies have suggested that Nef associates with lipid rafts and primes the T cell for 
activation by increasing the local concentration of TCR molecules (Djordjevic et al., 
2004; Wang et al., 2000). Disruption of the myristylation sequence results in drastic 
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abrogation of Nef’s function at the IS (Fenard et al., 2005) and has also been described to 
result in inhibitition of TCR-mediated T cell signaling (Baur et al., 1994). Collectively, 
these data suggest that Nef imparts its immunomodulatory function primarily at the inner 
leaflet of the plasma membrane where it gains access to molecules that participate in the 
early events of T cell activation, namely the TCR and Src family kinases. Surprisingly, a 
highly pathogenic strain of SIV, SIVpbj14, is able to replicate by causing activation of 
resting peripheral blood mononuclear cells (PBMCs) (Fultz, 1991) and has been 
associated with an ITAM-like sequence present in Nef (Du et al., 1995). Reconstitution 
of the of ITAM YxxL motif (17RQ ? 17YE) found in SIVpbj14 in SIVmac239 Nef 
resulted in increased tyrosine phosphorylation of SIVmac239 (17YE) Nef in addition to 
augmented T cell activation and acute disease, suggesting an extensive role of Nef in 
signal transduction and cellular activation (Du et al., 1995). Detailed investigation of 
Nef’s interaction with different components of the T cell signaling machinery may 
therefore provide insight into the mechanisms of Nef-mediated immune modulation as 
well as provide a new perspective into the differential immune activation profiles 
observed during natural HIV-1 and SIV infection. 
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Table I-2. Modulation of T cell activation by Nef 
 
Nef isolate Cells Mitogen Activation Measurement Reference 
Suppression of T cell activity 
HIV-1 NL4-3 Jurkat PMA + PHA, PMA + 
ionomycin 
IL-2 mRNA (Luria et al., 1991) 
HIV-1 NL4-3 Jurkat PHA + PMA NFκB (Niederman et al., 1992) 
HIV-1 NL4-3 Jurkat PHA + PMA AP-11 (Niederman et al., 1993) 
HIV-1 NL4-3 Jurkat anti-CD3 NFκB, AP-1 (Bandres and Ratner, 1994) 
HIV-1 SF22 Jurkat anti-TCRβ, PMA phosphorylation, 
Ca2+ flux, NFκB 
(Baur et al., 1994) 
HIV-1 NL4-3 Jurkat PMA + PHA, PMA + 
ionomycin, PMA + 
CD3  
IL-2, IFN (Greenway et al., 1996) 
HIV-1 BRU Jurkat PMA + ionomycin IL-2 transcription (Collette et al., 1996) 
HIV-1 NA7 Jurkat anti-CD3 CD69 (Iafrate et al., 1997) 
     
No effect on T cell activity 
HIV-1 LAI T cell clones, 
Jurkat 
PMA, PHA + PMA, 
anti-CD3 + PMA,      
anti-CD3 + CD28 
IL-2, TNF, cell 
proliferation 
(Schwartz et al., 1992) 
HIV-1 HxB3 T lymphocytes 
(transgenic) 
CD3 + PMA cell proliferation (Skowronski et al., 1993) 
HIV-1 Jurkat PMA, PMA + PHA, 
TNF, anti-CD3 
IL-2, TNF, IL-2R, 
NFκB, AP-1 
(Carreer et al., 1994) 
HIV-1 LAI T cell clones antigen-presenting cell TNF, CSF, IFN,  
IL-6 
(Page et al., 1997) 
HIV-1 NL4-3 Jurkat PMA, PHA NFκB, AP-1 (Yoon and Kim, 1999) 
     
Enhancement of T cell activity 
HIV-1 NL4-3 T lymphocytes 
(transgenic) 
anti-CD3 + PMA cell proliferation (Skowronski et al., 1993) 
HIV-1SF2 T cell hybridoma anti-CD3 IL-2 (Rhee and Marsh, 1994) 
HIV-1 SF2 Jurkat anti-TCRβ, PMA phosphorylation, 
Ca2+ flux, NFκB 
(Baur et al., 1994) 
SIVpbj143 Jurkat - - - NFAT (Luo and Peterlin, 1997) 
HIV-1 NL4-3 T lymphocytes 
(transgenic) 
anti-CD3 phosphorylation 
(LAT, MAPK) 
(Hanna et al., 1998b) 
HIV-1 SF23 Jurkat - - - FasL (Xu et al., 1999) 
HIV-1 NL4-3 Jurkat anti-CD3, anti-CD3 + 
anti-CD28 
IL-2 secretion (Schrager and Marsh, 1999) 
HIV-1 Jurkat anti-CD3 + anti-CD28, 
PMA 
IL-2, PI3K activity (Djordjevic et al., 2004) 
HIV-1 R7 Jurkat anti-CD3 + anti-CD28 IL-2 secretion,    
IL-2 transcription, 
NFAT, NFκB 
(Wang et al., 2000) 
HIV-1   NFkB NFAT (Fenard et al., 2005) 
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1 recruitment of AP-1 DNA-binding activity 
2 intracellular, not membrane-targeted Nef 
3 CD8-Nef fusion results in Nef-Nef dimer 
 
Modifed from (Marsh, 1999) 
 
 
.  
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CHAPTER II: Interaction of the HIV-1, HIV-2 and SIV Nef core domain 
with the T cell receptor zeta subunit 
 
Abstract 
Nef from HIV and SIV share a number of functions including downregulation of 
surface receptor molecules, modulation of T cell signaling pathways and enhancement of 
virion infectivity. However, recent studies have suggested that HIV-1 and SIV Nef are 
not interchangeable with respect to their ability to interact with the signaling ζ chain of 
the T cell receptor (TCRζ) or their ability to downmodulate TCR surface expression. 
Here we report that Nef from SIVmac239, HIV-2 ST and two isolates of HIV-1 (NL4-3, 
ELI) bind the cytoplasmic domain of TCRζ in vitro and that the conserved core domain 
of Nef mediates the interaction. The core domain of SIVmac239 Nef bound TCRζ with 
the highest affinity, followed by HIV-2 ST and HIV-1 ELI Nef. In addition, the Nef core 
domain from SIVmac239 and HIV-2 ST interacted with two distinct regions on 
TCRζ whereas the core domain of HIV-1 ELI Nef shared only the N-terminal binding 
site. However, the high affinity TCRζ-binding properties of the core domain of 
SIVmac239 Nef were found to be necessary but not sufficient to reduce TCR surface 
expression. An intact Nef protein, containing both the SIV N-terminal domain and the 
high affinity core domain was required for TCR downregulation. Collectively, these data 
suggest that the TCRζ-binding and downregulatory properties of Nef changed during the 
cross-species evolution of SIV to HIV-1 and may be responsible for the differential TCR-
mediated activation profiles seen in naturally infected HIV-1 and SIV hosts. 
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II.A. Introduction 
Human immunodeficiency virus 1 (HIV-1) infection and progression to acquired 
immunodeficiency syndrome (AIDS) is characterized by elevated immune activation, 
CD4+ lymphocyte depletion and high viral load. One of the critical determinants 
mediating HIV-1 pathogenesis is Nef, a myristoylated 27-35 kDa viral accessory protein 
unique to HIV and SIV that is expressed in abundance early in the viral life cycle. In 
studies where rhesus macaques were experimentally inoculated with SIV (Kestler et al., 
1991), nef-deleted strains of SIVmac239 failed to promote accelerated disease and 
instead resulted in markedly low viremia and reduced pathogenicity. In humans, several 
patients infected with nef-defective HIV-1 exhibited a long-term nonprogressor 
phenotype with delayed disease progression (Kirchhoff et al., 1995; Salvi et al., 1998). 
HIV-1 Nef itself is capable of inducing virulent behavior: HIV-1 nef-transgenic mice 
present with severe AIDS-like phenotypes (Hanna et al., 2009; Lindemann et al., 1994; 
Simard et al., 2002; Skowronski et al., 1993) and HIV-1 nef-transfected T-cells display 
enhanced sensitivity to external stimuli (Baur et al., 1994; Schrager and Marsh, 1999) and 
a transcriptional state nearly identical to that of T cells stimulated by mitogenic anti-CD3 
antibodies (Simmons et al., 2001). In contrast, natural infection of humans with HIV-2 or 
nonhuman primates with the orthologous simian immunodeficiency virus (SIV) is largely 
nonpathogenic and does not exhibit the augmented T cell activation profile nor 
progression to severe immunodeficiency observed with HIV-1 (Munch et al., 2005; 
Villinger et al., 1996). Understanding the differential effect of HIV-1 and HIV-2/SIV 
infection on T cell activation requires the elucidation and characterization of their 
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molecular targets. In this study, we investigate the interaction of HIV-1, HIV-2 and SIV 
Nef with the ζ chain of the T cell receptor (TCR), the primary signaling molecule in the 
TCR complex. 
Nef’s role in HIV-1 virulence is multifaceted but can be described as a 
combination of three distinct mechanisms that collectively determine the course of viral 
pathogenesis (reviewed in (Kirchhoff et al., 2008): (1) modulation of cell-surface 
expression of membrane proteins, (2) modulation of signal transduction pathways, and 
(3) enhancement of viral infectivity. Generally conserved among the HIV-1, HIV-2 and 
SIV Nef variants is the ability to downregulate surface expression of several type I 
membrane proteins including CD4 (Aiken et al., 1994; Anderson et al., 1993; Benson et 
al., 1993; Garcia and Miller, 1991; Mariani and Skowronski, 1993; Schindler et al., 
2006), major histocompatability complex (MHC) class I molecules (Collins et al., 1998; 
Le Gall et al., 1997; Schindler et al., 2006; Schwartz et al., 1996) and CD28 (Bell et al., 
2001; Schindler et al., 2006; Swigut et al., 2001). In contrast, downregulation of the TCR 
complex is not conserved among the different Nef variants; HIV-2/SIV Nef reduces TCR 
surface expression with high efficiency whereas HIV-1 Nef does not (Bell et al., 1998; 
Schindler et al., 2006). This disparity has been postulated recently (Schindler et al., 2006) 
to be the result of lentiviral evolution where the protective ability of SIV Nef to 
downregulate TCR expression and to suppress T-cell activation in its natural primate host 
was lost during zoonotic transfer to humans and development of virulent HIV-1. 
Modulation of TCR surface expression by HIV-2/SIV Nef is mediated by 
interaction with the cytoplasmic domain of the ζ signaling subunit of the T cell receptor 
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(TCRζ) (Bell et al., 1998; Howe et al., 1998; Schaefer et al., 2000) and cooperative 
recruitment of the endocytotic machinery protein AP-2 (Swigut et al., 2003). Although it 
has been demonstrated that HIV-1 Nef does not downregulate TCR surface expression 
(Schindler et al., 2006), its ability to bind TCRζ and to subsequently alter downstream 
signaling consequences is unclear. Initial yeast two-hybrid and GST-pulldown binding 
studies (Bell et al., 1998; Howe et al., 1998) suggested that HIV-2 and SIV Nef but not 
HIV-1 Nef could bind to the cytoplasmic domain of TCRζ and that the core domain 
(residues 98-235) of SIV Nef was responsible for the interaction. Further studies 
demonstrated that SIV Nef bound TCRζ at two distinct sites, coined SIV Nef interaction 
domains (SNIDs) (Schaefer et al., 2000). However, subsequent co-immunoprecipitation 
studies have shown that HIV-1 Nef also specifically binds TCRζ (Fackler et al., 2001; Xu 
et al., 1999) and that the interaction is responsible for mediating HIV-induced TCR-
dependent FasL expression (Xu et al., 1999). Confocal imaging studies have shown that 
HIV-1 Nef is recruited to the immunological synapse during engagement of the TCR and 
potentiates T-cell signaling (Fenard et al., 2005), a function largely attributed to HIV-1 
Nef acting directly on TCRζ (Fackler et al., 2001; Sigalov et al., 2008). Studies involving 
HIV-1 Nef are complicated by the use of different HIV-1 Nef isolates where some reports 
investigate several strains from a number of viral clades (Howe et al., 1998; Schindler et 
al., 2006) and others focus on individual HIV-1 isolates such as SF2 (Simmons et al., 
2001) or the laboratory strain NL4-3 (Fackler et al., 2001). Taken all together, it remains 
unclear whether or not the ability to bind TCRζ is a conserved function shared by Nef 
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proteins from a range of HIV and SIV isolates and if so, whether that interaction plays a 
role in both TCR downregulation and modulation of TCR-mediated T cell activation. 
Here we demonstrate that Nef proteins from representative strains of HIV-1, HIV-
2, and SIV all specifically bind the cytoplasmic domain of TCRζ in vitro and that the 
conserved core domain of Nef is responsible for mediating the interaction. SIVmac239 
Nef and the homologous HIV-2 ST Nef variant bind to the same two regions on TCRζ 
whereas HIV-1 ELI Nef only interacts with the N-terminal binding region. In addition, 
SIVmac239 Nef binds to both binding regions with relatively similar affinities whereas a 
more discrete difference in affinity is seen for HIV-2 ST Nef. In contrast, HIV-1 ELI Nef 
binds to only one region on TCRζ and with the lowest affinity, suggesting that the ability 
of Nef to bind TCRζ was attenuated during evolution and in the species crossover from 
SIV to HIV-1. Therefore, the affinity of Nef for TCRζ may be one of the primary factors 
that determines whether Nef has a nonpathogenic or pathogenic role in modulation of T-
cell signaling in SIV or HIV-1 infection, respectively. 
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II.B. Materials and Methods 
II.B.1. Nef and TCRζ expression plasmids.  
Prokaryotic nef expression plasmids were created by cloning the HIV-1 (ELI, NL4-3), 
HIV-2 ST and SIVmac239 genes into pET32a(+) (Novagen). Open reading frames of 
full-length HIV-1 isolate ELI (K4-N206), HIV-1 laboratory strain NL4-3 (K4-C206), 
HIV-2 ST (S4-S255) and SIVmac239 (A4-R263) nef and core domain HIV-1 ELI (A56-
N206), HIV-1 NL4-3 (A56-C206), HIV-2 ST (D94-S234) and SIVmac239 (D95-S235) 
nef were amplified by PCR from HIV-1 (ELI, NL4-3) provirus (kindly provided by M. 
Stevenson) and HIV-2 ST and SIVmac239 Nef cloning vectors (NIH AIDS Reagent 
Repository). The nef amplification products included 5’ KpnI and 3’ HindIII restriction 
digestion sites and an engineered thrombin cleavage site immediately upstream of the nef 
coding region. The nef full-length and core domain amplification products were digested 
with KpnI and HindIII and ligated into the pET32a(+). Prior to ligation, pET32a(+) was 
mutated to remove the thrombin cleavage site included in the original parent vector by 
site directed mutagenesis. The final Nef-encoding gene product included an N-terminal 
thioredoxin (Thx) tag, 6xHis affinity tag, S-tag, single thrombin cleavage site and nef 
gene. 
Eukaryotic nef expression plasmids encoding wildtype or mutant Nef-GFP fusion 
proteins were generated by cloning the HIV-1 ELI (M1-N206) and SIVmac239 (M1-
S263) genes into pEGFP-N1 (Clontech). Open reading frames of full-length HIV-1 ELI 
and SIVmac239 were amplified by PCR from their respective pET32a-nef expression 
plasmids with 5’ EcoRI-containing and 3’ BamHI-containing primers. The nef 
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amplification products were digested with EcoRI and BamHI and ligated into pEGFP-N1 
in frame with the downstream GFP sequence to allow for Nef-GFP fusion protein 
expression. In order to generate the mutant nef chimera expression plasmids, the BamHI 
restriction site downstream of the nef gene was removed by site directed mutagenesis, 
keeping the GFP gene still in frame with the nef gene. A BamHI restriction site was 
inserted by site-directed mutagenesis at the junction of the N-terminal domain and the 
core domain in HIV-1 ELI (W57) and SIVmac239 (D89). The N-terminal domains of 
HIV-1 ELI (M1-W57) and SIVmac239 (M1-D89) were amplified by PCR from their 
respective pEGFP-nef expression plasmids with 5’ EcoRI-containing and 3’ BamHI-
containing primers and ligated into their partner plasmid to generate the HIV/SIV (M1-
W57/V90-S263) and SIV/HIV (M1-D89/L58-N206) chimeric nef expression plasmids. 
In order to keep the N-terminal domain and C-terminal domain regions in frame, the 
internal BamHI restriction site was removed by site-directed mutagenesis. All of the 
primers used in the cloning and mutagenesis procedures are listed in Appendix A.1. 
Construction of plasmids expressing the cytoplasmic domain (K54-R163) of 
TCRζ (pET32a-TCRζcyt) and an N-terminal cysteine-containing (cys-L51-R163) 
construct (pET32a-cys-TCRζcyt) has been described previously (Aivazian and Stern, 
2000). 
 
II.B.2.Recombinant protein expression, purification and modification.  
Nef was expressed as a thioredoxin fusion protein in E. coli strain BL21 (DE3). 
Following induction at 37oC with 0.75 mM isopropyl-β-D-thiogalactopyranoside (IPTG), 
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cell cultures were harvested by centrifugation at 5,000xg. The cell pellets were re-
suspended in lysis buffer (100 mM NaH2PO4, 8M Urea, pH 8.0) and lysed at 4oC by 
stirring. After clearance of the cell lysate by centrifugation at 10,000xg, the soluble 
fraction was loaded onto a Ni-NTA agarose (Qiagen) column and the target fusion 
protein was eluted by a pH gradient (pH 8.0-pH 4.5) under denaturing conditions (8 M 
urea). Elution fractions containing the thioredoxin-Nef fusion protein were identified by 
12% SDS-PAGE and dialyzed against dialysis buffer (20 mM TRIS, 150 mM NaCl, 0.1 
mM DTT, pH 8.0) at 4oC. The dialysis products were then filtered through a 0.22 μm 
filter and total protein concentration was quantified by Bradford assay (Bio-Rad). 
Thrombin (MP Biomedicals) was added to each dialysis sample at a concentration of 5U 
thrombin/mg total protein and incubated at room temperature for 1 - 3 hrs. The digestion 
reactions were then quenched by addition of PMSF, diluted 4-fold with dilution buffer 
(20 mM Tris, pH 8.0) and loaded on a POROS 20 HQ (Applied Biosystems) anion 
exchange column. Cleaved Nef proteins were eluted with a salt gradient (0 - 600 mM 
NaCl) and fractions containing Nef were identified by 12% SDS-PAGE. Nef-containing 
fractions were pooled, concentrated and run over a Superdex 200 (Pharmacia) size 
exclusion chromatography column in PBS after which peak fractions were pooled and 
concentrated. Purification of TCRζcyt was performed as described (Sigalov et al., 2004). 
Purified cys-TCRζcyt was modified with an N-terminal biotin affinity tag by conjugating 
the free cysteine with maleimide-PEO2-biotin (Pierce) as directed by the manufactuer’s 
instructions. The TCRζ polypeptides DP1 (L51-D93) and DP2 (P94-R164) were purified 
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following trifluoroacetic acid (TFA)-mediated hydrolysis of the purified TCRζcyt protein 
by size exclusion chromatography. 
 
II.B.3. Surface plasmon resonance (SPR) analysis.  
SPR spectroscopy experiments were performed at 25oC on a Biacore 3000 system (GE 
Healthcare). 5000-8000 resonance units (RU) of neutravidin were coupled to a CM5 
sensor chip (GE Healthcare) in 10mM acetate buffer (pH 5.0) using standard amine 
coupling protocols; residual areas of activated surface were blocked with ethanolamine. 
For all binding experiments, 10-20 RU of each overlapping biotin-LC-TCRζ peptide 
(Anaspec) or 250 RU of biotin-cys-TCRζcyt were captured in different neutravidin-
coupled experimental flow cells leaving one flow cell unmodified as a control surface. 
Each immobilized TCRζ peptide or polypeptide was directed uniformly in an N-terminal 
to C-terminal orientation away from the neutravidin-CM5 surface due to placement of the 
biotin tag at the N-terminus. Binding of each Nef analyte was monitored after 
equilibrating the instrument at 25oC in PBS (150mM NaCl + 0.005% surfactant P20, pH 
7.4) under reducing (5mM DTT) and non-reducing conditions and achieving a stable 
immobilized surface with no baseline drift. In the initial screening experiments, purified 
samples of full-length and core domain Nef proteins from HIV-1 (ELI, NL4-3), HIV-2 
ST and SIVmac239 were injected at a flow rate of 30μl/min over each experimental flow 
cell for and the control flow cell, generating SPR sensorgrams. The sensorgram from the 
control neutravidin-only flow cell was subtracted from the experimental neutravidin-bio-
TCRζ peptide flow cell sensorgram (reference subtraction), generating a resultant Nef 
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binding sensorgram that described the specific binding of Nef for the captured TCRζ 
peptide and removed any nonspecific interaction with the CM5 or neutravidin surface. 
All Nef proteins were allowed to bind until reaching binding equilibrium and then 
exchanged with PBS. In the kinetic and equilibrium interaction analyses, Nef was 
injected in a 2-fold concentration series ranging from 0 - 50 μM (SIV mac239, HIV-2 
ST) or 0 - 200 μM (HIV-1 ELI). Each experiment was run in triplicate with each 
concentration injected at random. No regeneration step was required. 
In order to determine the affinity of each Nef-TCRζ fragment interaction, 
equilibrium and kinetic analyses was performed when appropriate. In the equilibrium 
binding analysis, the RU binding levels at equilibrium were extrapolated from each 
sensorgram in the concentration series. The RU levels from each triplicate Nef 
concentration injection were averaged and plotted against concentration to derive a 
binding curve. Scatchard analysis and appropriate affinity rate constants were determined 
in Prism 4.0 (Graphpad). Kinetic analysis was also performed where the binding 
sensorgrams had measurable association and disassociation rates that could be calculated 
by global fitting. Evaluation of different kinetic binding models and determination of the 
appropriate kinetic affinity measurements were performed using BIAevaluation 4.1 (GE 
Healthcare). The quality of the kinetic fit for each binding model was assessed by 
inspecting the statistical χ2 value and the residuals (observed - calculated) in order to 
determine the most accurate mode of interaction. The following binding models were 
used to describe the Nef-TCRζ interaction: 
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1. Simple model: single analyte-ligand interaction that corresponds to the 1:1 bimolecular 
Langmuir Equation. 
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where the affinity rate constant KD is the ratio of the dissociation rate koff and association 
rate kon. 
 
2. Heterogenous ligand model: heterogeneity in the ligand results in two unique 
interaction sites, each of which binds the same analyte with different association and 
diassociation rates. 
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where the ligands B1 and B2 refer to two unique ligand subset populations and AB1 and 
AB2 represent the resulting complexes when the homogenous analyte A binds each ligand 
binding site. Rate constants KD1 and KD2 represent the affinity of each ligand population 
for the  single analyte. 
 
II.B.4. Size exclusion chromatography. 
Analytical size exclusion chromatography was performed at room temperature using a 
BioSep-SEC-S2000 column (Phenomenex) on a BioCad Sprint Perfusion 
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Chromatography System. Samples containing SIV mac239 Nefcore, TCRζcyt, TCRζcyt  
DP1, TCRζcyt  DP2 and Nef in the presence of each TCRζcyt sample were flowed at 0.5 
ml/min in PBS and elution was monitored by recording of the absorbance at 280 nm. 
Peak fractions for each experimental sample were collected for analysis by 12% SDS-
PAGE. For calibration of the BioSep-SEC-S2000 column, the following molecular mass 
markers (Bio-Rad Laboratories, Hercules, CA) were used: bovine thyroglobulin (670 
kDa), bovine γ-globulin (158 kDa), chicken ovalbumin (44 kDa), horse myoglobulin (17 
kDa), and vitamin B12 (1.35 kDa). A calibration curve correlating retention time and 
molecular weight was generated and used to translate the peak retention time for each 
experimental sample to a calculated molecular weight. The stoichiometries of the 
different Nef-TCRζ peptide interactions were determined by comparing the different 
calculated molecular weights for each experimental sample. 
 
II.B.5. Cell culture and DNA transfections. 
CH7C17 Jurkat T cells (Hewitt et al., 1992) were cultured in RPMI 1640 medium 
supplemented with 2mM glutamine and 10% fetal bovine serum (FBS) and passaged 1:5 
every 3-4 days. Cells were transfected by electroporation at 262V, 1500uFd, 725ohms 
with 10ug of DNA on a BTX ECM 830 (Harvard Apparatus) electroporation generator. 
Following transfection, the cells cultured for 42-48h prior to flow cytometric analysis of 
Nef-GFP and surface CD3 expression. 
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II.B.6. Flow cytometry analysis.  
Transfected CH7C17 Jurkat T cells were stained for surface CD3 expression. 
Aliquots of 1x106 cells were incubated with saturating amounts of phycoerythrin (PE)-
conjugated anti-CD3ε monoclonal antibody (Sigma) at 4oC, washed with staining buffer 
(1xPBS, 0.5% BSA, 0.02% NaN3) and analyzed on a FACSCalibur flow cytometer (BD 
Biosciences). The effect of wildtype and mutant Nef expression on surface CD3 
expression was determined by correlating GFP and PE fluorescence. Flow cytometric 
plots were generated and analyzed in FlowJo (Treestar). 
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II.C. Results 
II.C.1 Full length and core domains of HIV-1 ELI, HIV-1 NL4-3, HIV-2 ST and 
SIVmac239 Nef bind the cytoplasmic domain of TCRζ in vitro. 
Previous studies have been contradictory with regard to the ability of Nef from 
HIV-1 strains to interact with TCRζ in comparison to the better characterized binding 
activity of HIV-2 and SIV Nef (Bell et al., 1998; Fackler et al., 2001; Howe et al., 1998; 
Schaefer et al., 2000; Xu et al., 1999). To directly address the discrepancy regarding the 
ability of Nef to specifically interact with TCRζ, surface plasmon resonance (SPR) 
binding studies were performed with representative strain variants of HIV-1, HIV-2 and 
SIV Nef (Figure II-1A)  and the cytoplasmic domain of human TCRζ (Figure II-1B), 
expressed and purified as recombinant proteins. HIV-1 Nef variants from the HIV-1 
laboratory strain NL4-3 (clade B) and HIV-1 isolate ELI (clade D) were selected as 
representative HIV-1 strains based on an arginine/threonine polymorphism at residue 71 
(Figure II-1A) that has been suggested to be a determining factor in the specificity of 
HIV-1 Nef for TCRζ (Fackler et al., 2001). An arginine present at residue 71, found in 
HIV-1 ELI Nef, has been reported to confer specificity for TCRζ whereas a threonine, 
present in HIV-1 NL4-3 Nef, does not. The cytoplasmic domain of TCRζ (L51-R164), 
modified with an N-terminal biotin affinity tag, was immobilized on a neutravidin-
coupled CM5 sensor chip to mimic the native orientation of TCRζ on the inner leaflet of 
the cell membrane. Full-length Nef proteins (50μM) were flowed over the sensor chips 
under reducing conditions to prevent adventitious disulfide-mediated dimerization 
observed for HIV-1, HIV-2 and SIV Nef. All four Nef variants from HIV-1, HIV-2 and  
  
37
 
Figure II-1. Primary sequence analysis of Nef and TCRζ. (A) Sequence homology of 
Nef from representative HIV-1, HIV-2, SIV and consensus sequences. The conserved 
core domain shared by all isolates shown is denoted by the solid line. Similar and 
identical residues are denoted by colons (:) and asterisks (*), respectively. (B) The 
primary sequence of the cytoplasmic domain of TCRζ (TCRζcyt) is shown with 
immunoreceptor tyrosine activation motifs (ITAMS) denoted by black ovals. The 
previously reported SIV Nef interaction domains (SNIDs) (Schaefer et al., 2000) are 
denoted by black lines. Overlapping 14-21 amino acid peptides spanning the length of 
TCRζcyt are illustrated by bars with their respective residue position labels. 
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SIV were observed to bind to immobilized TCRζ with resonance signals 10-200 RU 
above the neutravidin control surface (Figure II-2A, top panel). Since Nef from ELI and 
NL4-3 strains of HIV-1 are able to bind TCRζ, neither the R/T polymorphism at residue 
71 in HIV-1 Nef nor the HIV-1/HIV-2 subtype variation are crucial factors in the 
interaction of Nef with TCRζ. 
A previous study reported that the core domain (residues 98-235) of SIVmac239 
Nef is the primary region responsible for binding TCRζ (Howe et al., 1998). Alignment 
of the primary sequences from various HIV-1, HIV-2 and SIV Nef variants (Figure II-
1A) reveals that the core domain is highly conserved. In addition, the core domain spans 
the structurally ordered region of the HIV-1 protein as observed by crystallography 
(Arold et al., 1997; Lee et al., 1996) and NMR (Grzesiek et al., 1996a). Therefore, we 
investigated the possibility that TCRζ specificity was conferred by the conserved core 
domain present in all HIV-1, HIV-2 and SIV Nefs. We expressed and purified the Nef 
core domain (Nefcore) from HIV-1, HIV-2, and SIV strains described above, and analyzed 
their binding to immobilized TCRζ as was done with their respective full-length forms. 
Each Nef core domain bound to TCRζ with SPR signals of 25-160 RU, similar to that 
observed for the full-length proteins (Figure II-2A). Therefore, not only does Nef from 
HIV-1 ELI, HIV-2 ST and SIVmac239 show the ability to bind TCRζ, but the structured 
core domain that is conserved among the different subtypes seems to be sufficient for 
binding. 
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Figure II-2. HIV-1, HIV-2 and SIV Nef bind TCRζcyt. A. Full-length and core domain 
Nef proteins from HIV-1 ELI, HIV-1 NL4-3, HIV-2 ST and SIVmac239 were flowed at a 
concentration of 50μM over TCRζcyt immobilized on a CM5 bionsensor chip. Binding 
was recorded by changes in the SPR resonance unit (RU) signal. B. Core domain Nef 
(Nefcore) proteins from HIV-1 ELI, HIV-2 ST and SIVmac239 were injected at various 
concentrations (0-200μM for HIV-1 ELI Nefcore and 0-50μM for HIV-2 ST and 
SIVmac239 Nefcore were flowed over immobilized TCRζcyt. Binding models for simple 
1:1 Langmuir binding and heterogenous parallel reaction binding were fit to HIV-1 ELI 
Nefcore and HIV-2 ST/SIVmac239 Nefcore, respectively. Residuals of model fit are shown 
below the binding curves. The RU values measured at binding equilibrium (250-300s) 
were used to generate the binding plots (lower panel) and for Scatchard analysis (inset). 
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II.C.2. The conserved core domain of HIV-1 ELI, HIV-2 ST and SIV mac239 Nef bind 
TCRζ with different binding region specificities and affinities. 
In order to further characterize the Nef-TCRζ interaction and investigate any 
strain-dependent differences in binding, detailed SPR studies were performed with the  
Nefcore proteins. Two-fold dilution series of HIV-1 ELI (0-200μM), HIV-2 ST (0-50 μM) 
and SIVmac239 (0-50 μM) Nef core domains were flowed over immobilized TCRζ and 
changes in resonance signal were recorded. As illustrated in the binding sensorgrams 
(Figure II-2B), the core domains from all three Nef variants bound TCRζ with 
measurable association (kon) and dissociation (koff) phases, reaching apparent binding 
equilibrium during the experiment. To characterize the binding kinetics, we considered a 
number of different binding models for each Nefcore domain, as described below. 
In a previous study, SIVmac239 Nef was demonstrated to bind TCRζ at two 
unique regions (Schaefer et al., 2000), indicated as SNID-1 and SNID-2 in Figure II-1B. 
Therefore, we evaluated a heterogenous ligand binding model (A + B1 = AB1; A + B2 = 
AB2) that would account for the two binding regions. As shown in Figure II-2B, the 
SIVmac239 Nefcore-TCRζ binding sensorgrams fit well to the heterogenous ligand 
binding model with random and compact residuals. Other binding models, including 
bivalent analyte (A + B ↔ AB; AB + B ↔ AB2), conformational change (A + B ↔ AB; 
AB ↔ AB*), hetereogenous analyte (A1 + B ↔ A1B; A2 + B ↔ A2B) and simple 
langmuir bimolecular (A + B ↔ AB) models, did not fit the data as well; the respective 
modeled curves deviated significantly from the binding data and exhibited higher χ2 
values. Using the kinetic association and dissociation parameters, the equilibrium 
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dissociation constants of the binding of SIVmac239 Nefcore to TCRζ were calculated to 
be 0.3μM + 0.1 (KD1) and 3.9μM + 0.4 (KD2) (Table 1). We also estimated the 
equilibrium dissociation constants from the binding plot and accompanying scatchard 
analysis (Figure II-2) of the equilibrium binding values measured at 250-300s of each 
experiment. As observed from the kinetic analysis, the equilibrium binding curve of the 
SIVmac239 Nefcore-TCRζ interaction fit best to a two site binding model with the 
calculated affinity constants KD1 = 1.3μM + 0.6 and KD2 = 11.8μM + 6.6, closely 
matching the values from the kinetic analysis (Table 1). 
 Previous work has suggested that HIV-2 Nef might also bind to two regions on 
TCRζ (Schaefer et al., 2002). In our studies, the SPR sensorgrams of HIV-2 ST Nefcore 
binding TCRζ also fit best to a heterogenous ligand binding model in both the kinetic and 
equilibrium analyses. Consistent with the pronounced curvilinear fit of the scatchard plot, 
TCRζ has one high affinity binding site (K D1 = 0.2- 4.7μM) and one markedly weaker 
one (K D2 = 24.3 - 37.2μM). The presence of a strong and weak binding site on TCRζ 
correlates well with previous GST pull-down experiments that demonstrated that HIV-2 
ST Nef only weakly interacted with SNID-1 and exhibited more prominent binding to 
SNID-2 (Schaefer et al., 2002). In contrast, HIV-1 ELI Nefcore exhibited completely 
different TCRζ-binding behavior. Following evaluation of the different binding models 
with the binding sensorgrams, a simple langmuir bimolecular model (A + B ↔ AB) fit 
the best, suggesting that the hetereogeneity in the ligand population seen in the presence 
of SIVmac239 and HIV-2 ST Nef is absent and only a homogenous ligand surface exists. 
The linear regression curve observed on the scatchard plot of the equilibrium binding 
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data verified the simple bimolecular model and resulted in a calculated affinity 
measurement (KD = 47.8μM + 3.5) that corresponded with the observed kinetically-
derived affinity constant KD = 20.2μM + 5. (Figure II-2B).This suggests that TCRζ either 
1) has one weak affinity binding site specific for HIV-1 ELI Nefcore with any second site 
either absent or having affinity too weak to detect in our assays or 2) that the weak and 
strong binding sites on TCRζ seen with HIV-2 ST and SIVmac239 Nefcore have an 
identical affinity for HIV-1 ELI Nef and are thus indistinguishable. Collectively, these 
data demonstrate that TCRζ-binding is a conserved function among the core domains of 
HIV-1 ELI, HIV-2 ST and SIVmac239 Nef, and that each Nef variant binds TCRζ in a 
slightly different manner where the affinity of the interaction decreases from SIV ~ HIV-
2 > HIV-1.  
 
II.C.3. HIV-2 ST and SIV mac239 Nefcore bind to two regions on TCRζcyt whereas HIV-1 
ELI Nefcore binds to only one.  
Due to its structural intrinsic disorder in solution (Sigalov et al., 2004), the 
recombinant TCRζ proteins used in the SPR spectroscopy experiments are highly 
unlikely to contain conformational epitopes that participate in binding Nef. Alternatively, 
it is more likely that TCRζcyt interacts with Nef through linear epitopes that can be 
characterized through straightforward regional mapping studies. Therefore, in order to 
further investigate the nature of the two site and single site binding models describing 
HIV-2 ST/SIVmac239 and HIV-1 ELI Nefcore binding of TCRζ cyt, respectively, the 
regions on TCRζ responsible for binding each Nef variant were identified. Overlapping, 
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N-terminally biotinylated 14-21-mer peptides spanning the length of TCRζcyt (Figure I-
1B) were immobilized on neutravidin-coupled CM5 chips. Each TCRζ peptide was then 
screened for positive Nef-binding by flowing over HIV-1 ELI, HIV-2 ST and 
SIVmac239 Nefcore proteins and observing changes in the SPR signal. As shown in 
Figure II-3A, HIV-2 ST and SIVmac239 Nefcore both bind to one peptide near the N-
terminus (A61-R80) and two peptides located closer to the C-terminus (L110-G130, 
E121-G140), consistent with previous reports characterizing SNID-1 and SNID-2 
(Schaefer et al., 2000). In contrast, HIV-1 ELI Nefcore showed exclusive binding (RU = 
125) to only one (A61-R80) of the three TCRζ peptides that bound HIV-2 ST and 
SIVmac239 Nefcore. 
To determine the affinity of each Nefcore variant for their respective TCRζ-binding 
preptide partners, a 2-fold concentration series of each Nefcore protein were flowed over 
each peptide and allowed to reach equilibrium. Due to the association and disassociation 
rates being too rapid to fit to kinetic models (Figure II-3A), equilibrium analysis was 
performed on the binding data by plotting the measured equilibrium RU binding levels 
against the concentration of the injected Nefcore sample. Binding model curves were 
applied and assessed for best fit by evaluating the correlation coefficient R2 for each 
model. For all of the Nefcore-TCRζ peptide binding plots, the binding data fit best to a 
simple langmuir bimolecular binding curve (Figure II-3B) with R2 values ranging from 
0.974 to 0.992. SIVmac239 Nefcore displayed the highest affinity for each of the two 
TCRζ binding regions with KD affinity measurements of 5.9μM (+ 0.2) for the SNID-2-
containing region and 8.5μM (+ 0.5) for the SNID-1-containing region. In contrast, HIV-
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2 Nefcore displayed markedly reduced affinity for both TCRζ regions in comparison to 
SIVmac239 but more importantly revealed an approximate five-fold increase in affinity 
for the C-terminal SNID-2-containing region (KD = 21.9μM vs. 94.9μM) as compared to 
the N-terminal SNID-1-containing region. This preference for the C-terminal binding 
region is unique to HIV-2 as it was not observed for SIVmac239 nor HIV-1 ELI Nefcore 
which only showed specificity for the N-terminal SNID-1-containing domain. 
Interestingly, while HIV-1 ELI Nefcore displayed the weakest affinity for TCRζ among 
the Nef variants, it also bound to the weaker of the two interaction sites observed for 
HIV-2 ST Nefcore with even weaker affinity (KD > 100μM). These measurements support 
the experiments performed on the full TCRζcyt proteins where two site binding was 
observed for SIVmac239 and HIV-2 ST Nef and one site binding was observed for HIV-
1 ELI Nefcore. Taken together, these data suggest that the number of binding sites on 
TCRζ that Nefcore recognizes and the affinities associated with them are lentiviral subtype 
dependent where SIVmac239 Nefcore is the most specific and HIV-1 ELI Nefcore is the 
least. 
 To further confirm the presence of two distinct binding regions on TCRζ specific 
for SIVmac239 Nefcore and to further characterize the stoichiometry of the interaction, 
size exclusion chromatography experiments were performed. Two fragments of the 
cytoplasmic domain of TCRζ, TCRζDP1 (L51-D93) and TCRζDP2 (P94-R164), were 
generated by self cleavage under acidic conditions with each containing one of the two 
SIVmac239 Nefcore-binding regions. During size exclusion chromatography, TCRζDP1 
(20μM) and TCRζDP2 (20μM) eluted as 9.9 kDa and 15.6kDa species, respectively,  
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Figure II-3. SIVmac239 and HIV-2 Nefcore bind to two regions on TCRζ where HIV-
1 ELI binds to only one. A. HIV-1 ELI, HIV-2 ST and SIVmac239 Nefcore (50μM) were 
flowed over a series of overlapping 14-21 amino acid peptides spanning the length of 
TCRζcyt, each immobilized separately. Binding was detected by changes in the SPR 
signal (RU). B. Equilibrium affinity analysis. Bound (RU) levels of Nef core domain 
proteins from HIV-1 ELI, HIV-2 ST and SIVmac239 Nef were recorded for each peptide 
and plotted against Nef concentration. Affinity measurement (KD) was calculated by 
fitting a simple 1:1 langmuir binding model. Standard deviation is shown in parenthesis. 
C. SIVmac239 Nefcore (20μM) and the TCRζcyt polypeptides DP1 and DP2 (20μM) were 
injected alone and in combination over a BioSep-SEC-S2000 column. 
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consistent the calculated molecular weights of TCRζDP1 and TCRζDP2 homodimers 
(Figure II-3C). This was similar to the dimerization behavior described for the full 
cytoplasmic domain of TCRζ (Sigalov et al., 2004). In the presence of equimolar 
SIVmac239 Nefcore, both Nef + TCRζDP1 and Nef + TCRζDP2 samples eluted as a 
heterodimeric species with simple 1:1 stoichiometry, validating the SPR finding that 
SIVmac239 Nefcore was specific for an N-terminal and C-terminal binding site on 
TCRζcyt. The formation of a simple heterodimeric Nef- TCRζDP1 and Nef- TCRζDP2 
species supports our previous finding that SIVmac239 Nefcore disrupts the TCRζ 
homodimer during the formation of the heterodimeric Nef-TCRζ complex (Sigalov et al., 
2008). 
 
II.C.4. SIV Nef-mediated TCR downregulation is dependent on both the high affinity core 
domain and the N-terminal domain.  
A previous study suggested that HIV-1 and SIV Nef differ in their ability to 
modulate TCR surface expression where the majority of SIV isolates of Nef robustly 
downregulates TCR from the cell surface and HIV-1 Nef has no effect (Schindler et al., 
2006). Having demonstrated that the conserved core domains of HIV-1 ELI and 
SIVmac239 Nef share TCRζ-binding activity, we investigated the role of the non-
conserved N-terminal domain in TCR downregulation by generating HIV-1/SIV and 
SIV/HIV-1 Nef chimeras and measuring their effect on TCR surface expression. As 
shown in Figure II-4, SIVmac239 Nef-GFP reduces surface TCR levels whereas HIV-1 
ELI Nef-GFP and GFP alone do not. Surprisingly, both the HIV-1/SIV Nef-GFP  
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Figure II-4. TCR downregulation by wildtype and chimeric Nef. A. Schematic 
representation of wildtype and chimeric Nef transfection constructs. Full-length Nef from 
HIV-1 ELI and SIVmac239 are depicted in grey and black, respectively, with terminal 
residue positions labeled. SIV/HIV-1 and HIV-1/SIV Nef chimeric constructs, containing 
the HIV-1 or SIV unconserved N-terminal domain or conserved C-terminal domain, are 
illustrated with the corresponding residue positions. B. The N-terminal domain and C-
terminal domain of SIVmac239 Nef is necessary for downregulation of TCR. Flow 
cytometry analysis of CD3ε surface expression in JJK Jurkat T cells transiently 
expressing wildtype or chimeric Nef-GFP fusion proteins is shown. 
 
  
48
chimera, containing the N-terminal domain of HIV-1 ELI Nef (M1-W57) fused to the 
high affinity TCRζ-binding C-terminal domain of SIVmac239 Nef (V90-S263), and the 
SIV/HIV-1 Nef-GFP chimera, containing the N-terminal domain of SIVmac239 Nef 
(M1-D89) fused to the low affinity TCRζ-binding C-terminal domain of HIV-1 ELI Nef 
(L58-N206), failed to downregulate TCR. It has been suggested that SIV Nef may bind  
endocytotic factors, namely clathrin associated protein AP-2, through a cooperative 
binding mechanism with TCRζ exclusive from the classical AP-2 interaction domains 
(CAIDs) found in the SIV Nef N-terminal domain (Swigut et al., 2003). Our studies 
suggest that the SIVmac239 N-terminal domain is in fact necessary for SIV Nef’s ability 
to downregulate the TCR. However, because the SIV/HIV-1 Nef chimera was unable to 
reduce surface TCR expression, the N-terminal domain of SIVmac239 Nef is not 
sufficient for TCR downregulation. Therefore, TCR-downregulatory function and TCRζ-
binding activity are distinct functional properties but mutually dependent: Nef-mediated 
TCR downregulation not only requires the high affinity binding property of the core 
domain of SIVmac239 Nef but also the non-conserved N-terminal domain from 
SIVmac239 Nef. 
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Table II-1. Affinity measurements of the HIV-1, HIV-2 and SIV Nefcore-TCRζcyt 
interaction. 
 
  Kinetic Analysis  Equilibrium Analysis 
Nefcore  ka, 1/Ms kd, 1/s KD, μM  KD, μM 
HIV-1 ELI  6.74x102 (+ 25.1) 1.36x10-2 (+ 0.002) 20.2 (+ 5.1) 
 
 
47.8 (+ 3.5) 
[100%] 
HIV-2 ST  
6.0x102 (+ 8.3) 
4.05x104 (+ 40.5) 
2.81x10-3 (+ 0.02) 
1.51x10-2 (+ 0.001) 
4.7 (+ 0.7) 
37.2 (+ 5.4) 
 
0.2 (+ 0.2) [10%] 
24.3 (+ 4.1) [90%] 
SIVmac239  
2.26x104 (+ 18.2) 
1.71x104 (+ 16.7) 
8.72x10-2 (+ 0.01) 
5.51x10-3 (+ 0.003) 
0.3 (+ 0.1) 
3.9 (+ 0.4) 
 
1.3 (+ 0.6) [43%] 
11.8 (+ 6.6) [57%] 
 
Association (ka), dissociation rates (kd) and affinity constants (KD) calculated from 
kinetic analysis, on left, as well as affinity constants (KD) derived from equilibrium 
analysis, on right, are indicated for each Nefcore protein. Standard deviation is indicated in 
parentheses, (), and percentage of total binding is indicated in brackets, [].  
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II.D. Discussion 
In this study we demonstrate that the core domains of Nef from HIV-1 ELI, HIV-
2 ST and SIVmac239 collectively bind the cytoplasmic domain of TCRζ but with 
different affinities and site specificities. The core domain of HIV-1 ELI Nef bound TCRζ 
with the lowest affinity (KD = 20.2 - 47.8μM) and at only one region containing elements 
of ITAM 1. In contrast, the core domains of HIV-2 ST and SIVmac239 Nef bound TCRζ 
at two distinct regions containing elements of ITAM 1 (shared with HIV-1 ELI Nef) and 
ITAM 2, consistent with previous findings (Schaefer et al., 2000). Analysis of the SPR 
sensorgrams suggests that the core domains of HIV-2 ST and SIVmac239 Nef binds to 
each region with different affinity: one strong binding site (SIVmac239 Nef, KD = 0.3 - 
1.3μM; HIV-2 ST Nef, KD = 0.2 – 4.7μM) and one weaker binding site (SIVmac239 Nef, 
KD = 3.9 – 11.8μM; HIV-2 ST Nef, KD = 24.3 - 37.2μM) that corresponds closely with 
HIV-1 ELI Nef’s affinity for the full cytoplasmic domain of TCRζ.  
Previous studies based on yeast two-hybrid and GST-pulldown experiments 
suggested that the interaction of Nef with TCRζ was limited to SIV and HIV-2 (Bell et 
al., 1998; Howe et al., 1998). Co-immunoprecipitation experiments from Nef-transfected 
Jurkat T cells later refuted those findings and demonstrated that HIV-1 Nef was capable 
of binding TCRζ (Fackler et al., 2001; Xu et al., 1999) and that the R/T polymorphism at 
residue 71 on Nef determined its specificity (Fackler et al., 2001). Our results confirm the 
co-immunoprecipitation results but additionally demonstrate that the amino acid 
occupying residue 71 is not a primary determinant of the binding reaction between Nef 
and TCRζ as both the laboratory strain NL4-3 (T71) and the ELI isolate (R71) of Nef 
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bound TCRζ. Curiously, contradictory experimental findings were also observed for 
HIV-1 Nef regarding its ability to bind the SH3 domain of Src family protein tyrosine 
kinases. In SPR experiments, HIV-1 NL4-3 Nef was demonstrated to bind the SH3 
domain of Hck with high affinity (KD = 0.25μM) but only weakly to the SH3 domain of 
wildtype Fyn (KD > 20μM) (Lee et al., 1995). However, GST-pulldown experiments 
performed in parallel resulted in co-precipitation of only the SH3 domain of Hck and not 
Fyn in the presence of Nef, refuting their SPR binding results. Co-precipitation of the Fyn 
SH3 domain with Nef was later observed but only after the introduction of a point 
mutation in Fyn (F96I) that increased its affinity for Nef by over 50-fold (KD = 0.38μM). 
Therefore, co-precipitation studies may not be a reliable assay to measure the weaker 
interactions of Nef with its cellular partners that instead require more sensitive methods. 
HIV-1 Nef may also bind TCRζ through a cooperative mechanism that involves 
other binding partners. In co-immunoprecipitaton experiments, the interaction of HIV-1 
Nef with TCRζ was abrogated following mutation of the PxxP sequence found near the 
N-terminus of the core domain (Xu et al., 1999). Although the PxxP motif has been 
demonstrated to interact with the SH3 domains of Src family kinases (Arold et al., 1997; 
Lee et al., 1996), it is not expected to interact with TCRζ in the same manner. Therefore, 
HIV-1 Nef may bind TCRζ cooperatively with a Src family kinase to form a stable 
heterotrimeric complex that is within the detection range of co-precipitation binding 
studies. This would explain the discrepancy in the co-precipitation studies since TCRζ 
should only co-immunoprecipitate with HIV-1 Nef from Nef-transfected T cells that 
contain Src family kinases and not with Nef alone as was performed in the yeast-two 
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hybrid and GST-pulldown studies. A similar cooperative binding mechanism has been 
proposed for SIVmac239 Nef, TCRζ and the clathrin-associated adaptor protein AP-2 
(Swigut et al., 2003) based on the observation that Nef co-precipitated increased amounts 
of TCRζ and AP-2 when all three components were present as compared to TCRζ and 
AP-2 alone (Swigut et al., 2003). None of the classical AP-2 binding elements on Nef 
were found to be involved in the interaction with AP-2 thus raising the possibility that the 
SIV Nef-TCRζ interaction forms a high affinity binding site for AP-2 and vice-versa. 
Interestingly, the SH3 domain of Fyn has been demonstrated to order the N-terminus of 
the core domain of HIV-1 Nef into a polyproline type II helix that is not observed in the 
unliganded Nefcore protein (Arold et al., 1997). Therefore, HIV-1 Nef and Src family 
kinases may be acting in a similar fashion to SIVmac239 and AP-2 by coupling binding 
to the formation of a novel interaction interface that exhibits increased affinity for TCRζ.  
The cooperative binding mechanism of SIVmac239-TCRζ-AP-2 complex 
formation may also help to explain the differences in TCR downregulation observed for 
HIV-1 and SIV Nef. Our studies demonstrate that SIV Nef is only capable of 
downregulating TCR surface expression in its full length form that contains both the 
highly variable N-terminus and strong TCRζ-binding C-terminal domain. When either 
domain was swapped with HIV-1 Nef, downregulation was abrograted. Therefore, the 
AP-2 binding interface formed by the SIVmac239 Nef-TCRζ interaction likely contains 
elements of both domains that are not conserved with HIV-1. Therefore, we suggest that 
TCRζ-binding is a shared function of HIV-1, HIV-2 and SIV Nef and that TCRζ-binding 
does not directly lead to downregulation.  
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Nef functions primarily as an adaptor protein that forms multimeric complexes 
with host cellular proteins resulting in dysregulation of normal function. SIV Nef has 
been demonstrated extensively to bind TCRζ and AP-2 and induce downregulation of the 
T cell receptor. TCR downregulation has been suggested to serve as a protective 
mechanism that attenuates T cell activity and promotes commensal viability with its 
infected host (Schindler et al., 2006). In humans, this protective function is lost allowing 
HIV-1 Nef to potentially recruit proteins other than AP-2 to TCRζ. One intriguing group 
of candidates includes members of the Src family of protein kinases that initiate the T-
cell signaling cascasde following external stimulation of the TCR [reviewed in (Smith-
Garvin et al., 2009)]. By binding TCRζ and Src family kinases, HIV-1 Nef may enhance 
TCRζ phsophorylation and modulate downstream T cell activation events conducive to 
elevated viral replication. 
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CHAPTER III: Pseudo-merohedral twinning and non-crystallographic symmetry in 
orthorhombic crystals of SIVmac239 Nef core domain bound to different length 
TCR zeta fragments 
 
Abstract 
HIV/SIV Nef mediates many cellular processes through interactions with various 
cytoplasmic and membrane-associated host proteins, including the signalling zeta subunit 
of the T cell receptor (TCRζ). Here, the crystallization strategy, methods and refinement 
procedures used to solve structures of the core domain of the SIVmac239 isolate of Nef 
(Nefcore) in complex with two different TCRζ fragments are described. The structure of 
SIVmac239 Nefcore bound to the longer TCRζ polypeptide (L51-D93) was determined to 
3.7 Å (Rwork = 28.7%) in the tetragonal space group P43212. The structure of SIVmac239 
Nefcore in complex with the shorter TCRζ polypeptide was determined to 2.05 Å (Rwork = 
17.0%) but only after the detection of nearly perfect pseudo-merohedral crystal twinning 
and proper assignment of the orthorhombic space group P212121. The reduction in crystal 
space group symmetry induced by the truncated TCRζ polypeptide appears to be caused 
by the rearrangement of crystal contact hydrogen bonding networks and the substitution 
of crystallographic symmetry operations with similar non-crystallographic symmetry 
(NCS) operations. The combination of NCS rotations nearly parallel to the twin operation 
(k,h,-l) and unit cell lengths a and b nearly identical predisposed the P212121 crystal form 
to pseudo-merohedral twinning. 
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III.A. Introduction 
Protein crystallization occurs under supersaturating conditions where protein 
molecules organize by either non-crystallographic or crystallographic symmetry 
operations into repeating unit cells that pack to form a crystal lattice. Crystal twinning 
occurs when two or more crystal packings intersperse in one larger aggregate crystal. 
This has been reported to occur as a result of polymorphic transformation during physical 
stress (Govindasamy et al., 2004; Yeates, 1997) but occurs more commonly as a 
pathology of crystal growth. When the lattice of each crystal packing in the aggregate 
crystal do not overlap in three dimensions, the crystal exhibits epitaxial, or non-
merohedral, twinning that can be easily detected by the presence of split reflections on 
the crystal’s x-ray diffraction pattern. However, when the lattice axes of the individual 
crystals are parallel, the crystal is considered to be merohedrally twinned and the x-ray 
diffraction pattern will not provide any visual cues of crystal twinning. For protein 
molecules, merohedrally twinned crystals exist predominately as hemihedrally twinned 
crystals (Yeates, 1997) that contain two distinct twin domains that are related to each 
other by a twin law operation. The twin fraction α represents the fractional contribution 
of the less prevalent twin domain. The diffraction pattern of a hemihedrally twinned 
crystal is therefore the superimposition of two unique diffraction patterns, one of each 
twin domain, where each reflection intensity is the weighted sum of two twin-related 
intensities (Equations 1a, 1b) (Grainger, 1969). 
Iobs(h1) =(1-α) I(h1) + α I(h2)  (1a) 
Iobs(h2) =α I(h1) + (1-α) I(h2)  (1b) 
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The individual intensities I(h1) and I(h2) can be solved by combining the linear 
equations (Equations 2a, 2b). 
α
αα
2-1
(h2)I  - (h1)I )-(1  I(h1) obsobs=     (2a) 
α
αα
2-1
(h2)I ) -(1  (h1)I -  I(h2) obsobs +=   (2b) 
As the twin fraction α approaches 1/2, the crystal is considered to be perfectly twinned 
and the calculation of the intensities I(h1) and I(h2) begins to fail as the term (1-2α) 
begins to approach zero. This complicates the process of twin-related reflection intensity 
calculation, commonly referred to as detwinning. Structure determination has therefore 
has been preferentially performed for hemihedral crystals that exhibit non-perfect 
twinning. 
 Rare cases of twinning have been described where a twin law operation supports a 
higher Laue symmetry than that of the crystal unit cell (Rudolph et al., 2004). This type 
of twinning, referred to as pseudo-merohedral twinning, can occur in special 
circumstances such as a monoclinic system where the β angle approaches 90o (Larsen et 
al., 2002) or an orthorhombic system where the unit cell axes a and b are fortuitously 
similar in length (a ≈ b), resulting in the emulation of higher apparent tetragonal 
symmetry (Brooks et al., 2008). In this report we describe such a case, for crystals of the 
the complex of the Nef (negative factor) protein from simian immunodeficiency virus 
bound to a fragment of the one of Nef’s cellular targets, the cytosolic domain of the TCR 
zeta subunit (TCRζ). 
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Nef from human immunodeficiency virus (HIV) or simian immunodeficiency 
virus (SIV) is a 27-35 kDa viral accessory protein dispensable for replication but required 
for high infectivity and virulence (reviewed in (Arien and Verhasselt, 2008)). Expressed 
in abundance early in the viral life cycle, Nef performs a number of functions that can be 
generalized into three activities: enhancement of viral infectivity, downregulation of 
surface receptors and modulation of T cell activation. Notable among Nef’s functions is 
the interaction of Nef with the TCRζ (Bell et al., 1998; Fackler et al., 2001; Howe et al., 
1998; Schaefer et al., 2000; Sigalov et al., 2008; Swigut et al., 2000; Xu et al., 1999), the 
principal signaling component of the T cell antigen receptor. This interaction has been 
suggested to play a role in HIV-mediated modulation of membrane proximal T cell 
sigaling events (Fenard et al., 2005; Thoulouze et al., 2006) and in SIV-mediated 
downregulation of the T cell receptor (Munch et al., 2002; Schaefer et al., 2002; 
Schindler et al., 2006; Swigut et al., 2003; Willard-Gallo et al., 2001).  In previous work 
(Schaefer et al., 2000) as well as studies described in Chapter II of this thesis, Nef has 
been shown to bind TCRζ at two unique sites, the first containing elements of 
immunoreceptor tyrosine activation motif (ITAM) 1 that is shared by HIV-1 and SIV Nef 
and the second containing elements of ITAM 2 that is unique to SIV Nef.  However, the 
structural features on Nef that determine its specificity for TCRζ remain unknown. 
Nef contains two domains, an unstructured, highly variable, myristylated N-
terminal domain and a C-terminal structured core domain (Arold et al., 1997; Grzesiek et 
al., 1997; Lee et al., 1996) that exhibits high sequence conservation among different 
HIV-1, HIV-2 and SIV isolates. The Nef conserved core domain (Nefcore) has been 
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described to be responsible for the majority of Nef’s interactions (Peter, 1998), including 
SIV Nef’s TCRζ-binding activity.  For HIV-1 Nef, the core domain has been shown to be 
amenable to crystallization (Arold et al., 1997; Lee et al., 1996; Li et al., 2002). In this 
study, we aimed to determine the crystal structure of the Nef-TCRζ complex by 
crystallizing the high-affinity complex of the Nefcore protein, SIVmac239 Nefcore (Chapter 
2), with TCRζ fragment polypeptides containing the putative binding regions.  
Here, we describe the crystallization and structure determination of two 
complexes of SIVmac239 Nefcore with two different TCRζ polypeptides, TCRζL51-D93 and 
TCRζA63-R80. Structure determination of the SIVmac239 Nefcore- TCRζL51-D93 complex 
was hampered by the poor electron density maps calculated from the low resolution 
diffraction data phases derived from molecular replacement using the published HIV Nef 
core domain model.  Eventually we were able to determine this structure using the 
higher-resolution SIVmac239 Nefcore- TCRζA63-R80 complex as a starting model. 
However, determination of the high resolution SIVmac239 Nefcore- TCRζA63-R80 complex 
structure was hindered by the nearly perfect pseudo-merohedral crystal twinning that was 
detected by analysis of intensity statistics. Ultimately, a partially twinned crystal with a 
twin fraction of 0.424 was used to solve the structure of the SIVmac239 Nefcore- 
TCRζA63-R80 complex to 2.05 Å. The structures of the two complexes revealed that 
crystallization of SIVmac239 Nefcore with the shorter TCRζ polypeptide had reduced the 
space group symmetry from tetragonal to orthorhombic and introduced non-
crystallographic symmetry (NCS). Because the unit cell axes a and b were still nearly 
identical in the orthorhombic crystal form, the crystal was prone to twinning. This study 
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presents a unique case where pseudo-merohedral crystal twinning was a consequence of 
reduction in crystal symmetry induced by the truncation of a protein ligand.  
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III.B. Materials and methods 
III.B.1. Protein expression and purification 
The core domain of SIVmac239 Nef with a two residue linker, GS-Nef [D95-S235] 
(Nefcore), was expressed and purified as described (Chapter II, Sigalov et al., 2008a). 
Briefly, Nef was expressed as a 6xHis-thioredoxin fusion protein in BL21 (DE3) E. coli. 
Following cell lysis, the Nef fusion protein was isolated by Ni-NTA affinity 
chromatography (Qiagen) under denaturing conditions (8M urea) and then dialyzed 
against a non-denaturing buffer containing 20mM Tris, 150mM NaCl, 100uM DTT at pH 
8.0. The soluble fusion protein was then subjected to proteolysis with thrombin (MP 
Biochemicals), resulting in the cleaved Nefcore protein. SIVmac239 Nefcore was purified 
by anion exchange and size exclusion chromatography and concentrated to 700μM by 
ultrafiltration (Amicon) in PBS. 
 TCRζ cyt includes and acid-labile Asp-Pro sequence (Landon, 1977) at positions 
93-94. We made use of this to prepare two fragments of TCRζcyt, termed DP1 (L51-
D93) and DP2 (P94-R164). TCRζcyt, purified as described (Sigalov et al., 2004), was 
incubated at 1.3 mg/ml (0.1 mM) in 30% acetonitrile, 0.5% TFA (v/v) for 48 hrs at 50oC. 
Fragments were isolated by reverse-phase chromatography on a Vydac c18 300A pore 
size column using an acetonitrile gradient in 0.1% TFA, and recovered by lyophilization. 
Mass spectrometry was used to verify the identity of the fragments and lack of any 
additional chemical modification other than the desired amide hydrolysis. All TCRζ 
polypeptides were solubilized in 20mM Tris pH 8.0 to a final concentration of 700μM. 
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Full-length TCRζ was expressed and purified as reported previously (Sigalov et al., 
2004). 
 
III.B.2. Crystallization 
Crystals of SIVmac239 Nefcore in complex with the TCRζ polypeptides TCRζDP1 and 
TCRζA63-R80 were grown at 4oC using the hanging-drop vapor diffusion method 
(McPherson, 1982). Crystals of the Nefcore- TCRζ DP1complex were grown in a 2μl 
hanging drop by mixing 0.5μl SIVmac239 Nefcore (700μM), 0.5μl TCRζ DP1 (700μM) 
and 1μl crystallization buffer (15% PEG 3,350, 150mM KF, 100mM HEPES, pH 8.2). 
Crystals of the Nefcore- TCRζA63-R80 complex were grown in a 3μl hanging drop by 
mixing 1μl SIVmac239 Nefcore (700μM), 1μl TCRζ63-80 (700μM) and 1μl crystallization 
buffer (10-14% PEG 3,350, 200mM NH4F, 100mM HEPES, pH 7.4-7.5). The hanging 
drops were suspended on siliconized glass coverslips over 1ml crystallization buffer in 24 
well plates (Vydax). Crystals of the Nefcore-TCRζ polypeptide complexes grew to 
maximal size (750 x 150 x 150 μm) in 3-7 days. Prior to x-ray diffraction experiments, 
the Nefcore- TCRζ DP1and Nefcore- TCRζA63-R80 crystals were transferred into 
cryoprotectant solutions containing 20-25% ethylene glycol in their respective 
crystallization buffers and then flash-cooled in liquid nitrogen. 
 
III.B.3. Data collection and processing 
Sixteen data sets from various Nefcore- TCRζ crystals were collected, of which three were  
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used for data collection.  One low resolution data set (3.7 Å) of the SIVmac239 Nefcore- 
TCRζ DP1complex and two high resolution data sets (1.9 Å, 2.05 Å) of the SIVmac239 
Nefcore- TCRζA63-R80 complex were collected from single crystals at the National 
Synchrotron Light Source (beamline X29) using an ADSC Quantum-315r CCD detector 
system. The crystal-to-detector distance for the Nefcore- TCRζ DP1complex and Nefcore- 
TCRζA63-R80 crystals were 275mm and 250mm, respectively. The crystals were exposed 
for 1s with an oscillation of 1o per image. A total of 180 images were collected for each 
data set which were separately indexed, integrated and scaled in HKL2000 (Otwinowski 
et al., 1997). Detection and analysis of crystal twinning was performed in phenix.xtriage 
of the PHENIX software package (Adams et al., 2002). Determination of the twin law 
governing the pseudo-merohedrally twinned SIVmac239 Nefcore- TCRζA63-R80 crystals 
was performed following proper assignment of the crystal space group as described 
below. 
 
III.B.4. Structure determination and refinement 
The structures of the SIVmac239 Nefcore- TCRζA63-R80 and SIVmac239 Nefcore- 
TCRζ DP1 complexes were determined by molecular replacement. First, atomic 
coordinates of the Nef core domain from HIV-1 were extracted from the crystal 
structures of the unliganded HIV-1 isolate LAI Nef structure (PDB ID code 1AVV) 
(Arold et al., 1997), the HIV-1 isolate LAI Nef-Fyn SH3 domain complex  (PDB ID code 
1AVZ) (Arold et al., 1997) and HIV-1 isolate NL4-3 Nef-Fyn SH3 (R96I) domain 
complex (PDB ID code 1EFN) (Lee et al., 1996), and were modified with CHAINSAW 
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[CCP4, (1994)] to trim the side chains not shared by SIVmac239 Nef to methyl groups. 
The modified Nef coordinate sets were used as an ensemble search model for molecular 
replacement in PHASER (Storoni et al., 2004) and single solutions with translation z 
scores (TFZ) greater than 8.0 were as starting models.  The structure of the Nefcore- 
TCRζA63-R80 complex was solved by multiple rounds of twinned refinement using 
phenix.refine of the PHENIX software package (Adams et al., 2002) interspersed with 
rounds of manual model building and fitting of Fo - Fc and 2Fo - Fc electron density maps 
in Coot (Emsley and Cowtan, 2004). The twin operator k, h, -l was applied during each 
round of refinement which included three cycles of individual atomic displacement factor 
refinement and individual energy-minimization procedures, accompanied by refinement 
of the twin fraction α. Water molecules were added to the refined model using both 
phenix.refine and Coot. The quality of the final and refined SIVmac239 Nefcore- TCRζA63-
R80 structure was validated in PROCHECK (Laskowski et al., 1993). 
 The structure of the refined SIVmac239 Nefcore- TCRζA63-R80 complex was used 
as a search model to find a molecular replacement solution for the SIVmac239 Nefcore- 
TCRζ DP1data. A single top molecular solution (TFZ = 10.5, LLG = 266) was found and 
used as starting model. The structure of the SIVmac239 Nefcore- TCRζ DP1 structure was 
solved by refinement with several rounds of individual atomic displacement factor 
refinement and individual energy-minimization procedures using phenix.refine. Model 
inspection was performed between each round of refinement and the model was modified 
in Coot. The final refined structure was validated for acceptable chemical properties with 
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PROCHECK. Final model and refinement statistics for both SIVmac239 Nefcore-TCRζ 
polypeptide structures are shown in Table III-1. 
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III.C. Results and discussion 
III.C.1. Crystallization and data collection of two SIVmac239 Nefcore-TCRζ polypeptide 
complexes 
In order to determine the structure of the Nef-TCRζ complex, mixtures of the 
structured core domain of SIVmac239 Nef (D95-S235) with various polypeptides 
spanning the putative binding regions on TCRζ (Chapter II, Schaefer et al., 2000) were 
screened for crystal formation. Initial crystallization experiments were aimed at 
crystallizing the complex of Nefcore (SIVmac239, HIV-1 ELI and NL4-3) with the full-
length cytoplasmic domain of TCRζ (TCRζcyt), but these were unsuccessful as the 
complex precipitated at high concentration, possibly due to the largely unstructured 
nature of TCRζcyt (Aivazian and Stern, 2000; Sigalov et al., 2004). Therefore, a 
polypeptide crystallization screening strategy was employed to identify a minimal 
TCRζ polypeptide that bound SIVmac239 Nefcore, which among the SIV, HIV-1, and 
HIV-2 variants tested (SIVmac239, HIV-1 ELI and NL4-3, respectively), exhibited the 
highest affinity TCRζcyt binding (Chapter II) . 
Crystallization efforts focused on TCRζ fragments containing the N-terminal of 
the two SIV interaction domains (Figure III-1). Of a series of polypeptides spanning 
TCRζcyt a peptide included in this region, TCRζA61-R80, bound to Nefcore from HIV-1, 
HIV-2 and SIV strains (Chapter II), and structural information obtained on the higher-
affinity SIV variant might be relevant for HIV-1 as well as the more homologous HIV-2 
Nef proteins. Moreover, the TCRζDP1 (i.e. the N-terminal acid-cleavage fragment 
residues L51-D93) formed a 1:1 stoichiometric complex with SIVmac239 Nefcore, 
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(Chapter II) as did intact TCRζcyt (Sigalov et al., 2008). Therefore a series of 
polypeptides containing the original TCRζDP1 polypeptide, the shorter TCRζA61-R80 
polypeptide and several peptides containing the proposed SNID-1 (Schaefer et al., 2000) 
sequence, were either prepared from full-length TCRζcyt (TCRζDP1) or chemically 
synthesized (TCRζA61-R80 and variants) and used in crystallization experiments with 
SIVmac239 Nefcore.  
SIVmac239 Nefcore was previously demonstrated to bind to the TCRζ polypeptide 
spanning residues L51-D93 (i.e. the N-terminal acid-cleavage fragment TCRζDP1), 
forming a simple 1:1 heterodimeric complex in solution (Chapter II). SIVmac239 Nefcore 
was also shown to bind a smaller binding region on TCRζ (A61-R80) that contained the 
first YxxL motif of the N-terminal immunoreceptor tyrosine-based activation motif 
(ITAM), consistent with previous reports characterizing this region as one of the two SIV 
Nef interaction domains (Schaefer et al., 2000). Because Nefcore proteins from HIV-1, 
HIV-2 and SIV all bound the A61-R80 binding region on TCRζ (Chapter II), structural 
information of SIVmac239 Nefcore in complex with the N-terminal binding site might be 
relevant for HIV-1 as well as the more homologous HIV-2 Nef proteins. Therefore a 
series of polypeptides containing the original TCRζL51-D93 polypeptide, the shorter 
TCRζA61-R80 polypeptide and several peptides containing the proposed SNID-1 (Schaefer 
et al., 2000) sequence, were either expressed and purified from E.coli (for TCRζ DP1) or 
chemically synthesized (TCRζA61-R80  and variants) and used in crystallization 
experiments with SIVmac239 Nefcore (Figure III-1).  
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SIVmac239 Nefcore crystallized in complex with TCRζ DP1and TCRζA63-R80, under 
similar conditions. Crystals of the SIVmac239 Nefcore- TCRζ DP1complex grew readily as 
long tetragonal pyramids (Figure III-2A) but diffracted x-rays to low resolution (3.7 Å) 
(Figure III-2B), and could not be improved further by optimization of crystallization 
conditions. In contrast, crystals of SIVmac239 Nefcore bound to TCRζA63-R80 adopted a bi-
pyramidal shape (Figure III-2A) and diffracted x-rays to high resolution (1.9 – 2.05 Å) 
(Figure III-2B). Neither crystal form exhibited the concave or “re-entrant” features that 
have been suggested to predict the presence of twinned crystals (Yeates, 1997) nor did 
their diffraction patterns contain split reflections (Figure III-2B). 
 
III.C.2. Space group determination and molecular replacement for SIVmac239 Nefcore- 
TCRζ DP1 
The low resolution diffraction data for the SIVmac239 Nefcore- TCRζ DP1complex 
was indexed in the tetragonal Laue group 4/mmm (422 point group) with unit cell 
parameters a =  b = 51.638, c = 189.449 Å and an Rmerge of 0.051. The Matthews 
coefficient VM (Matthews, 1968) was calculated to be 2.86 (57.1% solvent), indicating 
the presence of one SIVmac239 Nefcore- TCRζ DP1 hetereodimer per asymmetric unit. 
After analysis of the h00, 0k0 and 00l reflection intensities, the space group was further 
assigned to P43212 or P41212 based on the indicated presence of screw axes along a and c. 
Using an ensemble of HIV-1 Nef core domain structures as a search model, a single 
molecular replacement solution (TFZ = 9.4, LLG = 63) was found in space group P43212. 
However, model refinement and building were hindered by the poor quality of the σΑ- 
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51        61        71        81        91    
    DP1  LRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRD 
    A61-R80           APAYQQGQNQLYNELNLGRR 
    A63-R80             AYQQGQNQLYNELNLGRR 
    Q65-R80               QQGQNQLYNELNLGRR 
    G67-R80                 GQNQLYNELNLGRR 
    N69-R80                   NQLYNELNLGRR 
    Q70-R79                    QLYNELNLGRREEYDVLDKR 
    Q66-D84                QGQNQLYNELNLGRREEYD 
    Q68-E82                  QNQLYNELNLGRREE 
 
Figure III-1. TCRζ polypeptide crystallization screen. The polypeptide sequences are 
shown with residue position numbers assigned on the left. The boxed region contains the 
sequence of the first of the two reported SIV Nef interaction domains (Schaefer et al., 
2000). The sequence of ITAM 1 is colored red. 
TC
R
ζ 
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Figure III-2. Crystallization and diffraction. A. Crystals of the SIVmac239 Nefcore- 
TCRζL51-D93 and the SIVmac239 Nefcore- TCRζA63-R80 complex. Both crystals grew to 750 
x 150 x 150μm at 4oC. B. Diffraction patterns of crystals of the SIVmac239 Nefcore-TCRζ 
polypeptide complexes collected at beamline X29 at the National Light Synchrotron 
Light Source, Brookhaven National Laboratories. C. Zoom view of the diffraction 
patterns. The diffraction pattern spot profiles are singular with no evidence of split spots. 
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weighted Fo - Fc and 2Fo - Fc electron density maps, resulting in the Rfree which could not 
be reduced below at 41%. Despite the difficulty in model refinement, crystal twinning 
was not suspected due to the lack of twinning possibilities in P43212 crystals. 
 
III.C.3. Initial space group determination and molecular replacement for SIVmac239 
Nefcore-TCRζA63-R80 
Two crystals of SIVmac239 Nefcore bound to the shorter TCRζA63-R80 diffracted x-
rays to higher resolution (1.9 - 2.05 Å) but space group determination proved to be more 
complicated than for the P43212 crystal form of the Nefcore-TCRζ DP1described above . 
Diffraction patterns observed for the Nefcore-TCRζA63-R80 appeared to be consistent with 
the lattice previously observed for the lower resolution Nefcore-TCRζ DP1 crystals, and 
initially the TCRζA63-R80 data (crystal 1) was indexed in the same tetragonal Laue group 
4/mmm with unit cell parameters a = b = 47.203, c = 182.939 Å.  Integration statistics 
were similar to those observed previously (Rmerge = 7.6%). All of the unit cell parameters 
were reduced 4-10% as compared to the SIVmac239 Nefcore-TCRζ DP1crystals, potentially 
consistent with the shorter length of the TCRζ polypeptide ligand. Analysis of the h00, 
0k0 and 00l intensities indicated the presence of 21 screw axes along a, b and c, 
suggesting a lower symmetry than the SIVmac239 Nefcore-TCRζ DP1crystals. In turn, the 
search for a molecular replacement solution in all P422 space groups yielded no results. 
A data set collected for a second SIVmac239 Nefcore-TCRζA63-R80 crystal (crystal 2) 
resulted in similar difficulties with molecular replacement. The ambiguous space group 
assignment and inability to find a molecular replacement solution for the SIVmac239 
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Nefcore-TCRζA63-R80 complex in the tetragonal Laue symmetry group suggested the 
possibility of crystal twinning and required space group re-evaluation. 
 
III.C.4. Detection and analysis of twinning 
A number of statistical methods have been developed to characterize crystal 
twinning, including the recently developed Padillia-Yeates algorithm to detect the 
presence of crystal twinning (Padilla and Yeates, 2003) and the Britton plot to estimate 
the twin fraction α (Britton, 1972). To assess twinning of the SIVmac239 Nefcore-TCRζ 
polypeptide crystals, several intensity statistics analyses were performed in 
phenix.xtriage. First, the second moment of intensities of acentric data (<I2>/<|I|2>) was 
calculated for all three SIVmac239 Nefcore-TCRζ polypeptide complexes. Untwinned and 
twinned data are expected to have <I2>/<|I|2> values of 2.0 and 1.5 respectively. The 
SIVmac239 Nefcore-TCRζL51-D93 crystal had an <I2>/<|I|2> value of 2.106, suggesting the 
absence of twinning, whereas the SIVmac239 Nefcore-TCRζA63-R80 crystals had <I2>/<|I|2> 
values of 1.676 (crystal 1) and 1.628 (crystal 2), indicating the presence of twinning in 
both crystals. A more robust method of twin detection that uses cumulative local intensity 
deviation distribution statistics as determined by the Padilla-Yeates algorithm (Padilla 
and Yeates, 2003) was also employed. In a plot of the local intensity difference |L| of non 
twin-related intensities versus the distribution of the local intensity differences, N|L|, the 
presence of twinning can be deduced by comparing the experimental plots to the 
expected plots for twinned and untwinned data (Padilla and Yeates, 2003). The 
SIVmac239 Nefcore-TCRζ DP1 data plot was linear, consistent with the expected curve for 
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untwinned data (Figure III-3, top). In contrast, both SIVmac239 Nefcore-TCRζA63-R80 
crystals 1 and 2 data plots were curved, suggesting the presence of crystal twinning 
(Figure III-3, top). The L test, also based on the local intensity differences of non twin-
related reflection pairs, was additionally employed to confirm twinning in the 
SIVmac239 Nefcore-TCRζA63-R80 crystals; for untwinned data, |L| and mean L2 are 
expected to equal 1/2 and 1/3, respectively, and for twinned data, 3/8 and 1/5. The 
SIVmac239 Nefcore-TCRζDP1 data had calculated |L| and L2 values of 0.473 and 0.307, 
consistent an absence of appreciable twinning. The SIVmac239 Nefcore-TCRζA63-R80 
crystals had calculated |L| and L2 values of 0.402 and 0.229 for crystal 1 and 0.390 and 
0.218 for crystal 2, further supporting the presence of crystal twinning. All of the 
twinning tests suggested that the low resolution SIVmac239 Nefcore-TCRζDP1 crystal was 
not appreciably twinned whereas the high resolution SIVmac239 Nefcore-TCRζA63-R80 
crystals were pseudo-merohedrally twinned with a twin fraction near 0.5. 
In order to estimate the twin fraction α in the two SIVmac239 Nefcore-TCRζA63-R80 
pseudo-merohedrally twinned crystals, Britton plot (Britton, 1972) and H plot (Yeates, 
1988) analyses were performed (Figure III-3, middle and bottom). Crystal 1 exhibited 
near perfect twinning with an estimated twin fraction of 0.452 from the Britton plot and 
0.477 from the H plot. In contrast, crystal 2 seemed to be only partially twinned with 
estimated twin fractions of 0.344 and 0.356 from the Britton plot and H plot, respectively. 
These initial estimates of the twin fraction refined upwards during structure 
determination to 0.500 and 0.426 for crystals 1 and 2, respectively (see below). 
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Figure III-3. Detection of twinning and estimation of the twin fraction α. Top, 
cumulative intensity difference plot of the intensity difference of local pairs of intensities 
that are not twin related  |L| {L = [I(h1) – I(h2)]/[I(h1) + I(h2)]} against the cumulative 
probability distribution, N(L), of the parameter L (Yeates, 2003). The expected plots of 
untwinned and twinned acentric data (red) and calculated plots of the SIVmac239 
Nefcore-TCRζ polypeptide data (blue) are shown. Middle, estimation of the twin fraction 
α by Britton plot analysis (Britton, 1972). The percentage of negative intensities after 
detwinning is plotted as a function as a function of the assumed value of a. 
Overestimation of the twin factor a results in an increase in the percentage of negative 
intensities. The estimated value for α is extrapolated from the linear fit (dashed line). 
Bottom, estimation of the twin fraction a using the H plot (Yeates, 1988). The cumulative 
fractional intensity difference of acentric twin-related intensities H {H = |I(h1) – 
I(h2)|/[I(h1) + I(h2)]} is plotted against H. The initial slope (dashed line) of the 
distribution is a measure of α. The expected slopes for the indicated twin fractions 0.0-
0.4 are shown (dotted lines).  
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Because the tetragonal P43212 space group does not support merohedral twinning, 
we explored the possibility that the twinned SIVmac239 Nefcore-TCRζA63-R80 crystals 
were orthorhombic crystals that emulated tetragonal symmetry due to pseudo-merohedral  
crystal twinning. The twinned SIVmac239 Nefcore-TCRζA63-R80 diffraction data was 
therefore re-indexed in the orthorhombic point group 222.  The unit cell parameters, a 
and b, constrained to be equal in point group 422 (Laue group 4/mmm), refined to 
slightly different values, a = 47.197, b = 47.208 for crystal 1 and a = 47.417, b = 47.421 
for crystal 2, with no significant changes in Rmerge values (Table III-1). Inspection of the 
h00, 0k0 and 00l intensities indicated the presence of 21 screw axes along each axis, 
suggesting a P212121 crystal space group. The Matthews coefficient VM (Matthews 1968) 
was calculated to be 2.64 (53.42% solvent) for crystal 1 and 2.64 (53.99% solvent) for 
crystal 2, consistent with two SIVmac239 Nefcore-TCRζA63-R80 heterodimers comprising 
the asymmetric unit. The reduction in symmetry from a fourfold axis along c to a twofold 
symmetry in the orthorhombic unit cell cell led to the identification of the pseudo-
merohedral twin operation (k, h, -l) that accounted for the apparent fourfold Laue 
symmetry observed in the diffraction data. 
The reduction in symmetry from a fourfold axis along c in the tetragonal unit cell 
to a twofold axis in the orthorhombic unit cell, together with an increase in the number of 
molecules per asymmetric unit,  helped us to identify the pseudo-merohedral twin 
operation (k, h, -l) that accounted for the apparent fourfold Laue symmetry observed in 
the diffraction data. Consider a P212121 unit cell with unit cell length a approximately 
equal to unit cell length b (Figure III-4). Pseudo-merohedral twinning can exchange the a  
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Figure III-4. Twinning in an orthorhombic P212121 crystal. A P43212 space group unit 
cell with 1 molecule (arrow) per asu (8 per unit cell) is shown with axes a, b, and c 
labeled. B. A P212121 space group unit cell with 1 molecule per asu (4 per unit cell) is 
shown (left) with its twin unit cell (right) related by the twin operator (y,x,-z). C. A 
P212121 space group unit cell with 2 molecules per asu (4 per unit cell) is shown (left) 
with its twin unit cell (right) related by the twin operator (y,x,-z). The asu is comprised of 
one blue and one black arrow related by non-crystallographic symmetry. 
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and b axis under the twin relationship (h,k,l) -> (k,h,-l), resulting in apparent tetragonal 
symmetry around the c axis (Figure III-4). The apparent symmetry observed in this case 
will be indistinguishable from a non-twinned P43212 (or P41212,) unit cell (Figure III-4). 
Note that in this case the twinned P212121 unit cell is less tightly packed with one 
molecule per asymmetric unit (4 per unit cell) than is the corresponding non-twinned 
tetragonal P43212 (or P41212,) cell with one molecule per asymmetric unit (8 per unit 
cell). Based on the Matthews coefficient, we expected 2 molecules per asymmetric unit 
for the twinned a P212121 unit cell.  Note that the non-twinned crystals of the SIVmac239 
Nefcore-TCRζDP1 complex, which did adopt true tetragonal symmetry with unit cell 
parameters similar to those of the twinned a P212121 crystal, had a Matthews coefficient 
consistent with 1 molecule per asymmetric unit. Because the SIVmac239 Nefcore-
TCRζDP1 and the SIVmac239 Nefcore-TCRζA63-R80 complexes had similar molecular sizes 
and crystallized in related unit cells with similar lengths and angles, we expected similar 
packing, but this was inconsistent with the different packing expected for the related 
twinned P212121 and non-twinned P43212 (or P41212,) unit cells shown in Figure 4. Non-
cystallographic symmetry relationships similar to crystallography symmetry operators 
also can result in observed symmetry higher than that actually present in the crystal. For 
example, breakdown of the crystallographic four-fold axis in a tetragonal cell could result 
in an orthorhombic cell with pseudo-fourfold symmetry. In this case the non-
crystallographic symmetry relationship is similar to the missing crystallographic operator, 
and the related tetragonal and orthorhombic unit cells would have similar packing (Figure 
III-4). This arrangement can be particularly prone to pseudo-merohedral twinning as a 
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result of the similarity of crystal packing along the a and b unit cell axes (Figure III-4). 
We explored this scenario as an explanation for the observed twinning in the P212121 
crystals with packing similar to non-twinned P43212 (or P41212,) crystals.   
 
III.C.5. Structure determination and refinement for SIVmac239 Nefcore-TCRζA63-R80 using 
twinned data 
After assignment of the SIVmac239 Nefcore-TCRζA63-R80 crystal data to the 
orthorhombic P212121 space group, several strong molecular replacement solutions were 
readily found with TFZ scores 6.1-9.2, using a consensus model derived from unliganded 
HIV-1 Nefcore crystal structures. In principle, molecular replacement solutions 
corresponding to both twin orientations and non-crystallographically related molecules 
are expected.   Transformations among these solutions were examined to assign each to a 
twin or NCS domain (Figure III-5). All solutions could be accounted for using a single 
NCS transformation, the (k,h,-l) twinning operator, and the P212121 space group 
symmetry.  Two nearby molecules (A, B) in the same twin domain related by an 
approximate 90o rotation were selected to comprise the asymmetric unit. 
Once the twinning arrangement was properly understood and taken into account, 
model building and refinement in the P212121 space group with 2 molecules per 
asymmetric unit was relatively straightforward. The twin operation (k,h,-l) was factored 
into each round of twinned refinement in phenix.refine that included three cycles of 
individual atomic displacement parameter (B factor) and energy minimization 
refinement. The twin fraction α was also refined in each round and used to detwin the  
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Figure III-5. Molecular replacement solutions. Five molecular replacement solutions 
(A-E) are shown with their translation function Z (TFZ) scores denoted. The relationship 
and rotation matrix relating each molecular replacement solution is shown.  
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intensity data in order to generate interpretable 2Fo - Fc and Fo - Fc omit electron density 
maps suitable for manual model building. However, during the first round of refinement, 
the twin fraction converged to 0.5 for crystal 1 and 0.426 for crystal 2. The calculated 2Fo 
– Fc electron density maps generated by phenix.refine were noticeably less interpretable 
for crystal 1 than for crystal 2. Therefore, structure determination proceeded with crystal 
2 through iterative cycles of twinned refinement interspersed with rounds of model 
inspection and building. As the model and twin fraction continued to refine, there was 
marked improvement in the quality of the electron density maps that allowed for the 
building of 5 additional residues at the N-terminus (V98-V102), 1 residue at the C-
terminus (G234) and 11 residues in the internal disordered loop (P197-W207) on Nef; the 
starting model generated from the published crystal structures of HIV-1 Nef was missing 
9 residues at the N-terminus, 2 residues at the C-terminus and 29 residues in the 
disordered loop. Clear density for the TCRζA63-R80 polypeptide ligand was observed, and 
this region also was built into the structure with 13 of the 16 resolved residues 
comprising a canonical alpha helix (Figure III-6A). Water molecules were added to the 
model using the automated water-picking functions in phenix.refine and Coot. The final 
structure (crystal 2) contained 120 residues on SIVmac239 Nef, 16 residues on TCRζ, 
116 ordered water molecules and had Rwork and Rfree values of 17.0 and 18.4%, 
respectively (Table III-1). 
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Figure III-6. 2 Fo – Fc electron density maps of the TCRζ polypeptide. 2Fo – Fc 
electron density maps contoured at 1σ calculated from the detwinned P212121 data of the 
SIVmac239 Nefcore –TCRζA63-R80 crystal (A) and P43212 data of the SIVmac239 Nefcore –
TCRζL51-D93 crystal (B) are shown for the region encompassing the TCR ζpolypeptide. 
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III.C.6. Structure determination and refinement of SIVmac239 Nefcore-TCRζDP1 
With a high-resolution structure for SIVmac239 Nefcore-TCRζA63-R80 structure in 
hand, we returned to the low resolution, non-twinned SIVmac239 Nefcore-TCRζ DP1 
P43212 dataset.  In order to determine the structure of the low resolution SIVmac239 
Nefcore-TCRζ DP1, the high resolution SIVmac239 Nefcore-TCRζA63-R80 structure was used 
as the starting model for refinement and building. Structure determination by molecular 
replacement was repeated for the non-twinned SIVmac239 Nefcore-TCRζ DP1 data. A 
stronger molecular replacement solution was found (TFZ = 10.5, LLG = 266) but in the 
same general orientation as that described previously. Refinement of atomic positions and 
individual b-factor was performed in phenix.refine, as described above for the twinned 
crystal, although without twin refinement and detwinning steps. The TCRζ DP1 peptide 
extends 12 residues futher at the N-terminus and 14 residues further at the C-terminus as 
compared to the TCRζA63-R80 polypeptide, but no additional electron density was 
observed beyond that seen in the SIVmac239 Nefcore-TCRζA63-R80 complex, (Figure III-
6B), suggesting that both the N- and C-termini of the -TCRζL51-D93 fragment were 
disordered, and that no additional Nef contacts were present. The final structure of the 
SIVmac239 Nefcore-TCRζ DP1 complex contained 111 residues on Nef, 16 residues on 
TCRζ and had Rwork and Rfree values of 0.287 and 0.332, respectively (Table III-1).  
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III.C.7. Analysis of the P212121 and P43212 crystal forms of the SIVmac239 Nefcore-TCRζ 
polypeptide complex 
As described above, the SIVmac239 Nefcore-TCRζ polypeptide complex 
crystallized in two related but different crystal lattices depending on the length of the 
TCRζ ligand. In the presence of the longer 43-residue TCRζ DP1 polypeptide, SIVmac239 
Nefcore crystallized in the tetragonal P43212 space group with one SIVmac239 Nefcore-
TCRζ DP1 heterodimer comprising the asymmetric unit. In the presence of the shorter 18 
residue TCRζA63-R80 polypeptide, the complex unexpectedly crystallized in the P212121 
space group with severe pseudo-hemihedral twinning.  In this crystal form, a rotation axis 
parallel to c exhibited pseudo-fourfold symmetry that deviated slightly from the 
crystallographic fourfold screw axis observed in the P43212 crystal form (Figure III-7). 
The overall packing of the unit cell was also condensed in orthorhombic crystal form as 
evidenced by a ~4Å (~8%) reduction in the a and b axes and a ~6Å (~3%) shortening of 
the c axis. 
The transformation from the tetragonal to orthorhombic crystal system was 
caused by the introduction of non-crystallographic symmetry (NCS) and the 
rearrangement of the hydrogen bonding network at the crystal contact sites. The P43212 
crystal form contained one molecule per asymmetric unit. The P212121 crystal form 
contained two molecules per asymmetric unit which were no longer related by a 
crystallographic twofold symmetry operation (y,x,-l) but instead by a twofold NCS 
operation. 
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Figure III-7. Crystal packing of the P43212 and P212121 crystal forms. A. The crystal 
symmetry organization of the P43212 crystal form (left) and the P212121 crystal form 
(right) is shown viewed down the four-fold symmetry axis and corresponding two fold 
symmetry axis for the two SIVmac239 Nefcore-TCRζ polypeptide complexes. In B, the 
crystal packing along the c axis is shown for both crystal forms. SIVmac239 
Nefcore/TCRζ are colored cyan/yellow (left) and magenta/green (right). 
A 
B 
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In the tetragonal crystal form, the SIVmac239 Nefcore-TCRζ DP1 complex and its 
symmetry-related partner (y,x,-z) form an anti-parallel dimer similar to the 
crystallographic dimer described previously for HIV-1 Nefcore (Arold et al., 1997).  
Structural alignment of one SIVmac239 Nefcore-TCRζA63-R80 complex from the P212121 
crystal form with its corresponding molecule in the P43212 crystallographic dimer reveals 
that the NCS-related molecule in the orthorhombic crystal form is rotated ~10o from its 
corresponding molecule in P43212 crystal form (Figure III-8A). The interface between the 
two molecules involves the C-terminus of SIVmac239 Nefcore and is predominantly 
occupied by aromatic residues (Y113, Y221, F171, Y223, Y226). Shown in Figure III-
8B, SIVmac239 Nefcore is rotated as a single rigid body in the orthorhombic crystal form 
with no significant changes in either main chain or side chain geometry, suggesting that 
the crystallographic Nefcore dimer interface is flexible and permissible to variations in 
crystal packing.   
Alternate crystal packing was also observed at the crystal contact of two 
asymmetric units in the orthorhombic crystal form and the corresponding symmetry-
related molecules (y,x,-z) and (1/2+y,1/2-x,1/4+z) in the tetragonal crystal form. The 
interface involves three proteins: SIVmac239 Nefcore and its bound TCRζ polypeptide 
ligand from the symmetry-related molecule (1/2+y,1/2-x,1/4+z) and SIVmac239 Nefcore 
from the symmetry-related molecule (y,x,-z) (Figure 3-7 A). Interestingly, the N-terminus 
of the TCRζ polypeptide abuts the neighboring SIVmac239 Nefcore protein, suggesting  
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Figure III-8. SIVmac239 Nefcore dimer interface in the P43212 and P212121 crystal 
forms. A. Overlay of the two molecules in the asymmetric unit of the P212121 crystal 
(magenta/green) and two symmetry-related molecules [(x,y,z), (y,x,-z) in the P43212 
crystal (cyan/yellow). SIVmac239 Nefcore is colored magenta (P212121 crystal) or cyan 
(P43212 crystal) and the TCRζ polypeptide is colored green (P212121 crystal) or yellow 
(P43212 crystal). The structures of the lower SIVmac239 Nefcore-TCRζ polypeptide 
complex were aligned by least-squared methods. The relative 10o counter-clockwise 
rotation of the top P212121 crystal SIVmac239 Nefcore-TCRζ polypeptide complex is 
depicted. B. Detailed view of the SIVmac239 Nefcore dimer interface in the P212121 
(magenta) and P43212 (blue) crystal. The aligned lower SIVmac239 Nefcore-TCRζ 
polypeptide complex is colored grey and the side chains of residues involved in the 
interface are shown in stick models. 
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that the length of the N-terminal sequence of the TCRζ polypeptide ligand directs the 
space group in which the SIVmac239 Nefcore-TCRζ polypeptide complex crystals grow. 
Superimposition of the TCRζ polypeptide helix from the symmetry-related molecule 
(1/2+y,1/2-x,1/4+z) with its corresponding partner in the P212121 crystal form reveals that 
the neighboring SIVmac239 Nefcore protein is rotated ~4.5o inward towards the pseudo-
fourfold symmetry axis in the P212121 crystal form (Figure III-9A). 
Accompanying the transformation is a possible reorganization of the hydrogen 
bonding network at the crystal contact site. In the orthorhombic crystal form, the 
TCRζA63-R80 polypeptide forms a main-chain hydrogen bond with the neighboring 
SIVmac239 Nefcore protein between the main-chain amide of TCRζ Y64 and the side-
chain carbonyl of Nef Q202 (Figure III-8B). TCRζ residue Q65 additionally participates 
in hydrogen bonding with the main chain amide and carbonyl of residues R103 and 
V102, respectively, on its bound SIVmac239 Nefcore partner. Interestingly, this 
interaction orders the proline-rich region in the N-terminus of the bound SIVmac239 
Nefcore into a polyproline type II (PPII) helix as evidenced by the clearly resolved 
electron density maps calculated from the P212121 crystal data for that region. This carries 
significant functional importance due to the regulatory role the PPII helix on HIV-1 Nef 
has been suggested to play in modulating kinase activity through its interaction with the 
SH3 domain of the kinase (Chapter IV, (Arold et al., 1997; Lee et al., 1996)). The PPII 
helix was found to be disordered in the unliganded HIV-1 Nefcore crystals and was only 
ordered in crystals containing the Fyn SH3 domain. Surprisingly, the hydrogen bonding 
network between the TCRζ polypeptide and its bound SIVmac239 Nefcore partner is  
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Figure III-9. Variation in the crystal contact hydrogen bond network. Overlay of the 
crystal packing interface between two asymmetric units of the P212121 crystal lattice 
(SIVmac239 Nef is green and TCRζ is yellow) and two symmetry-related molecules 
(y,x,-z) and (1/2+y,1/2-x,1/4+z) of the P43212 crystal lattice (SIVmac239 Nef is cyan and 
TCRζ is blue). Alignment was performed by least-squares methods of one SIVmac239 
Nef-TCRζ polypeptide complex (at bottom of panel A). Hydrogen bonds present in the 
crystal lattices are represented by dashed lines and are colored yellow and blue for the 
P212121 and P43212 crystal forms, respectively. 
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seemingly absent in the tetragonal crystal form; this explains the lack of electron density 
calculated from the P43212 data for the N-terminus of SIVmac239 Nefcore since the PPII 
helix would no longer be expected to be ordered. Instead of participating in a side chain 
main-chain hydrogen bond with its bound partner, residue Q65 on TCRζ is translocated 
in the tetragonal crystal form, bringing it in close enough proximity to residue Q202 on 
the neighboring SIVmac239 Nefcore protein to participate in a side chain-side chain 
hydrogen bond. The main chain-main chain hydrogen bond between the TCRζ 
polypeptide and the neighboring SIVmac239 Nefcore protein is also lost in the rearranged 
P43212 crystal contact interface. 
Since the proposed hydrogen bond between Q65 on TCRζ and Q202 on 
SIVmac239 was formed by TCRζ and an adjacent SIVmac239 Nefcore protein in the 
crystal lattice and not its interacting SIVmac239 Nefcore partner, it would likely be an 
artifact of crystallization that was necessary for the proper lattice packing in the 
tetragonal crystal form. Curiously, the more physiologically relevant interaction of Q65 
on TCRζ to its bound SIVmac239 Nefcore partner was restored when the TCRζ 
polypeptide was truncated. The loss of the crystal contact hydrogen bond reduced the 
crystal symmetry to an orthorhombic crystal lattice that was subsequently prone to 
twinning. This was unexpected due to the inclusion of a more complete TCRζ sequence 
in the tetragonal crystal and represents an interesting scenario where a protein-ligand 
interaction was disrupted by a crystal contact interaction that permitted higher order 
crystal packing.
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IV. Conclusions 
Crystal twinning can be induced by a number of perturbations, including heavy-
metal soaking, ligand binding, selenomethionine substitution, flash-freezing and the 
introduction of point mutations (Helliwell et al., 2006; Parsons, 2003). The structure 
determination of the two SIVmac239 Nefcore-TCRζ polypeptide complexes provides a 
unique example of crystal twinning caused by the modification of peptide ligand size. 
Truncation of the TCRζ polypeptide reduced the crystal symmetry from a tetragonal 
crystal system to an orthorhombic crystal system and introduced an NCS operation that 
only deviated slightly from the true fourfold symmetry axis. The pseudo-symmetry in the 
P212121 crystal made crystal growth highly susceptible to crystal twinning but 
serendipitously restored a physiologically relevant protein-ligand interaction at the crystal 
contact interface. 
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Table III-1. Data collection and refinement statistics (molecular replacement) 
 
 
Nefcore-TCRζDP1 Nefcore-TCRζA63-R80 Crystal 1 
Nefcore-TCRζA63-R80 
Crystal 2 
Data Collection    
Space Group P43212 P212121 P212121 
Cell dimensions    
     a, b, c (Å) 51.638, 51.638, 189.449 47.190, 47.236, 182.989 47.417, 47.421, 183.519 
α, β, γ(o) 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution* (Å) 50-3.70 (3.83-3.70)* 50-1.93 (2.02-1.93) 30-2.05 (2.12-2.05) 
Rmerge8*a 0.051 (0.393) 0.083 (0.513) 0.084 (0.498) 
I/σI* 12.8 9.7 (2.4) 9.6 (2.5) 
Completeness* (%) 99.4 (100.0) 99.5 (98.8) 99.1 (96.5) 
Redundancy* 12.6 (12.7) 6.9 (5.9) 6.8 (5.2) 
    
Refinement    
Resolution (Å) 36-3.70  27-2.05 
Total Reflections 2,923  25,896 
Rwork / Rfree 0.287 / 0.332  0.170 / 0.184 
Twin fraction (k,h,-l) N/A  0.424 
Number of atoms    
     Protein 1054  2223 
     Water N/A  116 
NCS deviations (Å) N/A  0.326 
Average B-factor, Å2    
     SIVmac239Nefcore   46.0 
     TCRζ polypeptide   49.2 
Waters N/A  45.2 
    
RMS deviations    
Bond lengths (Å) 0.011  0.003 
Bond angles (o) 1.326  0.564 
PDB ID code 3IOZ  3IK5 
* highest resolution shell in parentheses 
  
92
CHAPTER IV: Structure of the Nef-TCRζ complex and its role in modulation of 
Src family protein tyrosine kinase activity 
 
Abstract 
The HIV/SIV accessory factor Nef is known to target several cell surface 
receptors in an infected T cell and to alter receptor-mediated signaling pathways, but the 
structural basis for these interactions and their functional consequences are not well 
understood. Here we report the crystal structure of the complex of the conserved core 
domain of Nef from SIVmac239 bound to a polypeptide from the T cell receptor zeta 
subunit cytoplasmic domain and the effect of Nef-TCR zeta complex formation on Src 
family protein tyrosine kinase activity. The SIV Nef core domain adopts a three-
dimensional fold similar to that previously reported for HIV-1 Nef, but the T cell receptor 
polypeptide adopts a previously unobserved alpha-helical conformation. The dominant 
features of the binding interface on Nef include a basic patch and hydrophobic pocket, 
forming a novel interaction helping to explain the observed specificity for particular 
immunoreceptor tyrosine-based activation motifs.. The interaction with TCR zeta 
stabilizes the polyproline type II helix on Nef, disordered in the unliganded HIV-1 Nef 
structure, which previously has been implicated in interactions with the SH3 domain of 
the protein tyrosine kinase Fyn. In vitro phosphorylation of TCR zeta by Lck, Fyn and 
Src is enhanced in the presence of HIV-1 and SIV Nef, suggesting a functional role for 
the Nef-TCR zeta interaction in modulation of T cell signaling pathways. 
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IV.A. Introduction 
Nef is a 27-35 kDa myristylated viral accessory protein unique to HIV and SIV 
that plays a significant role in the pathogenesis of HIV and SIV infection. Although it 
lacks enzymatic function, Nef engages in a number of functions through protein-protein 
interactions that collectively enhance viral infectivity, viral replication and modulate 
immune activation (reviewed in (Arien and Verhasselt, 2008; Foster and Garcia, 2008; 
Kirchhoff et al., 2008). Notable among Nef’s functions is its association with the 
signaling components of the T cell signaling pathway, including the signaling ζ subunit 
the T cell receptor (TCRζ) and Src family protein tyrosine kinases (PTKs). Nef has also 
been reported to localize to the immunological synapse (IS) during T cell activation 
(Fenard et al., 2005; Thoulouze et al., 2006), suggesting that it may affect T cell 
activation at a very early step in the signaling pathway. However, the effect of Nef on 
TCR-mediated T cell activation has been a source of controversy with some studies 
reporting an enhancement of activation (Baur et al., 1994; Djordjevic et al., 2004; Fenard 
et al., 2005; Skowronski et al., 1993; Wang et al., 2000; Xu et al., 1999) while others 
demonstrate an inhibitory effect (Collette et al., 1996; Niederman et al., 1992; Niederman 
et al., 1993). 
T cell activation is initiated by the ligation of T cell receptors by MHC-peptide 
complexes on antigen presenting cells. Upon binding of surface TCR molecules at the IS, 
intracellular Src family PTKs such as Lck and Fyn phosphorylate tyrosine residues 
located within the immunoreceptor tyrosine-based activation motifs (ITAMs) found on 
the cytoplasmic domains of the of TCR signaling subunits γ, δ, ε, ζ. ITAMs have a 
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consensus sequence Yxx(L/I)X6-8Yxx(L/I) of which TCRζ, the primary signaling subunit 
of the TCR, contains three (ITAM 1,2,3). Phosphorylation of both tyrosines in each of the 
individual ITAMs on TCRζ results in the recruitment of the cellular kinase ZAP-70 and 
initiation of a phosphorylation cascade that culminates in full T cell activation [reviewed 
in (Smith-Garvin et al., 2009)]. 
Previous studies have demonstrated that SIV Nef binds TCRζ at two unique sites 
that include the YxxL/I motifs in ITAMs 1 an 2 (Schaefer et al., 2000) and that HIV-1 
Nef only shares the ITAM 1-binding region (Chapter II). However, the functional 
consequences of complex formation in T cell activation are undescribed. In addition, the 
structural features on Nef that determine its specificity for TCRζ remain unknown. In this 
work, we performed a detailed analysis of the crystal structure of the core domain of 
SIVmac239 Nef in complex with a TCRζ polypeptide that contains the Yxx(L/I) motif 
from ITAM 1 and investigated the role of complex formation in modulation of Src PTK 
activity. Our results reveal a novel interaction interface on Nef specific to TCRζ that is 
not shared by any of Nef's reported binding partners. In addition, the TCRζ orders the N-
terminus of Nef into a polyproline type II helix that we postulate mediates the 
enhancement of TCRζ-specific activity of Src PTKs.
  
95
IV.B. Materials and Methods 
IV.B.1. Protein expression and purification 
The cytoplasmic domain of TCRζ (residues L51-R164) and the core domain of Nef from 
SIVmac239 (residues D98-S235), HIV-1 laboratory strain NL4-3 (A56-N206) were 
expressed in E. coli and purified to >95% purity as described (Chapter II). Briefly, 
TCRζcyt and all of the Nefcore variants were expressed as thioredoxin fusion proteins and 
purified under denaturing conditions by Ni-NTA affinity chromatography. The proteins 
were then dialyzed against non-denaturing conditions and cleaved with thrombin (MP 
Biochemicals) to remove the N-terminal tag sequence. The cleaved proteins were purified 
by anion exchange (POROS HQ) and size exclusion chromatography (Superdex S-200). 
Nefcore and TCRζcyt proteins were concentrated to 700μM in PBS, pH 7.4. The TCRζ 
polypeptide TCRζA63-R80 was synthesized (21st Century Biochemicals), validated by mass 
spectrometry, and concentrated to 700μM in 20mM Tris, pH 8.0. The TCRζ polypeptide 
TCRζL71-D87 was synthesized (Sigma) with an N-terminal biotin affinity tag in 
unmodified, mono-phosphorylated (pY72 or pY83) or bi-phosphorylated (pY2, pY83) 
forms and validated by mass spectrometry. The FHIT peptide used in in vitro kinase 
experiments was purchased (Cell Signaling Technology) and validated by mass 
spectrometry. 
 
IV.B.2. Crystallization and data collection 
Crystals of SIVmac239 Nefcore in complex with TCRζA63-R80 were grown and optimized 
as described (Chapter III). Briefly, crystals of the SIVmac239 Nefcore-TCRζA63-R80 
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complex were grown over 3-7 days (approximate dimensions 400 x 150 x 150 μm) using 
the vapor diffusion method in hanging drops; 2μl of a 1:1 molar ratio of SIVmac239 
Nefcore and TCRζA63-R80 were mixed with 1μl reservoir solution (10-14% PEG 3,350, 
200mM NH4F, 100mM HEPES, pH 7.4-7.5) over a 1ml volume of reservoir solution. 
The single flash-frozen SIVmac239 Nefcore-TCRζA63-R80 crystal used for structure 
determination was orthorhombic (P212121; a = 47.417, b = 47.421, c =183.519) and 
nearly perfectly pseudo-merohedrally twinned with a twin fraction α = 0.424 (Chapter 
III). Data was collected to 2.05 Å resolution at beamline X29 at the National Synchrotron 
Light Source (NSLS) at Brookhaven National Laboratories (BNL) on a CCD detector at 
λ = 1.003 Å. The x-ray diffraction images were processed in HKL-2000 (Otwinowski 
and Minor, 1997) and assessed for quality and twinning in phenix.xtriage of the PHENIX 
software package (Adams et al., 2002). 
  
IV.2.C. Model building and refinement 
Structure determination of the SIVmac239 Nefcore-TCRζA63-R80 complex was performed 
by molecular replacement in the orthorhombic space group P212121 and is described 
extensively in Chapter III. Briefly, an ensemble of structures of the core domain of HIV-1 
Nef was used a search model to find a molecular replacement solution. Two molecules of 
Nefcore comprised the asymmetric unit and were related by non-crystallographic 
symmetry. Each molecule was refined individually in phenix.refine (Laskowski et al., 
1993); each round of refinement included three cycles of bulk solvent correction, atomic 
positional refinement and individual b-factor refinement. Following each round of 
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refinement, the data was detwinned in phenix.refine to calculate 2Fo – Fc and Fo- Fc 
electron density maps that were used to inspect and build into the model of the Nefcore-
TCRζA63-R80 complex in Coot. The TCRζA63-R80 polypeptide was built manually as an 
alpha helix with 16 of 18 residues clearly resolved in the electron density maps. Water 
molecules were added to the refined model using automated water picking procedures in 
phenix.refine. The stereochemistry of the final refined model was monitored with 
PROCHECK (Laskowski et al., 1993). 
 
IV.B.3. Surface plasmon resonance (SPR) 
SPR spectroscopy experiments were performed at 25oC on a Biacore 3000 system (GE 
Healthcare). 5000-8000 resonance units (RU) of neutravidin were coupled to a CM5 
sensor chip (GE Healthcare) in 10mM acetate buffer (pH 5.0) using standard amine 
coupling protocols as described previously (Chapter II). 25 RU of unmodified TCRζL71-
D87, mono-phosphorylated TCRζL71-D87 (pY72), mono-phosphorylated TCRζL71-D87 
(pY83) and bi-phosphorylated TCRζL71-D87 (pY72, pY83) were captured in different 
neutravidin-coupled experimental flow cells leaving one flow cell unbound as a control 
surface. Each immobilized TCRζ polypeptide was directed uniformly in an N-terminal to 
C-terminal orientation away from the neutravidin-CM5 surface due to placement of the 
biotin tag at the N-terminus. SIVmac239 Nefcore was injected at a flow rate of 30μl/min 
over each experimental flow cell and the control flow cell, generating SPR sensorgrams. 
The sensorgram from the control neutravidin-only flow cell was subtracted from the 
experimental neutravidin-bio-TCRζ polypeptide flow cell sensorgram (reference 
  
98
subtraction), generating a resultant Nef binding sensorgram that described the specific 
binding of Nef for the captured TCRζ polypeptide and removed any nonspecific 
interaction with the CM5 or neutravidin surface.  
 
IV.B.4. In vitro kinase assay 
Phosphorylation of the biotinylated FHIT substrate peptide (Cell Signaling Technology) 
(Pekarsky et al., 2004) by Src family protein tyrosine kinases (PTK) was assessed in the 
absence and presence of HIV-1 NL4-3 and SIVmac239 Nefcore using a modified protocol 
of the HTScan Lck Kinase Assay Kit (Cell Signaling Technology). FHIT peptide 
(1.5μM) was pre-incubated in an equimolar ratio with either HIV-1 NL4-3 Nefcore or 
SIVmac239 Nefcore in the kinase assay buffer (60mM HEPES, 5mM MgCl2, 5mM 
MnCl2, 3μM Na3VO4, 1.25mM DTT, 20μM ATP, pH 7.5) for 30 minutes at 25oC. 
Following the pre-incubation period, Lck (Cell Signaling Technology), Fyn (Invitrogen) 
or c-Src (Invitrogen) was added to each reaction volume (25μl) to a final concentration of 
12nM; each reaction mixture was immediately incubated for 0, 15, 30, 60 or 120 minutes 
at 37oC. The reaction mixtures were quenched by the addition of 25μl of 50mM EDTA, 
transferred to 96-well streptavidin-coated black plates (Pierce) and incubated at room 
temperature for 1 hour. Each well was washed three times with PBS + 0.05% Tween-20 
(PBS-T) and then incubated with a mouse anti-phosphotyrosine monoclonal antibody 
(Cell Signaling Technology) for 1 hour at room temperature. Following triplicate washes 
with PBS-T, each well was incubated with FITC-conjugated goat anti-mouse antibody 
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(BD Biosciences) for 30 minutes at room temperature. After triplicate washes in PBS-T, 
FITC fluoresence was measured on a FLUOstar OPTIMA (BMG) microplate reader. 
 
IV.B.4. In vitro TCRζ phosphorylation assay 
Phosphorylation of the cytoplasmic domain of TCRζ by Src family PTKs was assessed in 
the absence and presence of Nefcore proteins from HIV-1 NL4-3 and SIVmac239 by SDS-
PAGE. TCRζcyt (7.5μM) was pre-incubated alone and with each Nefcore protein for 30 
minutes at 4oC in the kinase assay buffer (60mM HEPES, 5mM MgCl2, 5mM MnCl2, 
3μM Na3VO4, 1.25mM DTT, 20μM ATP, pH 7.5). Lck (Cell Signaling Technology), 
Fyn (Invitrogen) or c-Src (Invitrogen) was added to each reaction volume (25μl) to a 
final concentration of 12nM; each reaction mixture was immediately incubated for 0, 15, 
30, 60 or 120 minutes at 37oC and quenched with 25μl 50mM EDTA. TCRζcyt 
phosphorylation was analyzed by SDS-PAGE and gel band analysis was performed in 
Quantity One (Bio-Rad). 
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IV.C. Results 
IV.C.1. Overall structure of the SIVmac239 Nefcore-TCRζA63-R80 complex 
 The structure of SIVmac239 Nefcore bound to TCRζA63-R80 was determined to 2.05 
Å by molecular replacement and twinned refinement procedures. The overall structure of 
the SIVmac239 Nefcore-TCRζA63-R80 complex (Figure IV-1A) exhibits significant 
structural conservation in the Nefcore protein and novel structural features on the TCRζ 
polypeptide. SIVmac239 Nefcore adopts a similar α/β fold to the core domain of HIV-1 
Nef as previously observed in the crystal structures of HIV-1 isolate LAI Nefcore (L58-
C206), SH3 domain-bound HIV-1 isolate LAI Nefcore (Arold et al., 1997) and SH3 
domain-bound HIV-1 laboratory strain NL4-3 Nefcore (A54-N205) (Lee et al., 1996) 
(Figure 1C) as well as the NMR solution structure of HIV-1 isolate BH10 (Δ2-39, Δ159-
173, T71R) Nef (Grzesiek et al., 1996a). The structural similarity is expected considering 
the significant sequence conservation observed for this region on Nef (Figure IV-1C). 
Superimposition of the SIVmac239 Nefcore structure with the crystal structures of HIV-1 
Nef (Figure IV-1B) results in a only small deviation in Cα coordinate position with an 
overall root mean square deviation (r.m.s.d.) of 0.65 - 0.89 Å. 
 The N-terminal region (R103-R109) is ordered in a left-handed polyproline type 
II (PPII) helical conformation as observed in the SH3 domain-bound forms of HIV-1 Nef 
(Arold et al., 1997; Lee et al., 1996). The PPII helix is followed by two large anti-parallel 
α-helices (α1, Y113-E125; α2 A136-E150) connected by a 10 residue loop (K126-S135) 
that collectively form the TCRζ-interacting region on Nef. The remainder of the core  
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Figure IV-1. Structure of the SIVmac239 Nefcore-TCRζ63-80 complex. A. Ribbon 
diagram of SIVmac239 Nefcore in complex with TCRζ63-80 polypeptide. B. Secondary 
structure alignment of Nef. Crystal structures of Nefcore were superimposed by least-
squares fitting of the folded core (V103-V181 for SIVmac239 Nef). Unliganded HIV-1 
LAI Nefcore (PDB code 1AVV) is colored cyan, SH3 domain-bound HIV-1 NL4-3 Nefcore 
(PDB code 1EFN) is purple and TCRζ63-80-bound SIVmac239 Nefcore is grey. C. Primary 
structure alignment of Nef. Residue numbering corresponds to SIVmac239 Nef. Identical 
residues are boxed and shaded in red and partially conserved residues are boxed and in 
pink. Secondary structure elements observed in SIVmac239 Nefcore (above sequence) and 
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HIV-1 NL4-3 Nefcore (below sequence) are denoted by curls for alpha helices (α1-α4) 
and arrows for beta strands (β1-β2) with loop regions denoted by gray lines. D. Primary 
structure alignment of TCRζ. The full length sequence of human and rhesus macaque 
TCRζ are shown with transmembrane region and ITAMs denoted in orange and green, 
respectively. Secondary structure elements observed for human TCRζ are denoted by 
curls for alpha helices and grey lines for loops.  
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domain consists of a pair of anti-parallel β strands (β1, W175-P180; β2, L211-F215) that 
form the bulk of the hydrophobic core of the protein and a pair of smaller α-helices (α3, 
P217-A220; α4, E224-R228) found near the C-terminus. The β strands do not form a 
contiguous β-sheet due to the structural distortion caused by two well conserved proline 
residues (P168, P179) in addition to the limited number of residues that participate in 
hydrogen bonding; a similar distortion of β-sheet topology is observed in the structures of 
HIV-1 Nef (Arold et al., 1997; Lee et al., 1996). A large loop (N181-H196) between β1 
and β2 is absent in the crystal structure due to significant disorder in that region as 
previously described for HIV-1 Nef (Arold et al., 1997; Grzesiek et al., 1997; Lee et al., 
1996). Although there are 11 extra residues built into the disordered region compared to 
the HIV-1 Nef structures, they are likely ordered due to crystallization artifact and 
therefore do not represent physiologically relevant structure (Chapter III). 
The majority of the TCRζ polypeptide adopts alpha helical structure. Of the 16 
residues (A63-G78) resolved in the calculated electron density (Figure IV-2B), 13 
residues (A63 - L75) comprise the alpha helix and 3 residues (N76-G78) form a loop at 
the C-terminus. The N-terminus of the alpha helix lies proximal to the N-terminus of Nef, 
suggesting that the TCRζ polypeptide is oriented in a physiologically relevant direction 
in the crystal structure. The alpha helical conformation of the TCRζ polypeptide is 
striking considering the largely disordered nature of the cytoplasmic domain of TCRζ 
(Duchardt et al., 2007; Laczko et al., 1998; Sigalov et al., 2004) and the lack of secondary 
structure observed previously for the ITAM 1 region (69-86) (Laczko et al., 1998).  
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Figure IV-2. Interaction between SIVmac239 Nefcore and TCRζ63-80. A. Electrostatic 
surface representation of Nef with bound TCRζA63-80. Positively charged regions are 
colored blue, negatively charged are colored red and neutral regions are colored white. 
ITAM 1 residue Y72 and the basic patch and hydrophobic pocket on Nef are indicated by 
arrow. The TCRζ polypeptide is drawn in ribbon diagram (green). B 2Fo-Fc electron 
density map of TCRζ63-80 countered at α=1.0. Surface representation of Nef is shown in 
grey. B. Salt bridge between SIVmac239 Nefcore (grey) and TCRζ63-80 (green). The 
possible hydrogen bonds between residue E74 on Nef and residues R137 and R138 on 
TCRζ are denoted by black dashed lines. C. TCRζ63-80 binds to a hydrophobic pocket on 
SIVmac239 Nef. Residues L75 and L77 on TCRζ (green) are buried in a hydrophobic 
pocket on Nef. Residues lining the pocket are labeled in grey.  
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Therefore, the TCRζA63-R80 polypeptide seems to undergo a disorder-to-order transition 
upon binding its Nefcore interaction partner. 
The accessible surface area of the unbound forms of SIVmac239 Nefcore and 
TCRζA63-R80 are 7655.9 Å2 and 1672.7 Å2, respectively. In the bound complex, the 
TCRζA63-R80 polypeptide occupies a hydrophobic crevice on Nef bordered by alpha 
helices α1 and α2. This results in a total buried surface area at the binding interface of 
1313.9 Å, with 595.6 Å2 and 718.3 Å2 contributed by Nefcore and TCRζ, respectively.  
 
IV.C.2. Specificity of the Nef-TCRζ interaction 
 The specificity of the TCRζA63-R80 polypeptide for Nefcore is conferred through a 
novel set of electrostatic and hydrophobic interactions (Figure IV-2). At the N-terminus 
of the α2 alpha helix on Nefcore, a glutamic acid on TCRζ (Ε74) forms a salt bridge with 
a positively charged patch on Nef consisting of two adjacent arginine residues (R137, 
R138) (Figure IV-2C). The di-arginine motif is highly conserved among the different Nef 
variants from HIV-1, HIV-2 and SIV and has been suggested to be important for 
affecting PAK1/2 function (Fackler et al., 2000; Sawai et al., 1995). However, a direct 
protein-protein interaction mediated by the diarginine motif on Nef has not been 
described previously. 
 The TCRζA63-R80 polypeptide also binds to an extensive hydrophobic surface on 
Nefcore formed by the C-terminus of α1, the N-terminus of α2 and the α1-α2 loop. 
Residues L75 and L77 on TCRζ are buried in a deep hydrophobic pocket lined by 
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residues I123, L129, L132, I141, L142, W173, W213 on Nef (Figure IV-2C). In addition, 
the first ITAM 1 YxxI/L tyrosine (Y72) rests on a cleft contiguous with the hydrophobic 
pocket that almost completely buries the hydroxyl group (Figure IV-2A). Summarized in 
Table IV-1 are the residues present at the Nef-TCRζ interface. 
 The electrostatic and hydrophobic contacts collectively explain the observed 
specificity of Nef for TCRζ among ITAM-containing proteins and specifically for the 
A61-R80 and E121-G140 regions on TCRζ observed to bind SIV Nef (Chapter II). The 
only two ITAM regions that satisfy the binding requirement for a tyrosine, negatively 
charged residue and two neutral residues (i.e. YxELxL) are the regions described 
previously to comprise SNID-1 (72-YNELNL-77) and SNID-2 (123-YSEIGM-128) 
(Schaefer et al., 2000). Therefore, it is likely that SIV Nef binds to the SNID-2 binding 
site in the same manner observed for SNID-1 binding in the crystal structure. 
 We demonstrated in Chapter II that HIV-1 Nef additionally bound TCRζ but only 
at the ITAM 1 region. Curiously, the only significant differences in the two binding 
sequences on TCRζ are the substitutions of two leucines (L75, L77) with an isoleucine 
(I126) and a methionine (M128) in the ITAM 2 binding site. Although the majority of 
residues on Nef surrounding L75 and L77 on TCRζ are highly conserved in HIV-1 Nef 
(Table IV-1), the isoleucine at residue position 123 in SIV Nef is substituted by a leucine 
(L92) in HIV-1 Nef which may serve as a determinant of TCRζ specificity. However, the 
precise mechanism by which the isoleucine-leucine substitution may reduce HIV-1 Nef’s 
interaction with the second ITAM binding region is unclear and will require further 
investigation. 
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IV.C.3. Phosphorylation of ITAM 1 residue Y72 abrogrates Nef binding 
 In the structure of the Nefcore-TCRζA63-R80 complex, the first YxxI/L motif 
tyrosine (Y72) in ITAM 1on TCRζ is partially buried on Nef. The close proximity of the 
hydroxyl group of Y72 on TCRζ and the interfacing side chain of residue E149 on Nef 
suggests that Nef (Figure IV-3A) would not be able to spatially nor electrostatically 
accommodate a negatively charged phosphorylation modification on Y72. Alternatively, 
phosphorylation of Y72 would not be expected to permit binding of Nef. In order to 
determine the effect of phosphorylation on Nef binding, SPR binding studies were 
performed using differentially phosphorylated TCRζ ITAM 1 peptides. Following 
immobilization of unphosphorylated (Y72, Y83), mono-phosphorylated (pY72 or pY83) 
and bi-phosphorylated (pY72, pY83) forms of the ITAM 1 TCRζ polypeptide (L710-
D87), SIVmac239 Nefcore was injected and binding sensorgrams were recorded. Shown in 
Figure IV-3B, the interaction of SIVmac239 Nef with ITAM 1 on TCRζ is abrogated 
when Y72 is phosphorylated, either alone or in combination with pY83. However, since 
phosphorylation of Y83 alone had no effect on Nef binding, phosphorylation of Y72 was 
the primary cause for disruption of Nef binding.  
 
IV.C.4. Interaction with TCRζ orders the SH3 binding motif on Nef 
 Nef contains several structurally disordered regions, including the N-terminus, C-
terminus and internal β1-β2 loop, that are not observed in the crystal (Arold et al., 1997) 
and NMR solution (Grzesiek et al., 1996a; Grzesiek et al., 1997) structures of HIV-1 Nef.  
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Figure IV-3. Phosphorylation of ITAM1 residue Y72 disrupts Nef binding. A. 2Fo-Fc 
electron density map at α=1.0 for the Nef-TCRζ interface region at residue Y72 on TCRζ 
is shown. TCRζ is depicted in green and SIVmac239 Nefcore is depicted in grey. B. SPR 
sensorgrams of the interaction of SIVmac239 Nefcore and differentially-phosphorylated 
ITAM 1 peptides. ITAM1 (Y72-L86) is denoted by a boxed outline and phosphorylation 
modification on residues Y72 and Y83 are marked with an encircled “P”. 
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One such region near the N-terminus of the core domain includes a PxxP motif (P104-
P107) that is disordered in the unliganded HIV-1 Nef structure but folds into a well 
ordered left-handed polyproline type II helix in SIV Nef when bound to TCRζA63-R80. 
Interestingly, the PPII helix is ordered by the bidentate hydrogen bonding of the terminal 
amide residues on Q65 of TCRζ with the main chain amide atoms on S103-R103 (Figure 
IV-4). A similar main chain torsional restraint resulting in induced PPII helix 
comformation has been observed previously for peptides bound to MHC molecules 
(Jardetzky et al., 1996). The homologous region on HIV-1 has also been observed to dopt 
a near identical PPII helix conformation when bound to the SH3 domain of Fyn (Arold et 
al., 1997; Lee et al., 1996). The PPII helix on Nef has been suggested to enhance the 
activity of Src PTKs by displacing the SH3 domain thus relieving the auto-inhibitory 
intramolecular constraints in the PTK (Lee et al., 1996; Moarefi et al., 1997). 
 
IV.C.5. Enhancement of TCRζ phosphorylation by Nef 
 In order to investigate the potential role of Nef-TCRζ complex formation on 
modulation of Src PTK activity, in vitro phosphorylation studies were performed. First, 
the effect of Nef on Src PTK activity was studied with the core domains of HIV-1 NL4-3 
and SIVmac239 Nef and a Src substrate peptide from FHIT (Pekarsky et al., 2004) that 
contains a single tyrosine susceptible to modification byt phosphorylation by Src PTKs.  
By observing the effect of Nef on the phosphorylation of a random Src PTK substrate not 
observed to interact with Nef (data not shown), the effect of Nef on Src PTK activity  
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Figure IV-4. TCRζ orders a PPII helix at the N-terminus of Nef. SIVmac239 Nefcore 
(grey) and TCRζ (green) are shown in ribbon diagram. The side chain-main chain 
hydrogen bonding network between Q65 (TCRζ) and S101, R103 (Nef) is illustrated by 
dashed black lines. 
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could be determined in a substrate-independent manner. HIV-1 NL4-3 and SIVmac239 
Nefcore were pre-incubated with the test FHIT peptide for 30 minutes after which the Src 
PTKs Lck, Fyn and Src were added independently. Shown in Figure IV-5, both HIV-1 
and SIV Nefcore significantly increased the amount of detected phosphorylated peptide at 
earlier time points for Lck as compared to Lck alone. In addition, HIV-1 NL4-3 Nefcore 
exhibited an enhancing effect on Src activity that exceeded SIVmac239 Nefcore effects. In 
contrast, Nefcore had either no effect (SIVmac239) or a small inhibitory effect (HIV-1 
NL4-3) on Fyn activity, respectively. Therefore, Nef appears to be capable of modulating 
Src PTK activity but exerts different effects specific to each kinase and Nef type. 
Furthermore, HIV-1 Nef is observed to enhance activity of Lck, contrary to a previous 
report (Greenway et al., 1996). 
 In order to explore the effect of Nef on TCRζ-specific Src PTK activity, the test 
peptide was replaced with purified TCRζcyt in the phosphorylation experiments. Due to 
the presence of six possible phosphorylation sites on TCRζcyt, and high percentage SDS-
PAGE gel mobility assay was used to evaluate the initiation and extent of 
phosphorylation on TCRζcyt. Previous studies have demonstrated that the mobility of 
TCRζcyt is reduced upon phosphorylation at each tyrosine due to the addition of negative 
charge on the protein by the phosphate modification and that all phosphorylated states 
(P1-P6) of TCRζcyt can be visualized by gel electrophoresis (Weissenhorn et al., 1996). 
However, due to the multiple phosphorylated states TCRζcyt, quantitative analysis of the 
unphosphorylated TCRζcyt protein gel band was performed to assess initiation of kinase  
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Figure IV-5. Modulation of in vitro Src PTK activity by Nefcore. Biotinylated FHIT 
peptide was incubated with or without SIVmac239 Nefcore or HIV-1 NL403 Nefcore for 
varying times in the presence of Lck, Fyn and Src. The phosphorylation reaction was 
quenched with 50mM EDTA. Quantity of phosphorylated peptide was detected by anti-
phosphotyrosine antibody ELISA. 
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activity; as TCRζcyt becomes phosphorylated, the amount of unmodified protein will 
decrease.  
In the absence of Nef, TCRζcyt was readily phosphorylated by Lck into multiple 
phosphorylated species early in the time course (Figure IV-6). By two hours, over 40% of 
the TCRζcyt protein was phosphorylated. In contrast, more mild activity was observed by 
Fyn and Src (Figure IV-6 A); at two hours, ~30% of the TCRζcyt protein was 
phosphorylated. However, in the presence of SIVmac239 Nefcore, TCRζcyt was more 
rapidly phosphorylated and to higher phosphorylated species by all of the Src PTKs and 
especially by Fyn and Src, leaving less than 30% unmodified TCRζcyt after two hours. 
HIV-1 NL4-3 Nefcore also augmented phosphorylation of TCRζcyt by all of the Src PTKs 
but to a lesser extent than that observed for SIVmac239 Nefcore with the exception of Lck. 
SIVmac239 Nefcore was also observed to migrate to a higher gel band indicating 
that the Src PTKs additionally phosphorylated Nefcore. In contrast, HIV-1 NL4-3 was not 
observed to become phosphorylated in the presence of Src PTKs,  confirming a previous 
report demonstrating that SIV Nef and not HIV-1 Nef was susceptible to modification by 
Lck (Cheng et al., 1999). Surprisingly, phosphorylation of SIVmac239 Nefcore in the 
reaction mixture including TCRζcyt was markedly increased as compared to when 
SIVmac239 Nefcore was incubated with Lck or Fyn alone (Figure IV-7). Incubation of 
SIVmac239 Nefcore with Src resulted in the generation of multiple differentially migrating 
gel bands suggesting multiple phosphorylated forms. In the reaction mixtures including 
TCRζcyt, these multiply phosphorylated Nef gel bands reduced to one, suggesting that the  
  
114
 
Figure IV-6. Modulation of TCRζcyt phosphorylation. A. SDS-PAGE analysis of 
TCRζcyt phosphorylation by Src PTKs. TCR cyt was incubated with Src PTKs in the 
absence or presence of SIVmac239 Nefcore and HIV-1 NL4-3core for 0, 5, 30 and 120 
minutes and then analyzed by 16% SDS-PAGE. Molecular weight positions are denoted  
on left and gel migration levels correlating to phosphorylated (TCRζcyt-P, Nefcore-P) and 
unphosphorylated (TCRζcyt, Nefcore) proteins are shown on right. B. Quantitaive analysis 
of unphosphorylated TCRζcyt. The gel band corresponding to the unphosphorylated 
TCRζcyt protein was intergrated for each reaction time point in Quantity One (Bio-Rad) 
and divided by the zero time point gel band generate the % unphosphorylated TCRζcyt 
values plotted. 
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Figure IV-7. Phosphorylation of  HIV-1 and SIV Nefcore by Src PTKs. SDS-PAGE 
analysis of Nefcore phosphorylation by Src PTKs. Nefcore from HIV-1 NL4-3 and 
SIVmac239 were ncubated with Src PTKs for 0, 5, 30 and 120 minutes and then analyzed 
by 16% SDS-PAGE. Molecular weight positions are denoted on left and gel migration 
levels correlating to phosphorylated (Nefcore-P) and unphosphorylated (Nefcore) Nefcore are 
shown on right. 
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Nef-TCRζ complex directed the phosphorylation of SIVmac239 to a single 
phosphorylated start species. 
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IV.D. Discussion 
Here we report the high resolution crystal structure of SIVmac239 Nefcore in 
complex with a TCRζ polypeptide and the investigation of the potential role of Nef-
TCRζ complex formation in the modulation of TCRζ-specific phosphorylation by Src 
PTKs. The structure of the Nefcore-TCRζ complex reveals that the core domain of 
SIVmac239 Nef adopts a similar fold to that observed for HIV-1 Nef (Arold et al., 1997; 
Grzesiek et al., 1997; Lee et al., 1996). Strikingly, the TCRζ polypeptide, which contains 
the N-terminal YxxL/I motif in ITAM 1, adopts an alpha helix in the Nef-bound form 
that partially buries the first tyrosine in ITAM 1 (Y72) in Nef. The presence of secondary 
structure in the Nef-bound TCRζ polypeptide refutes our previous assertation that 
TCRζcyt does not undergo a disorder-to-order transition upon binding SIVmac239 
Nefcore,. This conclusion was based on the lack of observed chemical shift changes and 
changes in cross-peak intensity between the HSQC spectra of TCRζcyt alone and in the 
presence of SIVmac239 Nefcore (Sigalov et al., 2008). However, no chemical shift 
changes were observed, including those that should have corresponded to the known 
binding sites on TCRζ. We therefore suggested that the observed lack of changes in the 
HSQC spectra of TCRζ in its free and Nef-bound state could be explained by the 
multivalency of TCRζ for Nef where each binding site could be bound or unbound at any 
point in the experiment (Sigalov et al., 2008). While this possibility may explain the 
discrepancy in the NMR and crystallography findings, a more detailed investigation will 
need to be performed. 
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 Crystal structures of TCRζ peptides in complex with other binding partners have 
been described previously (Hatada et al., 1995; Nam et al., 2005). However, none of the 
crystallized TCRζ peptides adopt significant secondary structure in their bound states, 
including the ZAP-70-bound ITAM 1 polypeptide (Q69-D87, pY72, pY83) that contains 
an overlapping sequence (D69-R80) with the TCRζA63-R80 polypeptide used in our 
studies. Therefore, the induction of secondary structure in TCRζ by Nef represents a 
novel mechanism by which TCRζ binds to a protein interaction partner. 
 The structural features on Nef that determine its specificity for the TCRζ form a 
novel interaction surface that includes a highly conserved diarginine motif (R137, R138) 
and a hydrophobic pocket that accommodates residues L75 and L77 on TCRζ. The 
diarginine motif has been suggested to be important for affecting PAK1/2 function 
(Fackler et al., 2000; Sawai et al., 1995), however direct bimolecular binding studies have 
not been performed. PAK1/2 may therefore share specificity to the diarginine motif with 
TCRζ or may alternatively cooperatively participate in the formation of a ternary 
complex with Nef and TCRζ. HIV-1 Nef’s interaction with PAK1/2 has been associated 
with the recruitment of PAK1/2 to lipid rafts (Krautkramer et al., 2004) where Nef is 
suggested to prime the T cell for activation (Wang et al., 2000). Interestingly, HIV-1 Nef 
has also been demonstrated recently to increase the association of TCRζ with lipid rafts 
(Djordjevic et al., 2004) further suggesting that Nef may be serving as an adaptor protein 
between PAK1/2 and TCRζ. 
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 In the crystal structures of the complex of HIV-1 Nefcore with the SH3 domain of 
Fyn (Arold et al., 1997; Lee et al., 1996), the N-terminus of Nef is ordered in a left-
handed polyproline helix that is otherwise disordered in the unliganded Nef protein. The 
ordered PPII helix has been suggested to play a vital role in binding SH3 domains but 
more importantly, in activating Src PTKs (Moarefi et al., 1997). In the structure of the 
SIVmac239 Nefcore-TCRζ complex, the N-terminus is strikingly ordered in the same PPII 
conformation observed for SH3 domain-bound HIV-1. Therefore, we postulate that 
binding of TCRζ to Nef facilitates the formation of a ternary complex with Src PTKs that 
is mediated by TCRζ-induced ordering of the PPII helix on Nef. In turn, binding of Src 
PTKs with Nef would be expected to enhance the binding of TCRζ. The functional 
outcome would be expected to be enhanced kinase activity specific to TCRζ. A similar 
cooperative model has been proposed for the association of HIV-1 Nef, the cytoplasmic 
tail of CD4 and Hck but the functional effects of complex formation is unknown 
(Grzesiek et al., 1996b). 
Our results demonstrate that TCRζ phosphorylation is significantly enhanced in 
the presence of HIV-1 and SIV Nefcore. The effect was most significant with the Src 
PTKs Fyn and Src and less with Lck which exhibited inherent elevated activity on TCRζ. 
The hyperactivation of Fyn is of particular importance considering its reduced functional 
role in T cells. Although both present in T cells and capable of phosphorylating TCRζ, 
Lck and Fyn differ in the kinetics of their activity where Lck activity peaks early 
following TCR stimulation and Fyn activity lags behind [(Filipp et al., 2003), reviewed in 
(Palacios and Weiss, 2004)]. In addition, Fyn was found to be either inactive (Filipp et 
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al., 2003) or to induce dysregulated T cell signaling patterns that led to markedly reduced 
Il-2 secretion (Denny et al., 2000) in Lck-deficient T cells. Therefore, hyperactivation of 
Fyn by the Nef-TCRζ complex may restore functionally competent kinase activity. 
Surprisingly, increased basal Fyn activity has been closely linked to its increased 
localization to lipid rafts (Filipp et al., 2004) where HIV-1 Nef has been demonstrated to 
also localize to affect T cell activation (Djordjevic et al., 2004; Fenard et al., 2005; 
Krautkramer et al., 2004).  
 The functional outcome of increased TCRζ phosphorylation mediated by the 
enhancement of Src PTK activity by the Nef-TCRζ complex would be expected to be an 
increase in T cell activation. However, studies of Nef-transfected cells and Nef-
transgenic mice have demonstrated that Nef can induce both hyperactivation and 
inhibition of T cell activation (Table I-2). Although this is likely the result of Nef’s many 
other effects in T cells, it may also come from Nef’s effect on TCRζ phosphorylation. 
Phosphorylation of the six ITAM tyrosines results in full activation of a T cell following 
stimulus through the TCR. However, partial phosphorylation of the TCRζ ITAMs has 
been demonstrated to not only reduce T cell signaling but to additionally suppress T cell 
activation (Kersh et al., 1999). The primary mediator of the suppressive outcome was the 
phosphorylated state of the N-terminal ITAM 1 YxxL/I motif tyrosine (Y72). In studies 
where each successive ITAM tyrosine was mutated to a phenylalanine, the mutation 
observed to have a functional effect was Y72 which when mutated, resulted in 
significantly reduced IL-2 secretion. In the Nef-bound state, Y72 on TCRζ is partially 
buried and likely inaccessible to free kinases. In addition, when Y72 is phosphorylated, 
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Nef binding activity was abolished. However, the accessibility of Y72 in a ternary 
complex including Lck, Fyn or Src is unknown. Therefore, depending on the bound state 
of Nef on TCRζ and the accessibility of Y72 to Src PTKs, Nef could potentially have an 
enhancing or suppressive effect on T cell activation. However, more detailed 
characterization of the effect of Nef-TCRζ complex formation on T cell activation will 
need to be pursued to clarify the discrepancy in Nef’s reported effects on T cell 
activation.
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Table IV-1. Residues involved in the Nef-TCRζ63-80 interaction 
TCRζ SIVmac239 Nef HIV-1 ELI Nef* HIV-2 ST Nef* 
Y64 K148 N117 K147 
 
Q65 
 
 
S101 
V102 
R103 
P70 
V71 
R72 
P100 
V101 
T102 
 
Q68 K148 N117 K147 
 
L71 I141 
I144 
L110 
L113 
V140 
L141 
 
Y72 I141 
I144 
Y145 
E149 
L110 
L113 
W114 
T118 
V140 
L143 
W144 
E148 
 
E74 
 
R137 
R138 
K106 
R107 
R136 
R137 
 
L75 
 
 
 
L129 
I141 
L142 
W213 
L98 
I110 
L111 
W182 
I129 
V140 
L141 
W212 
 
L77 I123 
L129 
I132 
L142 
W173 
L92 
L98 
L101 
L111 
W142 
I122 
I128 
L131 
L141 
W172 
 
* Residues are listed based on sequence homology to SIVmac239 Nef 
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CHAPTER V: Discussion 
 
HIV and its orthologous counterpart SIV encode a limited number of proteins but 
it is becoming more apparent that each protein engages in a number of activities that 
collectively enhance viral fitness in the infected host. For naturally infected nonhuman 
primates, viral fitness equates to commensal survival whereas in human hosts it leads to 
rampant viral production and increased susceptibility to fatal outcome. Recently, 
Schindler et al. suggested that downregulation of the T cell receptor was a prominent 
feature of nonpathogenic SIV infection and that the capability of the viral accessory 
protein Nef to suppress T cell activation was lost during the zoonotic transfer of SIV to 
HIV-1 (Schindler et al., 2006). This thesis was directed towards enhancing our 
knowledge of the interaction of Nef with the T cell receptor ζ subunit, elucidating the 
lentiviral type-dependency on the interaction and to exploring its potential effects on T 
cell activation.  
  
Conservation of TCRζ binding 
 Stimulation through the T cell receptor by exogenous stimuli results in TCR 
downregulation as part of the normal T cell response. SIV hijacked this feature of the T 
cell activation pathway through the viral accessory protein Nef that catalyzes TCR 
downregulation through the cooperative binding of the clathrin associated protein AP-2 
and TCRζ, a function not shared by HIV-1 Nef. Chapter II demonstrated that HIV-1 Nef 
binds to the cytoplasmic domain of TCRζ despite its inability to downregulate TCR 
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surface expression in T cells and that the binding activity was mediated by the core 
domain that is highly conserved among HIV-1, HIV-2 and SIV isolates. However, HIV-1 
Nefcore only bound an ITAM 1 region on TCRζ and with the lowest calculated affinity 
among the Nef proteins. HIV-2 and SIV Nef bound to the same ITAM 1 region but also 
bound a second site on TCRζ containing elements of ITAM 2. Chapter IV reported the 
structure of the core domain of SIV Nef bound to a polypeptide spanning the shared 
ITAM 1-binding site on TCRζ and revealed that the binding interface on Nef specific to 
TCRζ lies on a well-conserved face of the Nef protein (Figure V-1). This provides the 
structural basis for the conservation of TCRζ-binding by HIV-1, HIV-2 and SIV Nef. 
Furthermore the structural features on Nef and TCRζ revealed to form a novel interaction 
surface not shared by Nef’s other binding partners. Therefore, guided by the structure, 
mutagenesis experiments can now be performed to further understand the fine details of 
the Nef-TCRζ interaction and to provide further insight into the observed differences in 
affinity and specificity observed for HIV-1 and SIV Nef.  
 The retention of TCRζ-binding ability by HIV-1 Nef, despite its lost ability to 
downregulate the TCR, suggests that Nef likely mediates other functions at the TCR 
outside its downregulation. The most attractive activity would be modulation of TCR-
mediated T cell activation which HIV-1 Nef has been reported to have varying effects on 
(Table I-2). In addition, highly pathogenic variants of SIV Nef carrying ITAM-like 
sequences have been demonstrated to have significant effects on T cell activation and 
virulence presumably through its association with components of the T cell signaling  
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Figure V-1. Conservation in the TCRζ and SH3 domain binding interface on Nef. 
Surface representation of SIVmac239 Nefcore. Divergent residues not conserved among 
HIV-1, HIV-2 and SIV Nef are shaded blue. TCRζ (green) and the SH3 domain of Fyn 
(purple) are shown in ribbon diagram. Residues P104 and P107 (of the PxxP motif) are 
denoted by arrow. 
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machinery (Dehghani et al., 2002; Hodge et al., 1998; Lafont et al., 2003; Luo and 
Peterlin, 1997; Xu et al., 1999).Whether HIV-1 Nef may also affect T cell signaling in a 
similar role is unclear but it is evident that SIV and HIV-1 Nef not only share sequence 
conservation, but more structural and functional conservation than previously thought. 
 
Crystal Twinning and Structure Determination 
 Structure determination of protein-protein complexes provides unique insight into 
the fine details that determine the specificity of an interaction. However, complications 
with crystallization and structure determination can occur and are often detrimental. In 
Chapter III, the methods employed to determine the high and low resolution structures of 
the core domain of SIVmac239 Nef in complex with two different length TCRζ 
polypeptides are described. The structure determination of the high resolution structure 
was complicated by the presence of twinning in the crystal that was likely caused by the 
use of a truncated polypeptide ligand. However, systematic analysis of the x-ray 
diffraction data and identification of pseudo-merohedral twinning allowed for the 
determination of the structure of the SIVmac239 Nefcore-TCRζcyt complex to 2.05 Å 
resolution. Although crystal twinning has generally been considered a crystal pathology, 
the twinning caused by the fortuitous reduction in symmetry of tetragonal crystal form to 
an orthorhombic form likely played a role in the significantly enhanced resolution of the 
diffraction data as has been suggested for other cases (Yeates, 1997). Therefore, crystal 
twinning can be of benefit towards structure determination and should not be equated 
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with poor data quality. This work highlights the significant advances in crystallographic 
structure determination methods and provides a unique case of “twinning gone good”. 
 
The role of Nef-TCRζ complex formation on Src PTK activiity 
 The ζ subunit of T cell receptor serves as the primary mediator of signal 
propagation at the cell membrane. Therefore, the formation of a Nef-TCRζ complex has 
multiple implications ranging from activating the T cell signaling pathway through the 
recruitment Src PTKs to inhibiting the T signaling pathway by sequestering ITAM 
tyrosines important for activation. The structure of SIVmac239 Nefcore in complex with 
the ITAM 1 YxxL/I motif-containing TCRζ polypeptide described in Chapter IV 
suggests that both scenarios are conceivable and could lead to differential modulation of 
T cell activation. Based on the surprising ordering of the N-terminus of Nef into a PPII 
helix known to confer specificity to SH3 domains found in Src family kinases, a model 
for the ternary complex of Nef, TCRζ and a Src family kinase (i.e. Lck) as it exists at the 
cell membrane is presented (Figure V-2). The binding interface on Nef for TCRζ and the 
SH3 domain do not overlap and are accommodated by a single Nef molecule. In addition, 
the binding surfaces for TCRζ and the SH3 domain are well conserved among the Nef 
proteins from HIV-1, HIV-2 and SIV (Figure V-1) suggesting that the formation of a 
Nef-TCRζ-Src PTK complex is expected to be a conserved property of Nef proteins from 
all lentiviral subtypes. However, the order and kinetics of complex formation exhibited 
by Nef from HIV-1, HIV-2 and SIV both in vitro and in T cells is unknown. A simplified 
model of Nef’s activity on TCRζ is presented Figure V-3. 
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Figure V-2. Model of the Nef-TCRζ-Src PTK ternary complex at the cell 
membrane. Nef (grey), TCRζ polypeptide (green) and Src PTK (red) are represented in 
cartoon format oriented with their N-termini facing the inner leaflet of the cell membrane.  
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Figure V-3. Model of Nef activity on TCRζ. Successive steps in complex formation 
leading to downregulation and modulation of T cell activation are shown. All of the 
binding events occur at the cell membrane. Nef (grey), TCRζ (green) and Src PTK SH3 
domain (blue) are represented in ribbon diagram. 
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In the model, Nef is able to first bind the SH3 domain of Src PTKs or TCRζ. By 
binding Src PTKs, Nef may either have a direct effect on PTK activity (right) a substrate 
other than TCRζ. Alternatively, binding of Src PTKs may order the N-terminal PxxP 
loop into a PPII helix thus ordering the Nef-PTK complex into a TCRζ-receptive 
conformation. This results in the cooperative binding of TCRζ and ternary complex 
formation. Rapid phosphorylation of TCRζ ensues leading to modulation of T cell 
activation. Depending on the phosphorylated state of TCRζ, T cell activation could be 
enhanced or inhibited. 
  Alternatively, Nef could start the binding cascade by binding TCRζ. TCRζ 
would then order the PxxP motif on Nef into a PPII helix. The now PTK-receptive form 
of the Nef-TCRζ complex would bind a Src PTK in a cooperative manner (middle), 
release the kinase domain from its auto-inhibited state and induce phosphorylation of the 
bound TCRζ. As with the previously described binding cascade, T cell activation could 
be augmented or suppressed. For SIV and HIV-2 Nef, binding of TCRζ can also lead to 
the formation for an AP-2 binding surface that recruits AP-2 for downregulation of the 
TCR (left). 
 This model provides the foundation for a new avenue of investigation into Nef’s 
effect on T cell activation. In this model, the formation of the Nef-TCRζ-PTK ternary 
complex is essential to Nef’s function. By selectively investigating each component of 
the complex and the interactions that mediate complex formation, we can begin to 
elucidate the functional importance of the Nef-TCRζ-PTK complex. Furthermore, by 
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understanding the mechanisms of complex formation, comparative studies of SIV, HIV-2 
and HIV-1 Nef can be performed to gain insight into the host effect that may influence 
Nef’s TCRζ-specific and Src PTK-specific effects.  
Nef has been demonstrated to participate in a number of activities that may not be 
easily dissected. However, the ability of Nef to impart a number of mechanistic 
perturbations in an infected cell may comprise its overall regulatory function. Through 
the enchancement or suppression of specific signaling pathways in a T cell, Nef may shift 
the homeostatic balance from with the T cell intracellular environment from one that is 
deleterious to viral infection to one that is permissible to enhanced viral replication. For 
example, the enhancement of Fyn activity on TCRζ by Nef may result in the 
augmentation of Fyn-mediated T cell signaling pathways that are distinct from Lck-
mediated pathways (reviewed in (Palacios and Weiss, 2004; Salmond et al., 2009)) and 
may provide an “active” environment for viral fitness but not necessarily for T cell 
function. Clearly, Nef’s effects in a T cell are multifaceted and collectively participate in 
viral survival. Therefore, continued detailed investigation of the molecular mechanisms 
of Nef activity such as that presented here for the Nef-TCRζ interaction will need to be 
performed. In addition, by understanding Nef’s perturbation of normal T cell activity, 
insight into normal T cell processes will be gained. 
 
Future Directions 
The in vitro evidence of the ability of select HIV-1 Nef variants to bind TCRζ and in a 
specificity/affinity profile unique to the HIV-1 Nef variants studied raises the question of 
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whether Nef proteins from all HIV-1 clades are able to bind TCRζ in a specific manner. 
Preliminary sequence analysis of Nef proteins from various HIV-1 clades suggests that 
the binding determinants on Nef are highly conserved, but detailed biochemical studies 
should be pursued with both full-length and core domain Nef proteins to confirm the 
universal specificity of the Nef-TCRζ interaction and more importantly, correlate those 
binding results with functional outcome. Furthermore, the binding experiments described 
here were predominately performed with core domain protein constructs. Therefore, these 
experiments should be extended to the full length proteins to determine if there are any 
effects of the N-terminal domain on binding activity. 
The crystal structure of the complex of the core domain of SIVmac239 Nef with 
the first YxxL motif in ITAM1 of TCRζ revealed that a salt bridge and hydrophobic 
pocket were the primary structural determinants that mediated the interaction of Nef with 
TCRζ. In order to confirm these findings, mutational analyses should be performed by 
substituting the residues on Nef involved in the salt bridge (R137, R138) to either non-
charged (A137, A138) or negatively charged residues (E137, E138) and observe the 
effects on binding. In addition, point mutations could be introduced in the hydrophobic 
pocket as well as the YxxL motif tyrosine residue in ITAM 1 to determine the functional 
significance of those interacting residues. Furthermore, the residues involved in the 
interaction of Nef with TCRζ that are not conserved among SIV and HIV-1 could be re-
introduced into the lower-affinity HIV-1 Nef protein to identify the primary residues that 
determine SIV Nef’s higher affinity for TCRζ. One other major feature of the interaction 
of SIV and HIV-2 Nef with TCRζ is the dual site specificity that was not observed for 
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HIV-1 Nef. Therefore, as an extension of the mutagenesis studies in HIV-1 Nef, the 
residues that confer dual site-specificity in HIV-2 and SIV Nef may be identified. 
Collectively, these mutation studies would 1) confirm the relevance of the residues 
involved in the SIV Nef-TCRζ interaction, 2) determine the residues that confer 
increased affinity for TCRζ and 3) identify the residues that determine Nef’s ability to 
bind to two unique YxxL motifs on TCRζ.  
 Since the structure of the Nef-TCRζ polypeptide complex only involved the first 
ITAM YxxL motif where SIV Nef was shown to bind to two unique regions, little is 
known about whether the same binding site on Nef is shared by the two regions on 
TCRζ. Based on sequence analysis, we have extrapolated that Nef shares the same 
binding site for TCRζ’s two binding regions, but this has not been experimentally 
explored. Therefore, simple mutagenesis/binding studies can be performed to determine 
the specificity of Nef for each region. However, the crystal structure of the complex of 
SIV Nef with the second binding site found on ITAM 2 should be determined to confirm 
that one binding site on Nef binds to both TCRζ binding regions but to also identify if the 
alpha helix is also present in the second ITAM region. These results would not only 
highlight the significance of the TCRζ-binding site on Nef, but additionally provide 
insight into TCRζ’s structural components.  
The primary focus of these studies has been to explore the interaction of Nef with 
TCRζ and determine its functional role during infection. Comments on the functional 
outcome of the interaction have been primarily a literature survey and require further 
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attention. With the determined binding parameters and structure of the Nef-TCRζ 
complex, a number of experiments can be performed in T cells to determine if this 
specific interaction is vital to viral fitness and more importantly, if we are more enabled 
to perturb its enhancement of viral survival.  In the preliminary experiments, the effect of 
the Nef proteins used in this studiy on T cell activation should be explored through 
transfection experiments of Nef constructs and observation of Nef’s effects on TCR 
downregulation as well as T-cell activation in the presence of an exogenous stimulus. 
Introduction of the mutated proteins described above should further determine the 
functional importance of the interaction and if abrogation of binding has a negative 
impact on viral replication. Functional outcomes, including membrane-proximal T cell 
signaling events (i.e. TCRζ, Lck, Fyn, ERK, PLC-γ phosphorylation) and late activation 
markers (i.e. IL-2 transcription, secretion), should be monitored to determine Nef’s 
effects early and late in the signaling pathway. Another approach to determine the 
functional importance of the Nef- TCRζ interaction is to develop novel chemical 
inhibitors that exploit the structural determinants of the Nef-TCRζ interaction. As 
observed the crystal structure, the primary binding motifs include a salt bridge and 
hydrophobic pocket on Nef. Therefore, chemical libraries and rational drug design efforts 
could be applied to invent inhibitors that could be used in binding studies, functional 
studies in cells as well as potential therapeutics in animal models and human trials. Nef’s 
effect on T cell activation is expected to be complicated by its numerous effects on its 
various binding partners, however careful analysis and segregation of the TCRζ-specific 
effects will provide invaluable insight. 
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APPENDIX 
A.1. Protein sequence inventory 
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A.1. Protein Sequence Inventory 
Nef (HIV-1; ARV2/SF2; Accession# P03407) fl [M1-C210] 
 
MGGKWSKRSMGGWSAIRERMRRAEPRAEPAADGVGAVSRDLEKHGAITSSNTAATNADCAWLEAQEEEEVG
FPVRPQVPLRPMTYKAALDISHFLKEKGGLEGLIWSQRRQEILDLWIYHTQGYFPDWQNYTPGPGIRYPLT
FGWCFKLVPVEPEKVEEANEGENNSLLHPMSLHGMEDAEKEVLVWRFDSKLAFHHMARELHPEYYKDC 
 
Nef (HIV-1; ARV2/SF2; Accession# P03407) AL [K4-C210] 
 
GSKWSKRSMGGWSAIRERMRRAEPRAEPAADGVGAVSRDLEKHGAITSSNTAATNADCAWLEAQEEEEVGF
PVRPQVPLRPMTYKAALDISHFLKEKGGLEGLIWSQRRQEILDLWIYHTQGYFPDWQNYTPGPGIRYPLTF
GWCFKLVPVEPEKVEEANEGENNSLLHPMSLHGMEDAEKEVLVWRFDSKLAFHHMARELHPEYYKDC 
 
Nef (HIV-1; ARV2/SF2; Accession# P03407) AS [A60-C210] 
 
GSAWLEAQEEEEVGFPVRPQVPLRPMTYKAALDISHFLKEKGGLEGLIWSQRRQEILDLWIYHTQGYFPDW
QNYTPGPGIRYPLTFGWCFKLVPVEPEKVEEANEGENNSLLHPMSLHGMEDAEKEVLVWRFDSKLAFHHMA
RELHPEYYKDC 
 
Nef (HIV-1; Consensus; Accession# AAA03700) fl [M1-C206] 
 
MGGKWSKRSVSGWPAVRERMRRAEPAAEGVGAVSRDLEKHGAITSSNTAATNAACAWLEAQEEEEVGFPVR
PQVPLRPMTYKAAVDLSHFLKEKGGLEGLIYSQKRQDILDLWVYHTQGYFPDWQNYTPGPGIRYPLTFGWC
FKLVPVEPEKVEEANEGENNCLLHPMSQHGMDDPEKEVLVWKFDSKLAFHHMARELHPEYYKDC 
 
Nef (HIV-1; Consensus; Accession# AAA03700) CL [K4-C206] 
  
GSKWSKRSVSGWPAVRERMRRAEPAAEGVGAVSRDLEKHGAITSSNTAATNAACAWLEAQEEEEVGFPVRP
QVPLRPMTYKAAVDLSHFLKEKGGLEGLIYSQKRQDILDLWVYHTQGYFPDWQNYTPGPGIRYPLTFGWCF
KLVPVEPEKVEEANEGENNCLLHPMSQHGMDDPEKEVLVWKFDSKLAFHHMARELHPEYYKDC 
 
Nef (HIV-1; Consensus; Accession# AAA03700) CS [A56-C206] 
  
GSAWLEAQEEEEVGFPVRPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIYSQKRQDILDLWVYHTQGYFPDW
QNYTPGPGIRYPLTFGWCFKLVPVEPEKVEEANEGENNCLLHPMSQHGMDDPEKEVLVWKFDSKLAFHHMA
RELHPEYYKDC 
 
Nef (HIV-1; ELI; Accession# P04604) fl [M1-N206] 
 
MGGKWSKSSIVGWPAIRERIRRTNPAADGVGAVSRDLEKHGAITSSNTASTNADCAWLEAQEESDEVGFPV
RPQVPLRPMTYKEALDLSHFLKEKGGLEGLIWSKKRQEILDLWVYNTQGIFPDWQNYTPGPGIRYPLTFGW
CYELVPVDPQEVEEDTEGETNSLLHPICQHGMEDPERQVLKWRFNSRLAFEHKAREMHPEFYKN 
 
Nef (HIV-1; ELI; Accession# P04604) EL [K4-N206] 
 
GSKWSKSSIVGWPAIRERIRRTNPAADGVGAVSRDLEKHGAITSSNTASTNADCAWLEAQEESDEVGFPVR
PQVPLRPMTYKEALDLSHFLKEKGGLEGLIWSKKRQEILDLWVYNTQGIFPDWQNYTPGPGIRYPLTFGWC
YELVPVDPQEVEEDTEGETNSLLHPICQHGMEDPERQVLKWRFNSRLAFEHKAREMHPEFYKN 
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Nef (HIV-1; ELI; Accession# P04604) ES [A56-N206] 
 
GSAWLEAQEESDEVGFPVRPQVPLRPMTYKEALDLSHFLKEKGGLEGLIWSKKRQEILDLWVYNTQGIFPD
WQNYTPGPGIRYPLTFGWCYELVPVDPQEVEEDTEGETNSLLHPICQHGMEDPERQVLKWRFNSRLAFEHK
AREMHPEFYKN 
 
Nef (HIV-1; LAI; Accession# Q9QPN3) fl [M1-C206] 
 
MGGKWSKSSVVGWPTVRERMRRAEPAADGVGAASRDLEKHGAITSSNTAATNAACAWLEAQEEEEVGFPVT
PQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWC
YKLVPVEPDKVEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC 
 
Nef (HIV-1; LAI; Accession# Q9QPN3) LL [K4-C206] 
 
GSKWSKSSVVGWPTVRERMRRAEPAADGVGAASRDLEKHGAITSSNTAATNAACAWLEAQEEEEVGFPVTP
QVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWCY
KLVPVEPDKVEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC 
 
Nef (HIV-1; LAI; Accession# Q9QPN3) LS [A56-C206] 
 
GSAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGYFPDW
QNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVA
RELHPEYFKNC 
 
Nef (HIV-1; NL4-3; Accession# AAK08490) fl [M1-C206] 
        
MGGKWSKSSVIGWPAVRERMRRAEPAADGVGAVSRDLEKHGAITSSNTAANNAACAWLEAQEEEEVGFPVT
PQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWC
YKLVPVEPDKVEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC 
 
Nef (HIV-1; NL4-3; Accession# AAK08490) NL [K4-C206] 
        
GSKWSKSSVIGWPAVRERMRRAEPAADGVGAVSRDLEKHGAITSSNTAANNAACAWLEAQEEEEVGFPVTP
QVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWCY
KLVPVEPDKVEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC 
 
Nef (HIV-1; NL4-3; Accession# AAK08490) NS [A56-C206] 
        
GSAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGYFPDW
QNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVA
RELHPEYFKNC 
 
Nef (HIV-2; ST; Accession# AAB01359) fl [M1-S255] 
  
MGASGSKKRSEPSRGLRERLLQTPGEASGGHWDKLGGEYLQSQEGSGRGQKSPSCEGRRYQQGDFMNTPWR
APAEGEKGSYKQQNMDDVDSDDDDLVGVPVTPRVPLREMTYRLARDMSHLIKEKGGLEGLYYSDRRRRVLD
IYLEKEEGIIGDWQNYTHGPGVRYPKFFGWLWKLVPVDVPQEGDDSETHCLVHPAQTSRFDDPHGETLVWR
FDPTLAFSYEAFIRYPEEFGYKSGLPEDEWKARLKARGIPFS 
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Nef (HIV-2; ST; Accession# AAB01359) HL [S4-S255] 
 
GSSGSKKRSEPSRGLRERLLQTPGEASGGHWDKLGGEYLQSQEGSGRGQKSPSCEGRRYQQGDFMNTPWRA
PAEGEKGSYKQQNMDDVDSDDDDLVGVPVTPRVPLREMTYRLARDMSHLIKEKGGLEGLYYSDRRRRVLDI
YLEKEEGIIGDWQNYTHGPGVRYPKFFGWLWKLVPVDVPQEGDDSETHCLVHPAQTSRFDDPHGETLVWRF
DPTLAFSYEAFIRYPEEFGYKSGLPEDEWKARLKARGIPFS 
 
Nef (HIV-2; ST; Accession# AAB01359) HS [D94-Y234] 
 
GSDDLVGVPVTPRVPLREMTYRLARDMSHLIKEKGGLEGLYYSDRRRRVLDIYLEKEEGIIGDWQNYTHGP
GVRYPKFFGWLWKLVPVDVPQEGDDSETHCLVHPAQTSRFDDPHGETLVWRFDPTLAFSYEAFIRYPEEFG
Y 
 
Nef (SIV; mac239; Accession# AAU14056) fl [M1-R263] 
 
MGGAISMRRSRPSGDLRQRLLRARGETYGRLLGEVEDGYSQSPGGLDKGLSSLSCEGQKYNQGQYMNTPWR
NPAEEREKLAYRKQNMDDIDEEDDDLVGVSVRPKVPLRTMSYKLAIDMSHFIKEKGGLEGIYYSARRHRIL
DIYLEKEEGIIPDWQDYTSGPGIRYPKTFGWLWKLVPVNVSDEAQEDEEHYLMHPAQTSQWDDPWGEVLAW
KFDPTLAYTYEAYVRYPEEFGSKSGLSEEEVRRRLTARGLLNMADKKETR 
 
Nef (SIV; mac239; Accession# AAU14056) SL [A4-R263] 
 
GSAISMRRSRPSGDLRQRLLRARGETYGRLLGEVEDGYSQSPGGLDKGLSSLSCEGQKYNQGQYMNTPWRN
PAEEREKLAYRKQNMDDIDEEDDDLVGVSVRPKVPLRTMSYKLAIDMSHFIKEKGGLEGIYYSARRHRILD
IYLEKEEGIIPDWQDYTSGPGIRYPKTFGWLWKLVPVNVSDEAQEDEEHYLMHPAQTSQWDDPWGEVLAWK
FDPTLAYTYEAYVRYPEEFGSKSGLSEEEVRRRLTARGLLNMADKKETR 
 
Nef (SIV; mac239; Accession# AAU14056) SS [D95-S235] 
  
GSDDLVGVSVRPKVPLRTMSYKLAIDMSHFIKEKGGLEGIYYSARRHRILDIYLEKEEGIIPDWQDYTSGP
GIRYPKTFGWLWKLVPVNVSDEAQEDEEHYLMHPAQTSQWDDPWGEVLAWKFDPTLAYTYEAYVRYPEEFG
S 
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A.2. DNA Inventory 
A. pEGFP-N1 
 
GAATTC (EcoRI) 
GGATCC (BamHI) 
 
TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 
CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC CCCGCCCATT 
GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC ATTGACGTCA 
ATGGGTGGAG TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC 
AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA 
CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 
CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG ACTCACGGGG 
ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC AAAATCAACG 
GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT 
ACGGTGGGAG GTCTATATAA GCAGAGCTGG TTTAGTGAAC CGTCAGATCC GCTAGCGCTA 
CCGGACTCAG ATCTCGAGCT CAAGCTTCG 
 
AATTCTGCAGTCGACGGTACCGCGGGCCCGG 
 
GATCCACCGG TCGCCACCAT GGTGAGCAAG GGCGAGGAGC TGTTCACCGG GGTGGTGCCC 
ATCCTGGTCG AGCTGGACGG CGACGTAAAC GGCCACAAGT TCAGCGTGTC CGGCGAGGGC 
GAGGGCGATG CCACCTACGG CAAGCTGACC CTGAAGTTCA TCTGCACCAC CGGCAAGCTG 
CCCGTGCCCT GGCCCACCCT CGTGACCACC CTGACCTACG GCGTGCAGTG CTTCAGCCGC 
TACCCCGACC ACATGAAGCA GCACGACTTC TTCAAGTCCG CCATGCCCGA AGGCTACGTC 
CAGGAGCGCA CCATCTTCTT CAAGGACGAC GGCAACTACA AGACCCGCGC CGAGGTGAAG 
TTCGAGGGCG ACACCCTGGT GAACCGCATC GAGCTGAAGG GCATCGACTT CAAGGAGGAC 
GGCAACATCC TGGGGCACAA GCTGGAGTAC AACTACAACA GCCACAACGT CTATATCATG 
GCCGACAAGC AGAAGAACGG CATCAAGGTG AACTTCAAGA TCCGCCACAA CATCGAGGAC 
GGCAGCGTGC AGCTCGCCGA CCACTACCAG CAGAACACCC CCATCGGCGA CGGCCCCGTG 
CTGCTGCCCG ACAACCACTA CCTGAGCACC CAGTCCGCCC TGAGCAAAGA CCCCAACGAG 
AAGCGCGATC ACATGGTCCT GCTGGAGTTC GTGACCGCCG CCGGGATCAC TCTCGGCATG 
GACGAGCTGT ACAAGTAAAG CGGCCGCGAC TCTAGATCAT AATCAGCCAT ACCACATTTG 
TAGAGGTTTT ACTTGCTTTA AAAAACCTCC CACACCTCCC CCTGAACCTG AAACATAAAA 
TGAATGCAAT TGTTGTTGTT AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA 
ATAGCATCAC AAATTTCACA AATAAAGCAT TTTTTTCACT GCATTCTAGT TGTGGTTTGT 
CCAAACTCAT CAATGTATCT TAAGGCGTAA ATTGTAAGCG TTAATATTTT GTTAAAATTC 
GCGTTAAATT TTTGTTAAAT CAGCTCATTT TTTAACCAAT AGGCCGAAAT CGGCAAAATC 
CCTTATAAAT CAAAAGAATA GACCGAGATA GGGTTGAGTG TTGTTCCAGT TTGGAACAAG 
AGTCCACTAT TAAAGAACGT GGACTCCAAC GTCAAAGGGC GAAAAACCGT CTATCAGGGC 
GATGGCCCAC TACGTGAACC ATCACCCTAA TCAAGTTTTT TGGGGTCGAG GTGCCGTAAA 
GCACTAAATC GGAACCCTAA AGGGAGCCCC CGATTTAGAG CTTGACGGGG AAAGCCGGCG 
AACGTGGCGA GAAAGGAAGG GAAGAAAGCG AAAGGAGCGG GCGCTAGGGC GCTGGCAAGT 
GTAGCGGTCA CGCTGCGCGT AACCACCACA CCCGCCGCGC TTAATGCGCC GCTACAGGGC 
GCGTCAGGTG GCACTTTTCG GGGAAATGTG CGCGGAACCC CTATTTGTTT ATTTTTCTAA 
ATACATTCAA ATATGTATCC GCTCATGAGA CAATAACCCT GATAAATGCT TCAATAATAT 
TGAAAAAGGA AGAGTCCTGA GGCGGAAAGA ACCAGCTGTG GAATGTGTGT CAGTTAGGGT 
GTGGAAAGTC CCCAGGCTCC CCAGCAGGCA GAAGTATGCA AAGCATGCAT CTCAATTAGT 
CAGCAACCAG GTGTGGAAAG TCCCCAGGCT CCCCAGCAGG CAGAAGTATG CAAAGCATGC 
ATCTCAATTA GTCAGCAACC ATAGTCCCGC CCCTAACTCC GCCCATCCCG CCCCTAACTC 
CGCCCAGTTC CGCCCATTCT CCGCCCCATG GCTGACTAAT TTTTTTTATT TATGCAGAGG 
CCGAGGCCGC CTCGGCCTCT GAGCTATTCC AGAAGTAGTG AGGAGGCTTT TTTGGAGGCC 
WMK55
WMK56
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TAGGCTTTTG CAAAGATCGA TCAAGAGACA GGATGAGGAT CGTTTCGCAT GATTGAACAA 
GATGGATTGC ACGCAGGTTC TCCGGCCGCT TGGGTGGAGA GGCTATTCGG CTATGACTGG 
GCACAACAGA CAATCGGCTG CTCTGATGCC GCCGTGTTCC GGCTGTCAGC GCAGGGGCGC 
CCGGTTCTTT TTGTCAAGAC CGACCTGTCC GGTGCCCTGA ATGAACTGCA AGACGAGGCA 
GCGCGGCTAT CGTGGCTGGC CACGACGGGC GTTCCTTGCG CAGCTGTGCT CGACGTTGTC 
ACTGAAGCGG GAAGGGACTG GCTGCTATTG GGCGAAGTGC CGGGGCAGGA TCTCCTGTCA 
TCTCACCTTG CTCCTGCCGA GAAAGTATCC ATCATGGCTG ATGCAATGCG GCGGCTGCAT 
ACGCTTGATC CGGCTACCTG CCCATTCGAC CACCAAGCGA AACATCGCAT CGAGCGAGCA 
CGTACTCGGA TGGAAGCCGG TCTTGTCGAT CAGGATGATC TGGACGAAGA GCATCAGGGG 
CTCGCGCCAG CCGAACTGTT CGCCAGGCTC AAGGCGAGCA TGCCCGACGG CGAGGATCTC 
GTCGTGACCC ATGGCGATGC CTGCTTGCCG AATATCATGG TGGAAAATGG CCGCTTTTCT 
GGATTCATCG ACTGTGGCCG GCTGGGTGTG GCGGACCGCT ATCAGGACAT AGCGTTGGCT 
ACCCGTGATA TTGCTGAAGA GCTTGGCGGC GAATGGGCTG ACCGCTTCCT CGTGCTTTAC 
GGTATCGCCG CTCCCGATTC GCAGCGCATC GCCTTCTATC GCCTTCTTGA CGAGTTCTTC 
TGAGCGGGAC TCTGGGGTTC GAAATGACCG ACCAAGCGAC GCCCAACCTG CCATCACGAG 
ATTTCGATTC CACCGCCGCC TTCTATGAAA GGTTGGGCTT CGGAATCGTT TTCCGGGACG 
CCGGCTGGAT GATCCTCCAG CGCGGGGATC TCATGCTGGA GTTCTTCGCC CACCCTAGGG 
GGAGGCTAAC TGAAACACGG AAGGAGACAA TACCGGAAGG AACCCGCGCT ATGACGGCAA 
TAAAAAGACA GAATAAAACG CACGGTGTTG GGTCGTTTGT TCATAAACGC GGGGTTCGGT 
CCCAGGGCTG GCACTCTGTC GATACCCCAC CGAGACCCCA TTGGGGCCAA TACGCCCGCG 
TTTCTTCCTT TTCCCCACCC CACCCCCCAA GTTCGGGTGA AGGCCCAGGG CTCGCAGCCA 
ACGTCGGGGC GGCAGGCCCT GCCATAGCCT CAGGTTACTC ATATATACTT TAGATTGATT 
TAAAACTTCA TTTTTAATTT AAAAGGATCT AGGTGAAGAT CCTTTTTGAT AATCTCATGA 
CCAAAATCCC TTAACGTGAG TTTTCGTTCC ACTGAGCGTC AGACCCCGTA GAAAAGATCA 
AAGGATCTTC TTGAGATCCT TTTTTTCTGC GCGTAATCTG CTGCTTGCAA ACAAAAAAAC 
CACCGCTACC AGCGGTGGTT TGTTTGCCGG ATCAAGAGCT ACCAACTCTT TTTCCGAAGG 
TAACTGGCTT CAGCAGAGCG CAGATACCAA ATACTGTCCT TCTAGTGTAG CCGTAGTTAG 
GCCACCACTT CAAGAACTCT GTAGCACCGC CTACATACCT CGCTCTGCTA ATCCTGTTAC 
CAGTGGCTGC TGCCAGTGGC GATAAGTCGT GTCTTACCGG GTTGGACTCA AGACGATAGT 
TACCGGATAA GGCGCAGCGG TCGGGCTGAA CGGGGGGTTC GTGCACACAG CCCAGCTTGG 
AGCGAACGAC CTACACCGAA CTGAGATACC TACAGCGTGA GCTATGAGAA AGCGCCACGC 
TTCCCGAAGG GAGAAAGGCG GACAGGTATC CGGTAAGCGG CAGGGTCGGA ACAGGAGAGC 
GCACGAGGGA GCTTCCAGGG GGAAACGCCT GGTATCTTTA TAGTCCTGTC GGGTTTCGCC 
ACCTCTGACT TGAGCGTCGA TTTTTGTGAT GCTCGTCAGG GGGGCGGAGC CTATGGAAAA 
ACGCCAGCAA CGCGGCCTTT TTACGGTTCC TGGCCTTTTG CTGGCCTTTT GCTCACATGT 
TCTTTCCTGC GTTATCCCCT GATTCTGTGG ATAACCGTAT TACCGCCATG CAT 
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B. Nef (Full Length) / No GFP Fusion (-G) 
 
ELI (M1-N206) 
AATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAATGGTCAAAAAGTAGTATAGTGGGATGGCCTGCTATA
AGGGAAAGAATAAGAAGAACTAATCCAGCAGCAGATGGGGTAGGAGCAGTATCTCGAGACCTGGAAAAACA
TGGGGCAATCACAAGTAGCAATACAGCAAGTACTAATGCTGACTGTGCCTGGCTAGAAGCACAAGAAGAGA
GCGACGAGGTGGGCTTTCCAGTCAGACCCCAGGTACCTTTAAGACCAATGACTTACAAAGAAGCTCTAGAT
CTCAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTTGGTCCAAAAAGAGACAAGAGATCCT
TGATCTTTGGGTCTACAACACACAAGGCATCTTCCCTGATTGGCAAAACTACACACCAGGGCCAGGGATCA
GATATCCACTAACCTTTGGATGGTGCTACGAGCTAGTACCAGTTGATCCACAGGAGGTAGAAGAAGACACT
GAAGGAGAGACCAACAGCTTGTTACACCCTATATGCCAGCATGGAATGGAGGACCCGGAGAGACAAGTGTT
AAAATGGAGATTTAACAGCAGACTAGCATTTGAGCACAAGGCCCGAGAGATGCATCCGGAGTTCTACAAAA
ACTAATGAG 
 
NL4-3 (M1-C206) 
AATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTGCTGTA
AGGGAAAGAATGAGACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATCTCGAGACCTAGAAAAACA
TGGAGCAATCACAAGTAGCAATACAGCAGCTAACAATGCTGCTTGTGCCTGGCTAGAAGCACAAGAGGAGG
AAGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTT
AGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGA
TCTGTGGATCTACCACACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGGGCCAGGGGTCAGAT
ATCCACTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATAAA
GGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGATGACCCTGAGAGAGAAGTGTTAGA
GTGGAGGTTTGACAGCCGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACT
GCTAATGAG 
 
HIV-2 (M1-S255) 
AATTCATGGGCGCCAGTGGCTCCAAGAAGCGTTCCGAGCCTTCGCGAGGGCTACGGGAGAGACTCTTACAA
ACGCCTGGAGAGGCTTCTGGGGGACACTGGGACAAATTGGGAGGGGAATACTTGCAGTCCCAAGAAGGATC
AGGCAGGGGGCAGAAATCACCCTCCTGTGAGGGACGGCGGTATCAACAGGGAGATTTTATGAATACCCCAT
GGAGAGCCCCAGCAGAAGGGGAGAAAGGCTCGTACAAGCAACAAAATATGGATGATGTAGATTCAGATGAT
GATGACCTAGTAGGGGTCCCTGTCACACCAAGAGTACCATTAAGAGAAATGACATATCGTTTGGCAAGAGA
TATGTCACATTTGATAAAAGAAAAGGGGGGACTGGAAGGGCTGTATTACAGTGATAGAAGACGTAGAGTGC
TAGACATATACTTAGAAAAGGAAGAGGGAATAATTGGAGACTGGCAGAACTATACTCATGGACCAGGAGTA
AGGTATCCAAAGTTCTTTGGGTGGTTATGGAAGCTAGTACCAGTAGATGTCCCACAAGAGGGAGATGACAG
TGAGACTCACTGCTTAGTGCATCCAGCACAAACAAGCAGGTTTGATGACCCGCATGGAGAAACATTAGTTT
GGAGGTTTGACCCCACGCTAGCTTTTAGCTACGAGGCCTTTATTCGATACCCAGAGGAGTTTGGGTACAAG
TCAGGCCTGCCAGAGGATGAATGGAAGGCAAGACTGAAAGCAAGAGGGATACCGTTTAGCTAATGAG 
 
SIV (M1-R263) 
AATTCATGGGCGGCGCTATTTCCATGAGGCGGTCCAGGCCGTCTGGAGATCTGCGACAGAGACTCTTGCGG
GCGCGTGGGGAGACTTATGGGAGACTCTTAGGAGAGGTGGAAGATGGATACTCGCAATCCCCAGGAGGATT
AGACAAGGGCTTGAGCTCACTCTCTTGTGAGGGACAGAAATACAATCAGGGACAGTATATGAATACTCCAT
GGAGAAACCCAGCTGAAGAGAGAGAAAAATTAGCATACAGAAAACAAAATATGGATGATATAGATGAGGAA
GATGATGACTTGGTAGGGGTATCAGTGAGGCCAAAAGTTCCCCTAAGAACAATGAGTTACAAATTGGCAAT
AGACATGTCTCATTTTATAAAAGAAAAGGGGGGACTGGAAGGGATTTATTACAGTGCAAGAAGACATAGAA
TCTTAGACATATACTTAGAAAAGGAAGAAGGCATCATACCAGATTGGCAGGATTACACCTCAGGACCAGGA
ATTAGATACCCAAAGACATTTGGCTGGCTATGGAAATTAGTCCCTGTAAATGTATCAGATGAGGCACAGGA
GGATGAGGAGCATTATTTAATGCATCCAGCTCAAACTTCCCAGTGGGATGACCCTTGGGGAGAGGTTCTAG
CATGGAAGTTTGATCCAACTCTGGCCTACACTTATGAGGCATATGTTAGATACCCAGAAGAGTTTGGAAGC
AAGTCAGGCCTGTCAGAGGAAGAGGTTAGAAGAAGGCTAACCGCAAGAGGCCTTCTTAACATGGCTGACAA
GAAGGAAACTCGCTAATGAG 
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C. Nef (Full Length) / GFP Fusion (+G) 
 
ELI (M1-N206) 
AATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAATGGTCAAAAAGTAGTATAGTGGGATGGCCTGCTATA
AGGGAAAGAATAAGAAGAACTAATCCAGCAGCAGATGGGGTAGGAGCAGTATCTCGAGACCTGGAAAAACA
TGGGGCAATCACAAGTAGCAATACAGCAAGTACTAATGCTGACTGTGCCTGGCTAGAAGCACAAGAAGAGA
GCGACGAGGTGGGCTTTCCAGTCAGACCCCAGGTACCTTTAAGACCAATGACTTACAAAGAAGCTCTAGAT
CTCAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTTGGTCCAAAAAGAGACAAGAGATCCT
TGATCTTTGGGTCTACAACACACAAGGCATCTTCCCTGATTGGCAAAACTACACACCAGGGCCAGGGATCA
GATATCCACTAACCTTTGGATGGTGCTACGAGCTAGTACCAGTTGATCCACAGGAGGTAGAAGAAGACACT
GAAGGAGAGACCAACAGCTTGTTACACCCTATATGCCAGCATGGAATGGAGGACCCGGAGAGACAAGTGTT
AAAATGGAGATTTAACAGCAGACTAGCATTTGAGCACAAGGCCCGAGAGATGCATCCGGAGTTCTACAAAA
AC 
 
NL4-3 (M1-C206) 
AATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTGCTGTA
AGGGAAAGAATGAGACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATCTCGAGACCTAGAAAAACA
TGGAGCAATCACAAGTAGCAATACAGCAGCTAACAATGCTGCTTGTGCCTGGCTAGAAGCACAAGAGGAGG
AAGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTT
AGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGA
TCTGTGGATCTACCACACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGGGCCAGGGGTCAGAT
ATCCACTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATAAA
GGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGATGACCCTGAGAGAGAAGTGTTAGA
GTGGAGGTTTGACAGCCGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACT
GC 
 
HIV-2 (M1-S255) 
AATTCATGGGCGCCAGTGGCTCCAAGAAGCGTTCCGAGCCTTCGCGAGGGCTACGGGAGAGACTCTTACAA
ACGCCTGGAGAGGCTTCTGGGGGACACTGGGACAAATTGGGAGGGGAATACTTGCAGTCCCAAGAAGGATC
AGGCAGGGGGCAGAAATCACCCTCCTGTGAGGGACGGCGGTATCAACAGGGAGATTTTATGAATACCCCAT
GGAGAGCCCCAGCAGAAGGGGAGAAAGGCTCGTACAAGCAACAAAATATGGATGATGTAGATTCAGATGAT
GATGACCTAGTAGGGGTCCCTGTCACACCAAGAGTACCATTAAGAGAAATGACATATCGTTTGGCAAGAGA
TATGTCACATTTGATAAAAGAAAAGGGGGGACTGGAAGGGCTGTATTACAGTGATAGAAGACGTAGAGTGC
TAGACATATACTTAGAAAAGGAAGAGGGAATAATTGGAGACTGGCAGAACTATACTCATGGACCAGGAGTA
AGGTATCCAAAGTTCTTTGGGTGGTTATGGAAGCTAGTACCAGTAGATGTCCCACAAGAGGGAGATGACAG
TGAGACTCACTGCTTAGTGCATCCAGCACAAACAAGCAGGTTTGATGACCCGCATGGAGAAACATTAGTTT
GGAGGTTTGACCCCACGCTAGCTTTTAGCTACGAGGCCTTTATTCGATACCCAGAGGAGTTTGGGTACAAG
TCAGGCCTGCCAGAGGATGAATGGAAGGCAAGACTGAAAGCAAGAGGGATACCGTTTAGC 
 
SIV (M1-R263) 
AATTCATGGGCGGCGCTATTTCCATGAGGCGGTCCAGGCCGTCTGGAGATCTGCGACAGAGACTCTTGCGG
GCGCGTGGGGAGACTTATGGGAGACTCTTAGGAGAGGTGGAAGATGGATACTCGCAATCCCCAGGAGGATT
AGACAAGGGCTTGAGCTCACTCTCTTGTGAGGGACAGAAATACAATCAGGGACAGTATATGAATACTCCAT
GGAGAAACCCAGCTGAAGAGAGAGAAAAATTAGCATACAGAAAACAAAATATGGATGATATAGATGAGGAA
GATGATGACTTGGTAGGGGTATCAGTGAGGCCAAAAGTTCCCCTAAGAACAATGAGTTACAAATTGGCAAT
AGACATGTCTCATTTTATAAAAGAAAAGGGGGGACTGGAAGGGATTTATTACAGTGCAAGAAGACATAGAA
TCTTAGACATATACTTAGAAAAGGAAGAAGGCATCATACCAGATTGGCAGGATTACACCTCAGGACCAGGA
ATTAGATACCCAAAGACATTTGGCTGGCTATGGAAATTAGTCCCTGTAAATGTATCAGATGAGGCACAGGA
GGATGAGGAGCATTATTTAATGCATCCAGCTCAAACTTCCCAGTGGGATGACCCTTGGGGAGAGGTTCTAG
CATGGAAGTTTGATCCAACTCTGGCCTACACTTATGAGGCATATGTTAGATACCCAGAAGAGTTTGGAAGC
AAGTCAGGCCTGTCAGAGGAAGAGGTTAGAAGAAGGCTAACCGCAAGAGGCCTTCTTAACATGGCTGACAA
GAAGGAAACTCGC 
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D. Nef (Full Length) / GFP Fusion (+G) / Internal BamHI site 
 
ELI (M1-W57.BamHI.L58-N206) 
AATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAATGGTCAAAAAGTAGTATAGTGGGATGGCCTGCTATA
AGGGAAAGAATAAGAAGAACTAATCCAGCAGCAGATGGGGTAGGAGCAGTATCTCGAGACCTGGAAAAACA
TGGGGCAATCACAAGTAGCAATACAGCAAGTACTAATGCTGACTGTGCCTGGGGATCCCTAGAAGCACAAG
AAGAGAGCGACGAGGTGGGCTTTCCAGTCAGACCCCAGGTACCTTTAAGACCAATGACTTACAAAGAAGCT
CTAGATCTCAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTTGGTCCAAAAAGAGACAAGA
GATCCTTGATCTTTGGGTCTACAACACACAAGGCATCTTCCCTGATTGGCAAAACTACACACCAGGGCCAG
GGATCAGATATCCACTAACCTTTGGATGGTGCTACGAGCTAGTACCAGTTGATCCACAGGAGGTAGAAGAA
GACACTGAAGGAGAGACCAACAGCTTGTTACACCCTATATGCCAGCATGGAATGGAGGACCCGGAGAGACA
AGTGTTAAAATGGAGATTTAACAGCAGACTAGCATTTGAGCACAAGGCCCGAGAGATGCATCCGGAGTTCT
ACAAAAAC 
 
NL4-3 (M1-W57.BamHI.L58-C206) 
AATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTGCTGTA
AGGGAAAGAATGAGACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATCTCGAGACCTAGAAAAACA
TGGAGCAATCACAAGTAGCAATACAGCAGCTAACAATGCTGCTTGTGCCTGGGGATCCCTAGAAGCACAAG
AGGAGGAAGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTA
GATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATAT
CCTTGATCTGTGGATCTACCACACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGGGCCAGGGG
TCAGATATCCACTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCC
AATAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGATGACCCTGAGAGAGAAGT
GTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCA
AGAACTGC 
 
HIV-2 (M1-D88.BamHI.V89-S255) 
AATTCATGGGCGCCAGTGGCTCCAAGAAGCGTTCCGAGCCTTCGCGAGGGCTACGGGAGAGACTCTTACAA
ACGCCTGGAGAGGCTTCTGGGGGACACTGGGACAAATTGGGAGGGGAATACTTGCAGTCCCAAGAAGGATC
AGGCAGGGGGCAGAAATCACCCTCCTGTGAGGGACGGCGGTATCAACAGGGAGATTTTATGAATACCCCAT
GGAGAGCCCCAGCAGAAGGGGAGAAAGGCTCGTACAAGCAACAAAATATGGATGATGGATCCGTAGATTCA
GATGATGATGACCTAGTAGGGGTCCCTGTCACACCAAGAGTACCATTAAGAGAAATGACATATCGTTTGGC
AAGAGATATGTCACATTTGATAAAAGAAAAGGGGGGACTGGAAGGGCTGTATTACAGTGATAGAAGACGTA
GAGTGCTAGACATATACTTAGAAAAGGAAGAGGGAATAATTGGAGACTGGCAGAACTATACTCATGGACCA
GGAGTAAGGTATCCAAAGTTCTTTGGGTGGTTATGGAAGCTAGTACCAGTAGATGTCCCACAAGAGGGAGA
TGACAGTGAGACTCACTGCTTAGTGCATCCAGCACAAACAAGCAGGTTTGATGACCCGCATGGAGAAACAT
TAGTTTGGAGGTTTGACCCCACGCTAGCTTTTAGCTACGAGGCCTTTATTCGATACCCAGAGGAGTTTGGG
TACAAGTCAGGCCTGCCAGAGGATGAATGGAAGGCAAGACTGAAAGCAAGAGGGATACCGTTTAGC 
 
SIV (M1-D89.BamHI.V90-S263) 
AATTCATGGGCGGCGCTATTTCCATGAGGCGGTCCAGGCCGTCTGGAGATCTGCGACAGAGACTCTTGCGG
GCGCGTGGGGAGACTTATGGGAGACTCTTAGGAGAGGTGGAAGATGGATACTCGCAATCCCCAGGAGGATT
AGACAAGGGCTTGAGCTCACTCTCTTGTGAGGGACAGAAATACAATCAGGGACAGTATATGAATACTCCAT
GGAGAAACCCAGCTGAAGAGAGAGAAAAATTAGCATACAGAAAACAAAATATGGATGATGGATCCATAGAT
GAGGAAGATGATGACTTGGTAGGGGTATCAGTGAGGCCAAAAGTTCCCCTAAGAACAATGAGTTACAAATT
GGCAATAGACATGTCTCATTTTATAAAAGAAAAGGGGGGACTGGAAGGGATTTATTACAGTGCAAGAAGAC
ATAGAATCTTAGACATATACTTAGAAAAGGAAGAAGGCATCATACCAGATTGGCAGGATTACACCTCAGGA
CCAGGAATTAGATACCCAAAGACATTTGGCTGGCTATGGAAATTAGTCCCTGTAAATGTATCAGATGAGGC
ACAGGAGGATGAGGAGCATTATTTAATGCATCCAGCTCAAACTTCCCAGTGGGATGACCCTTGGGGAGAGG
TTCTAGCATGGAAGTTTGATCCAACTCTGGCCTACACTTATGAGGCATATGTTAGATACCCAGAAGAGTTT
GGAAGCAAGTCAGGCCTGTCAGAGGAAGAGGTTAGAAGAAGGCTAACCGCAAGAGGCCTTCTTAACATGGC
TGACAAGAAGGAAACTCGC 
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E. Nef (Full Length) / GFP Fusion (+G) / Internal BamHI site / Chimera 
 
ELI-SIV (M1-W57.BamHI.V90-S263) 
AATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAATGGTCAAAAAGTAGTATAGTGGGATGGCCTGCTATA
AGGGAAAGAATAAGAAGAACTAATCCAGCAGCAGATGGGGTAGGAGCAGTATCTCGAGACCTGGAAAAACA
TGGGGCAATCACAAGTAGCAATACAGCAAGTACTAATGCTGACTGTGCCTGGGGATCCATAGATGAGGAAG
ATGATGACTTGGTAGGGGTATCAGTGAGGCCAAAAGTTCCCCTAAGAACAATGAGTTACAAATTGGCAATA
GACATGTCTCATTTTATAAAAGAAAAGGGGGGACTGGAAGGGATTTATTACAGTGCAAGAAGACATAGAAT
CTTAGACATATACTTAGAAAAGGAAGAAGGCATCATACCAGATTGGCAGGATTACACCTCAGGACCAGGAA
TTAGATACCCAAAGACATTTGGCTGGCTATGGAAATTAGTCCCTGTAAATGTATCAGATGAGGCACAGGAG
GATGAGGAGCATTATTTAATGCATCCAGCTCAAACTTCCCAGTGGGATGACCCTTGGGGAGAGGTTCTAGC
ATGGAAGTTTGATCCAACTCTGGCCTACACTTATGAGGCATATGTTAGATACCCAGAAGAGTTTGGAAGCA
AGTCAGGCCTGTCAGAGGAAGAGGTTAGAAGAAGGCTAACCGCAAGAGGCCTTCTTAACATGGCTGACAAG
AAGGAAACTCGC 
 
NL4-3-SIV (M1-W57.BamHI.V90-S263) 
AATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTGCTGTA
AGGGAAAGAATGAGACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATCTCGAGACCTAGAAAAACA
TGGAGCAATCACAAGTAGCAATACAGCAGCTAACAATGCTGCTTGTGCCTGGGGATCCATAGATGAGGAAG
ATGATGACTTGGTAGGGGTATCAGTGAGGCCAAAAGTTCCCCTAAGAACAATGAGTTACAAATTGGCAATA
GACATGTCTCATTTTATAAAAGAAAAGGGGGGACTGGAAGGGATTTATTACAGTGCAAGAAGACATAGAAT
CTTAGACATATACTTAGAAAAGGAAGAAGGCATCATACCAGATTGGCAGGATTACACCTCAGGACCAGGAA
TTAGATACCCAAAGACATTTGGCTGGCTATGGAAATTAGTCCCTGTAAATGTATCAGATGAGGCACAGGAG
GATGAGGAGCATTATTTAATGCATCCAGCTCAAACTTCCCAGTGGGATGACCCTTGGGGAGAGGTTCTAGC
ATGGAAGTTTGATCCAACTCTGGCCTACACTTATGAGGCATATGTTAGATACCCAGAAGAGTTTGGAAGCA
AGTCAGGCCTGTCAGAGGAAGAGGTTAGAAGAAGGCTAACCGCAAGAGGCCTTCTTAACATGGCTGACAAG
AAGGAAACTCGC 
 
SIV-ELI (M1-D89.BamHI.L58-N206) 
AATTCATGGGCGGCGCTATTTCCATGAGGCGGTCCAGGCCGTCTGGAGATCTGCGACAGAGACTCTTGCGG
GCGCGTGGGGAGACTTATGGGAGACTCTTAGGAGAGGTGGAAGATGGATACTCGCAATCCCCAGGAGGATT
AGACAAGGGCTTGAGCTCACTCTCTTGTGAGGGACAGAAATACAATCAGGGACAGTATATGAATACTCCAT
GGAGAAACCCAGCTGAAGAGAGAGAAAAATTAGCATACAGAAAACAAAATATGGATGATGGATCCCTAGAA
GCACAAGAAGAGAGCGACGAGGTGGGCTTTCCAGTCAGACCCCAGGTACCTTTAAGACCAATGACTTACAA
AGAAGCTCTAGATCTCAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTTGGTCCAAAAAGA
GACAAGAGATCCTTGATCTTTGGGTCTACAACACACAAGGCATCTTCCCTGATTGGCAAAACTACACACCA
GGGCCAGGGATCAGATATCCACTAACCTTTGGATGGTGCTACGAGCTAGTACCAGTTGATCCACAGGAGGT
AGAAGAAGACACTGAAGGAGAGACCAACAGCTTGTTACACCCTATATGCCAGCATGGAATGGAGGACCCGG
AGAGACAAGTGTTAAAATGGAGATTTAACAGCAGACTAGCATTTGAGCACAAGGCCCGAGAGATGCATCCG
GAGTTCTACAAAAAC 
 
SIV-NL4-3 (M1-D89.BamHI.L58-C206) 
AATTCATGGGCGGCGCTATTTCCATGAGGCGGTCCAGGCCGTCTGGAGATCTGCGACAGAGACTCTTGCGG
GCGCGTGGGGAGACTTATGGGAGACTCTTAGGAGAGGTGGAAGATGGATACTCGCAATCCCCAGGAGGATT
AGACAAGGGCTTGAGCTCACTCTCTTGTGAGGGACAGAAATACAATCAGGGACAGTATATGAATACTCCAT
GGAGAAACCCAGCTGAAGAGAGAGAAAAATTAGCATACAGAAAACAAAATATGGATGATGGATCCCTAGAA
GCACAAGAGGAGGAAGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTAAGACCAATGACTTACAAGGC
AGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGAC
AAGATATCCTTGATCTGTGGATCTACCACACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGGG
CCAGGGGTCAGATATCCACTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGA
AGAGGCCAATAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGATGACCCTGAGA
GAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAG
TACTTCAAGAACTGC 
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F. Nef (Full Length) / GFP Fusion (+G) / Chimera 
 
ELI-SIV (M1-W57.BamHI.V90-S263) 
AATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAATGGTCAAAAAGTAGTATAGTGGGATGGCCTGCTATA
AGGGAAAGAATAAGAAGAACTAATCCAGCAGCAGATGGGGTAGGAGCAGTATCTCGAGACCTGGAAAAACA
TGGGGCAATCACAAGTAGCAATACAGCAAGTACTAATGCTGACTGTGCCTGGATAGATGAGGAAGATGATG
ACTTGGTAGGGGTATCAGTGAGGCCAAAAGTTCCCCTAAGAACAATGAGTTACAAATTGGCAATAGACATG
TCTCATTTTATAAAAGAAAAGGGGGGACTGGAAGGGATTTATTACAGTGCAAGAAGACATAGAATCTTAGA
CATATACTTAGAAAAGGAAGAAGGCATCATACCAGATTGGCAGGATTACACCTCAGGACCAGGAATTAGAT
ACCCAAAGACATTTGGCTGGCTATGGAAATTAGTCCCTGTAAATGTATCAGATGAGGCACAGGAGGATGAG
GAGCATTATTTAATGCATCCAGCTCAAACTTCCCAGTGGGATGACCCTTGGGGAGAGGTTCTAGCATGGAA
GTTTGATCCAACTCTGGCCTACACTTATGAGGCATATGTTAGATACCCAGAAGAGTTTGGAAGCAAGTCAG
GCCTGTCAGAGGAAGAGGTTAGAAGAAGGCTAACCGCAAGAGGCCTTCTTAACATGGCTGACAAGAAGGAA
ACTCGC 
 
NL4-3-SIV (M1-W57.BamHI.V90-S263) 
AATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTGCTGTA
AGGGAAAGAATGAGACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATCTCGAGACCTAGAAAAACA
TGGAGCAATCACAAGTAGCAATACAGCAGCTAACAATGCTGCTTGTGCCTGGATAGATGAGGAAGATGATG
ACTTGGTAGGGGTATCAGTGAGGCCAAAAGTTCCCCTAAGAACAATGAGTTACAAATTGGCAATAGACATG
TCTCATTTTATAAAAGAAAAGGGGGGACTGGAAGGGATTTATTACAGTGCAAGAAGACATAGAATCTTAGA
CATATACTTAGAAAAGGAAGAAGGCATCATACCAGATTGGCAGGATTACACCTCAGGACCAGGAATTAGAT
ACCCAAAGACATTTGGCTGGCTATGGAAATTAGTCCCTGTAAATGTATCAGATGAGGCACAGGAGGATGAG
GAGCATTATTTAATGCATCCAGCTCAAACTTCCCAGTGGGATGACCCTTGGGGAGAGGTTCTAGCATGGAA
GTTTGATCCAACTCTGGCCTACACTTATGAGGCATATGTTAGATACCCAGAAGAGTTTGGAAGCAAGTCAG
GCCTGTCAGAGGAAGAGGTTAGAAGAAGGCTAACCGCAAGAGGCCTTCTTAACATGGCTGACAAGAAGGAA
ACTCGC 
 
SIV-ELI (M1-D89.BamHI.L58-N206) 
AATTCATGGGCGGCGCTATTTCCATGAGGCGGTCCAGGCCGTCTGGAGATCTGCGACAGAGACTCTTGCGG
GCGCGTGGGGAGACTTATGGGAGACTCTTAGGAGAGGTGGAAGATGGATACTCGCAATCCCCAGGAGGATT
AGACAAGGGCTTGAGCTCACTCTCTTGTGAGGGACAGAAATACAATCAGGGACAGTATATGAATACTCCAT
GGAGAAACCCAGCTGAAGAGAGAGAAAAATTAGCATACAGAAAACAAAATATGGATGATCTAGAAGCACAA
GAAGAGAGCGACGAGGTGGGCTTTCCAGTCAGACCCCAGGTACCTTTAAGACCAATGACTTACAAAGAAGC
TCTAGATCTCAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTTGGTCCAAAAAGAGACAAG
AGATCCTTGATCTTTGGGTCTACAACACACAAGGCATCTTCCCTGATTGGCAAAACTACACACCAGGGCCA
GGGATCAGATATCCACTAACCTTTGGATGGTGCTACGAGCTAGTACCAGTTGATCCACAGGAGGTAGAAGA
AGACACTGAAGGAGAGACCAACAGCTTGTTACACCCTATATGCCAGCATGGAATGGAGGACCCGGAGAGAC
AAGTGTTAAAATGGAGATTTAACAGCAGACTAGCATTTGAGCACAAGGCCCGAGAGATGCATCCGGAGTTC
TACAAAAAC 
 
SIV-NL4-3 (M1-D89.BamHI.L58-C206) 
aattcATGggcggcgctatttccatgaggcggtccaggccgtctggagatctgcgacagagactcttgcgg
gcgcgtggggagacttatgggagactcttaggagaggtggaagatggatactcgcaatccccaggaggatt
agacaagggcttgagctcactctcttgtgagggacagaaatacaatcagggacagtatatgaatactccat
ggagaaacccagctgaagagagagaaaaattagcatacagaaaacaaaatatggatgatctagaagcacaa
gaggaggaagaggtgggttttccagtcacacctcaggtacctttaagaccaatgacttacaaggcagctgt
agatcttagccactttttaaaagaaaaggggggactggaagggctaattcactcccaaagaagacaagata
tccttgatctgtggatctaccacacacaaggctacttccctgattggcagaactacacaccagggccaggg
gtcagatatccactgacctttggatggtgctacaagctagtaccagttgagccagataaggtagaagaggc
caataaaggagagaacaccagcttgttacaccctgtgagcctgcatggaatggatgaccctgagagagaag
tgttagagtggaggtttgacagccgcctagcatttcatcacgtggcccgagagctgcatccggagtacttc
aagaactgc
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A.3. Primer Inventory 
 
WMK1: 5’ mutagenesis primer for pET32a-Nef(SS;SL;HS;HL) to eliminate 1st 
of 2 thrombin cleavage sites. Substitution of residue 129 from R to Q 
(R129Q); (126)-LVPRGS-(131) to (126)-LVPQGS-(131). Non-coding strand. 
Bases 686-709. 24 bases. 2 mismatched bases (GC?CT). 0.1mM stock. Tm = 
69.0oC. 
 
 5’-CATACCAGAACCCTGTGGCACCAG-3’ 
 
WMK2: 3’ mutagenesis primer (complementary to WMK1) for pET32a-
Nef(SS;SL;HS;HL) to eliminate 1st of 2 thrombin cleavage sites. 
Substitution of residue 129 from R to Q (R129Q); (126)-LVPRGS-(131) to 
(126)-LVPQGS-(131). Coding strand. Bases 686-709. 24 bases. 2 
mismatched bases (GC?AG). 0.1mM stock. Tm = 69.0oC. 
 
 5’-CTGGTGCCACAGGGTTCTGGTATG-3’ 
 
WMK3: 5’ mutagenesis primer for pET32a-Nef(SS;SL;HS;HL) to eliminate 1st 
of 2 thrombin cleavage sites. Substitution of residue 129 from R to Q 
(R129Q); (126)-LVPRGS-(131) to (126)-LVPQGS-(131). Non-coding strand. 
Bases 682-717. 36 bases. 2 mismatched bases (GC?CT). 0.1mM stock. Tm = 
66oC. 
 
 5’-CTTTCATACCAGAACCCTGTGGCACCAGACCAGAAG-3’ 
 
WMK4: 3’ mutagenesis primer (complementary to WMK3) for pET32a-
Nef(SS;SL;HS;HL) to eliminate 1st of 2 thrombin cleavage sites. 
Substitution of residue 129 from R to Q (R129Q); (126)-LVPRGS-(131) to 
(126)-LVPQGS-(131). Coding strand. Bases 682-717. 36 bases. 2 
mismatched bases (GC?AG). 0.1mM stock. Tm = 66oC. 
 
 5’-CTTCTGGTCTGGTGCCACAGGGTTCTGGTATGAAAG-3’ 
 
WMK5: 3’ sequencing primer for pET32a. Non-coding strand. Bases 117-
142. 26 bases. GC content = 53.8%. 0.1mM stock. Tm = 61.6oC. 
 
 5’-GCTTTGTTAGCAGCCGGATCTCAGTG-3’ 
 
WMK6: 5’ mutagenesis primer for pT7consnefhis6 and pUC19-ARV2/SF2 to 
eliminate KpnI restriction digestion site (5’-GGTACC-3’). Coding 
strand. Bases 205-239 (coding region). 35 bases. 1 mismatched bases 
(A?G). 0.1mM stock. Tm = 66oC. 
 
 5’-CCAGTCAGACCTCAGGTGCCTTTAAGACCAATGAC-3’ 
 
WMK7: 3’ mutagenesis primer for pT7consnefhis6 and pUC19-ARV2/SF2 to 
eliminate KpnI restriction digestion site (5’-GGTACC-3’). Non-coding 
strand. Bases 205-239 (coding region). 35 bases. 1 mismatched bases 
(T?C). 0.1mM stock. Tm = 66oC. 
 
 5’-GTCATTGGTCTTAAAGGCACCTGAGGTCTGACTGG-3’ 
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WMK8: 5’ subcloning primer extracting the full-length HIV-1 Nef 
(consensus) coding region from pT7consnefhis6. Comprised of 27 non 
homologous bases and 35 homologous bases (starts with ATG). Contains 5’ 
KpnI restriction site (5’-GGTACC-3’) for cloning into pET32a-Nef (SS) 
expression vector. Coding strand. 62 bases. 0.1mM stock. Tm = 67oC. 
 
 5’-CTGGGTACCCTGGTTCCTCGTGGCAGCATGGGTGGCAAGTGGTCAAAACGTAGTGTGAGTGG-3’ 
 
WMK9: 3’ subcloning primer extracting the full-length HIV-1 Nef 
(consensus) coding region from pT7consnefhis6 and HIV-1 Nef (ARV-2/SF2) 
coding region from HIV-1 (SF2) provirus. Comprised of 15 non homologous 
bases and 32 homologous bases (starts with GCA). Contains 5’ HindIII 
restriction site (5’-AAGCTT-3’) for cloning into pET32a-Nef (SS) 
expression vector. Non-coding strand. 47 bases. 0.1mM stock. Tm = 66oC. 
 
 5’-CGCAAGCTTTCATTAGCAGTCTTTGTAGTACTCCGGATGCAGCTCTC-3’ 
 
WMK10: 5’ subcloning primer extracting the K4-C206 HIV-1 Nef 
(consensus) coding region from pT7consnefhis6. Comprised of 27 non 
homologous bases and 35 homologous bases (starts with AAG; K4). 
Contains 5’ KpnI restriction site (5’-GGTACC-3’) for cloning into 
pET32a-Nef (SS) expression vector. Coding strand. 62 bases. 0.1mM 
stock. Tm = 67oC. 
 
 5’-CTGGGTACCCTGGTTCCTCGTGGCAGCAAGTGGTCAAAACGTAGTGTGAGTGGATGGCCTGC-3’ 
 
WMK11: 5’ subcloning primer extracting the A56-C206 HIV-1 Nef 
(consensus) coding region from pT7consnefhis6. Comprised of 27 non 
homologous bases and 35 homologous bases (starts with GCC; A56). 
Contains 5’ KpnI restriction site (5’-GGTACC-3’) for cloning into 
pET32a-Nef (SS) expression vector. Coding strand. 62 bases. 0.1mM 
stock. Tm = 67oC. 
 
 5’-CTGGGTACCCTGGTTCCTCGTGGCAGCGCCTGGCTAGAAGCACAAGAGGAGGAAGAAGTGGG-3’ 
 
WMK12: 5’ mutagenesis primer for pET32a-Nef(HS/HL) to correct errors at 
residues 113 and 117. Substitution at 113 (AAG?CGT; K113R) and 117 
(AAT?GAT; N117D). Coding strand. 39 bases. 4 mismatched bases. 0.1mM 
stock. Tm = 61oC. 
 
 5’-GAAATGACATATCGTTTGGCAAGAGATATGTCACATTTG-3’ 
 
WMK13: 3’ mutagenesis primer for pET32a-Nef(HS/HL) to correct errors at 
residues 113 and 117. Substitution at 113 (AAG?CGT; K113R) and 117 
(AAT?GAT; N117D). Non-Coding strand. 39 bases. 4 mismatched bases. 
0.1mM stock. Tm = 61oC. 
 
 5’-CAAATGTGACATATCTCTTGCCAAACGATATGTCATTTC-3’ 
 
WMK14: 5’ mutagenesis primer for pET32a-Nef(HS/HL) to correct errors at 
residues 138 and 140. Substitution at 138 (CAT?CGT; H138R) and 140 
(ATC?GTG; I140V). Coding strand. 38 bases. 3 mismatched bases. DILUTED 
TO 0.05mM stock.Tm = 57oC.  
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 5’-CAGTGATAGAAGACGTAGAGTGCTAGACATATACTTAG-3’ 
 
WMK15: 3’ mutagenesis primer for pET32a-Nef(HS/HL) to correct errors at 
residues 138 and 140. Substitution at 138 (CAT?CGT; H138R) and 140 
(ATC?GTG; I140V). Non-Coding strand. 38 bases. 3 mismatched bases. 
0.1mM stock. Tm = 57oC. 
 
 5’-CTAAGTATATGTCTAGCACTCTACGTCTTCTATCACTG-3’ 
 
WMK16: 5’ mutagenesis primer for pET32a-Nef(SL) to correct errors at 
residue 64. Substitution at residue 64 (CAT?CGT; R64Q). Coding strand. 
39 bases. 1 mismatched base. 0.1mM stock. Tm = 60oC. 
 
 5’-CAGAAATACAATCAGGGACAGTATATGAATACTCCATGG-3’ 
 
WMK17: 5’ mutagenesis primer for pET32a-Nef(SL) to correct errors at 
residue 64. Substitution at residue 64 (CAT?CGT; R64Q). Non-Coding 
strand. 39 bases. 1 mismatched base. 0.1mM stock. Tm = 60oC. 
 
 5’-CCATGGAGTATTCATATACTGTCCCTGATTGTATTTCTG-3’ 
 
WMK18: 5’ sequencing primer for pET32a. Coding strand. Bases. 21 bases. 
GC content = 60.4%. 0.1mM stock. Tm = 63.9oC. 
 
 5’-CGGTGAAGTGGCGGCAACCAAAG-3’ 
 
WMK19: 5’ subcloning primer extracting the K4-C210 HIV-1 Nef (ARV-
2/SF2) coding region from HIV-1 (SF2) provirus. Comprised of 27 non 
homologous bases and 35 homologous bases (starts with AAG; K4). 
Contains 5’ KpnI restriction site (5’-GGTACC-3’) for cloning into 
pET32a-Nef (SS) expression vector. Coding strand. 62 bases. 0.1mM 
stock. 
 
 5’-CTGGGTACCCTGGTTCCTCGTGGCAGCAAGTGGTCAAAACGTAGTATGGGTGGATGGTCTGC-3’ 
 
WMK20: 5’ subcloning primer extracting the A60-C210 HIV-1 Nef (ARV-
2/SF2) coding region from HIV-1 (SF2) provirus. Comprised of 27 non 
homologous bases and 35 homologous bases (starts with GCC; A60). 
Contains 5’ KpnI restriction site (5’-GGTACC-3’) for cloning into 
pET32a-Nef (SS) expression vector. Coding strand. 62 bases. 0.1mM 
stock. 
 
 5’-CTGGGTACCCTGGTTCCTCGTGGCAGCGCCTGGCTAGAAGCACAAGAGGAGGAAGAGGTGGG-3’ 
 
WMK21: 5’ subcloning primer extracting the K4-N206 HIV-1 Nef (ELI) 
coding region from HIV-1 (ELI) provirus. Comprised of 27 non homologous 
bases and 35 homologous bases (starts with AAA; K4). Contains 5’ KpnI 
restriction site (5’-GGTACC-3’) for cloning into pET32a-Nef (SS) 
expression vector. Coding strand. 62 bases. 0.1mM stock. 
 
 5’-CTGGGTACCCTGGTTCCTCGTGGCAGCAAATGGTCAAAAAGTAGTATAGTGGGATGGCCTGC-3’ 
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WMK22: 5’ subcloning primer extracting the A56-N206 HIV-1 Nef (ELI) 
coding region from HIV-1 (ELI) provirus. Comprised of 27 non homologous 
bases and 35 homologous bases (starts with GCC; A60). Contains 5’ KpnI 
restriction site (5’-GGTACC-3’) for cloning into pET32a-Nef (SS) 
expression vector. Coding strand. 66 bases. 0.1mM stock. 
 
 5’CTGGGTACCCTGGTTCCTCGTGGCAGCGCCTGGCTAGAAGCACAAGAAGAGAGCGACGAGGTGGGC 
 -3’ 
 
WMK23: 3’ subcloning primer extracting HIV-1 Nef (ELI) coding region 
from HIV-1 (ELI) provirus. Comprised of 15 non homologous bases and 37 
homologous bases (starts with GCA). Contains 3’ HindIII restriction 
site (5’-AAGCTT-3’) for cloning into pET32a-Nef (SS) expression vector. 
Non-coding strand. 52 bases. 0.1mM stock. 
 
 5’-CGCAAGCTTTCATTAGTTTTTGTAGAACTCCGGATGCATCTCTCGGGCCTTG-3’ 
 
WMK24: 5’ subcloning primer extracting the K4-Y202 HIV-1 Nef (LAI) 
coding region from HIV-1 (LAI) provirus. Comprised of 27 non homologous 
bases and 35 homologous bases (starts with AAG; K4). Contains 5’ KpnI 
restriction site (5’-GGTACC-3’) for cloning into pET32a-Nef (SS) 
expression vector. Coding strand. 62 bases. 0.1mM stock. 
 
 5’-CTGGGTACCCTGGTTCCTCGTGGCAGCAAGTGGTCAAAAAGTAGTGTGGTTGGATGGCCTGC-3’ 
 
WMK25: 5’ subcloning primer extracting the A56-Y202 HIV-1 Nef (LAI) 
coding region from HIV-1 (LAI) provirus. Comprised of 27 non homologous 
bases and 35 homologous bases (starts with GCC; A56). Contains 5’ KpnI 
restriction site (5’-GGTACC-3’) for cloning into pET32a-Nef (SS) 
expression vector. Coding strand. 62 bases. 0.1mM stock. 
 
 5’-CTGGGTACCCTGGTTCCTCGTGGCAGCGCCTGGCTAGAAGCACAAGAGGAGGAGGAGGTGGG-3’ 
 
WMK26: 3’ subcloning primer extracting truncated HIV-1 Nef (LAI) coding 
region (M1-Y202) from HIV-1 (LAI) provirus. Comprised of 15 non 
homologous bases and 33 homologous bases (starts with GTA). Contains 3’ 
HindIII restriction site (5’-AAGCTT-3’) for cloning into pET32a-Nef 
(SS) expression vector. Non-coding strand. 48 bases. 0.1mM stock. DO 
NOT USE!!!! 
 
 5’-CGCAAGCTTTCATTAGTACTCCGGATGCAGCTCTCGGGCCACGTGATG-3’ 
 
WMK27: 5’ subcloning primer extracting the K4-C206 HIV-1 Nef (NL4-3) 
coding region from HIV-1 (NL4-3) provirus. Comprised of 27 non 
homologous bases and 35 homologous bases (starts with AAG; K4). 
Contains 5’ KpnI restriction site (5’-GGTACC-3’) for cloning into 
pET32a-Nef (SS) expression vector. Coding strand. 62 bases. 0.1mM 
stock. 
 
 5’-CTGGGTACCCTGGTTCCTCGTGGCAGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTGC-3’ 
 
WMK28: 5’ subcloning primer extracting the A56-C206 HIV-1 Nef (NL4-3) 
coding region from HIV-1 (NL4-3) provirus. Comprised of 27 non 
homologous bases and 35 homologous bases (starts with GCC; A56). 
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Contains 5’ KpnI restriction site (5’-GGTACC-3’) for cloning into 
pET32a-Nef (SS) expression vector. Coding strand. 62 bases. 0.1mM 
stock. 
 
 5’-CTGGGTACCCTGGTTCCTCGTGGCAGCGCCTGGCTAGAAGCACAAGAGGAGGAAGAGGTGGG-3’ 
 
WMK29: 3’ subcloning primer extracting HIV-1 Nef (LAI, NL4-3) coding 
region from HIV-1 (NL4-3) provirus. Comprised of 15 non homologous 
bases and 35 homologous bases (starts with GCA). Contains 3’ HindIII 
restriction site (5’-AAGCTT-3’) for cloning into pET32a-Nef (SS) 
expression vector. Non-coding strand. 50 bases. 0.1mM stock. Tm = oC. 
 
 5’-CGCAAGCTTTCATTAGCAGTTCTTGAAGTACTCCGGATGCAGCTCTCGGG- 3’ 
 
WMK30: 5’ subcloning primer extracting the M1-C210 HIV-1 Nef (ARV-
2/SF2) coding region from HIV-1 (SF2) provirus. Comprised of 27 non 
homologous bases and 35 homologous bases (starts with ATG; M1). 
Contains 5’ EcoRI restriction site (5’-GAATTC-3’) for cloning into 
pUC19 and pEGFP-N1. Coding strand. 62 bases. 0.1mM stock. 
 
 5’-CTGGAATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAGTGGTCAAAACGTAGTATGGGTGG-3’ 
 
WMK31: 5’ subcloning primer extracting the M1-N206 HIV-1 Nef (ELI) 
coding region from HIV-1 (ELI) provirus. Comprised of 27 non homologous 
bases and 35 homologous bases (starts with ATG; M1). Contains 5’ EcoRI 
restriction site (5’-GAATTC-3’) for cloning into pUC19 and pEGFP-N1. 
Coding strand. 62 bases. 0.1mM stock. 
 
 5’-CTGGAATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAATGGTCAAAAAGTAGTATAGTGGG-3’ 
 
WMK32: 5’ subcloning primer extracting the M1-C206 HIV-1 Nef (LAI) 
coding region from HIV-1 (LAI) provirus. Comprised of 27 non homologous 
bases and 35 homologous bases (starts with ATG; M1). Contains 5’ EcoRI 
restriction site (5’-GAATTC-3’) for cloning into pUC19 and pEGFP-N1. 
Coding strand. 62 bases. 0.1mM stock. 
 
 5’-CTGGAATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAGTGGTCAAAAAGTAGTGTGGTTGG-3’ 
 
WMK33: 5’ subcloning primer extracting the M1-C206 HIV-1 Nef (NL4-3) 
coding region from HIV-1 (NL4-3) provirus. Comprised of 27 non 
homologous bases and 35 homologous bases (starts with ATG; M1). 
Contains 5’ EcoRI restriction site (5’-GAATTC-3’) for cloning into 
pUC19 and pEGFP-N1. Coding strand. 62 bases. 0.1mM stock. 
 
 5’-CTGGAATTCCTGGTTCCTCGTGGCAGCATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGG-3’ 
 
WMK34: 5’ mutagenesis primer for HIV-1 (ELI) to eliminate KpnI 
restriction digestion site (5’-GGTACC-3’). Coding strand. Bases  
(coding region). 35 bases. 1 mismatched bases (A?G). 0.1mM stock. Tm 
=66oC. 
 
 5’-CCAGTCAGACCCCAGGTGCCTTTAAGACCAATGAC-3’ 
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WMK35: 3’ mutagenesis primer for HIV-1 (ELI) to eliminate KpnI 
restriction digestion site (5’-GGTACC-3’). Non-coding strand. Bases  
(coding region). 35 bases. 1 mismatched bases (T?C). 0.1mM stock. Tm 
=66oC. 
 
 5’-GTCATTGGTCTTAAAGGCACCTGGGGTCTGACTGG-3’ 
 
WMK36: 5’ mutagenesis primer for HIV-1 (LAI, NL4-3) to eliminate KpnI 
restriction digestion site (5’-GGTACC-3’). Coding strand. Bases  
(coding region). 35 bases. 1 mismatched bases (A?G). 0.1mM stock. Tm 
=66oC. 
 
 5’-CCAGTCACACCTCAGGTGCCTTTAAGACCAATGAC-3’ 
 
WMK37: 3’ mutagenesis primer for HIV-1 (LAI, NL4-3) to eliminate KpnI 
restriction digestion site (5’-GGTACC-3’). Non-coding strand. Bases  
(coding region). 35 bases. 1 mismatched bases (T?C). 0.1mM stock. Tm 
=66oC. 
 
 5’-GTCATTGGTCTTAAAGGCACCTGAGGTGTGACTGG-3’ 
 
WMK38: 3’ sequencing primer for pET32a. Non-coding strand. Bases. 18 
bases. 0.1mM stock. Tm = oC. 
 
 5’-CCGCTGCTGCTAAATTCG-3’ 
 
WMK39: 5’ sequencing primer for pET32a. Non-coding strand. Bases. 20 
bases. 0.1mM stock. Tm = oC. 
 
 5’-CGGGCTTTGTTAGCAGCCGG-3’ 
 
WMK40: 5’ subcloning primer extracting the D94-T234 HIV-2 Nef (ST) 
coding region from pET32a-HL. Comprised of 27 non homologous bases and 
34 homologous bases (starts with GAT; D94). Contains 5’ KpnI 
restriction site (5’-GGTACC-3’) for cloning into pET32a expression 
vector. Coding strand. 61 bases. 0.1mM stock. 
 
 5’-CTGGGTACCCTGGTTCCTCGTGGCAGCGATGACCTAGTAGGGGTCCCTGTCACACCAAGAG-3’ 
WMK41: 3’ subcloning primer extracting the D94-T234 HIV-2 Nef (ST) 
coding region from pET32a-HL. Comprised of 15 non homologous bases and 
34 homologous bases (starts with GCA). Contains 3’ HindIII restriction 
site (5’-AAGCTT-3’) for cloning into pET32a-Nef (SS) expression vector. 
Non-coding strand. 49 bases. 0.1mM stock. 
 
 5’-CGCAAGCTTTCATTAGTACCCAAACTCCTCTGGGTATCGAATAAAGGCC-3’ 
 
WMK42: 5’ mutagenesis primer for pUC19-ARV2/SF2, pET32a-AS to correct 
errors at residues 105 and 106. Substitution at 105 (GCTG?AAGA; L105R) 
and 106 (CTA?AGA; L106R). Coding strand. 40 bases. 6 mismatched bases. 
0.1mM stock. Tm = 61oC. 
 
 5’-GGGCTAATTTGGTCCCAAAGAAGACAAGAGATCCTTGATC-3’ 
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WMK43: 3’ mutagenesis primer for pUC19-ARV2/SF2, pET32a-AS to correct 
errors at residues 105 and 106. Substitution at 105 (GCTG?AAGA; L105R) 
and 106 (CTA?AGA; L106R). Non-Coding strand. 40 bases. 6 mismatched 
bases. 0.1mM stock. Tm = 61oC. 
 
 5’-GATCAAGGATCTCTTGTCTTCTTTGGGACCAAATTAGCCC-3’ 
 
WMK44: 5’ mutagenesis primer for pUC19-ARV2/SF2, pET32a-AS to correct 
error at residue 135 (T frameshift deletion). Insert at residue 135 
(GAAT?GATAT). Coding strand. 24 bases. 1 mismatched bases. 0.1mM stock. 
Tm = 61oC. 
 
 5’-CCAGGGATCAGATATCCACTGACC-3’ 
 
WMK45: 3’ mutagenesis primer for pUC19-ARV2/SF2, pET32a-AS to correct 
error at residue 135 (T frameshift deletion). Insert at residue 135 
(GAAT?GATAT). Non-Coding strand. 24 bases. 1 mismatched bases. 0.1mM 
stock. Tm = 61oC. 
 
 5’-GGTCAGTGGATATCTGATCCCTGG-3’ 
 
WMK46: 3’ subcloning primer extracting the full-length HIV-1 Nef 
(consensus) coding region from pT7consnefhis6 and pUC19-ARV-2/SF2. 
Comprised of 15 non homologous bases and 30 homologous bases (starts 
with GCA). Contains 5’ BamHI restriction site (5’-GGATCC-3’) for 
cloning into pEFGP-N1 expression vector. Non-coding strand. 45 bases. 
0.1mM stock. 
 
 5’-CGCGGATCCTCATTAGCAGTCTTTGTAGTACTCCGGATGCAGCTC-3’ 
 
WMK47: 3’ subcloning primer extracting HIV-1 Nef (ELI) coding region 
from pUC19-ELI. Comprised of 15 non homologous bases and 30 homologous 
bases (starts with GCA). Contains 5’ BamHI restriction site (5’-GGATCC-
3’) for cloning into pEFGP-N1 expression vector. Non-coding strand. 45 
bases. 0.1mM stock. 
 
 5’-CGCGGATCCTCATTAGTTTTTGTAGAACTCCGGATGCATCTCTCG-3’ 
WMK48: 3’ subcloning primer extracting HIV-1 Nef (LAI) coding region 
from pUC19-LAI. Comprised of 15 non homologous bases and 30 homologous 
bases (starts with GCA). Contains 5’ BamHI restriction site (5’-GGATCC-
3’) for cloning into pEFGP-N1 expression vector. Non-coding strand. 45 
bases. 0.1mM stock. 
 
 5’-CGCGGATCCTCATTAGTACTCCGGATGCAGCTCTCGGGCCACGTG-3’ 
 
WMK49: 3’ subcloning primer extracting HIV-1 Nef (NL4-3) coding region 
from pUC19-NL4-3. Comprised of 15 non homologous bases and 30 
homologous bases (starts with GCA). Contains 5’ BamHI restriction site 
(5’-GGATCC-3’) for cloning into pEFGP-N1 expression vector. Non-coding 
strand. 45 bases. 0.1mM stock. 
 
 5’-CGCGGATCCTCATTAGCAGTTCTTGAAGTACTCCGGATGCAGCTC- 3’ 
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WMK50: 5’ subcloning primer extracting the S4-S255 HIV-2 Nef (ST) 
coding region from pET32a-HL. Comprised of 18 non homologous bases and 
26 homologous bases (starts with AGT; S4). Contains 5’ EcoRI 
restriction site (5’-GAATTC-3’) for cloning into pEFGP-N1. Contains M1-
A3 N-terminal residues not present in the pET32a-HL expression vector. 
Coding strand. 44 bases. 0.1mM stock. 
 
 5’-CTGGAATTCATGGGCGCCAGTGGATCCAAGAAGCGTTCCGAGCC-3’ 
 
WMK51: 3’ subcloning primer extracting the S4-S255 HIV-2 Nef (ST) 
coding region from pET32a-HL. Comprised of 15 non homologous bases and 
29 homologous bases (starts with GCA). Contains 5’ BamHI restriction 
site (5’-GGATCC-3’) for cloning into pEFGP-N1 expression vector. Non-
coding strand. 44 bases. 0.1mM stock. 
 
 5’-CGCGGATCCTCATTAGCTAAACGGTATCCCTCTTGCTTTCAGTC- 3’ 
 
WMK52: 5’ subcloning primer extracting the A4-R263 SIV Nef (mac239) 
coding region from pET32a-SL. Comprised of 18 non homologous bases and 
27 homologous bases (starts with GCT; A4). Contains 5’ EcoRI 
restriction site (5’-GAATTC-3’) for cloning into pEFGP-N1. Contains M1-
G3 N-terminal residues not present in the pET32a-SL expression vector. 
Coding strand. 45 bases. 0.1mM stock. 
 
 5’-CTGGAATTCATGGGCGGCGCTATTTCCATGAGGCGGTCCAGGCCG-3’ 
 
WMK53: 3’ subcloning primer extracting the A4-R263 SIV Nef (mac239) 
coding region from pET32a-SL. Comprised of 9 non homologous bases and 
36 homologous bases (starts with GCG). Contains 5’ BamHI restriction 
site (5’-GGATCC-3’) for cloning into pEFGP-N1 expression vector. Non-
coding strand. 45 bases. 0.1mM stock. 
 
 5’-CGCGGATCCTCATTAGCGAGTTTCCTTCTTGTCAGCCATGTTAAG- 3’ 
 
WMK54: 5’ subcloning primer extracting the full-length HIV-1 Nef 
(consensus) coding region from pT7consnefhis6. Comprised of 9 non 
homologous bases and 35 homologous bases (starts with ATG; M1). 
Contains 5’ EcoRI restriction site (5’-GAATTC-3’) for cloning into 
pEFGP-N1 expression vector. Coding strand. 44 bases. 0.1mM stock. Tm = 
oC. 
 
 5’-CTGGAATTCATGGGTGGCAAGTGGTCAAAACGTAGTGTGAGTGG-3’ 
 
WMK55: 5’ sequencing primer for pEGFP-N1. Coding strand. Bases 561-580. 
20 bases. 0.1mM stock. 
 
 5’-GCAGAGCTGGTTTAGTGAAC-3’ 
 
WMK56: 3’ sequencing primer for pEGFP-N1. Non-coding strand. Bases 724-
705. 20 bases. 0.1mM stock. 
 
 5’-GGATGGGCACCACCCCGGTG-3’ 
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WMK57: 5’ sequencing primer for pUC19. Provided by CFAR (UMass Medical 
School) as M13F(-40). Coding strand. 17 bases. 0.1mM stock. 
 
 5’-GTTTTCCCAGTCACGAC-3’ 
 
WMK58: 3’ sequencing primer for pUC19. Provided by CFAR (UMass Medical 
School) as M13R(-24). Non-Coding strand. 16 bases. 0.1mM stock. 
 
 5’-AACAGCTATGACCATG-3’ 
 
WMK59: 5’ sequencing primer for T7-based expression vector. Provided by 
CFAR (UMass Medical School) as T7. Coding strand. 19 bases. 0.1mM 
stock. 
 
 5’-TAATACGACTCACTATAGG-3’ 
 
WMK60: 5’ mutagenesis primer to delete stop codons (5’-TAATGAG-3’) from 
pEGFP-N1-SIV. SIVmac239 nef sequence ends with 5’-CGC-3’ and pEGFP-N1 
sequence starts with 5’-GAT-3’. Comprised of 40 homologous bases. 
Coding strand. 40 bases. 0.1mM stock. 
 
 5’-GGCTGACAAGAAGGAAACTCGCGATCCACCGGTCGCCACC-3’ 
 
WMK61: 3’ mutagenesis primer to delete stop codons (5’-TAATGAG-3’) from 
pEGFP- 
N1-SIV. Reverse complement of WMK60. Comprised of 40 homologous bases. 
Non-coding strand. 40 bases. 0.1mM stock. 
 
 5’-GGTGGCGACCGGTGGATCGCGAGTTTCCTTCTTGTCAGCC-3’ 
 
WMK62: 5’ mutagenesis primer to delete stop codons (5’-TAATGAG-3’) from 
pEGFP-N1-HIV-2. HIV-2 nef sequence ends with 5’-AGC-3’ and pEGFP-N1 
sequence starts with 5’-GAT-3’. Comprised of 39 homologous bases. 
Coding strand. 39 bases. 0.1mM stock. 
 
 5’-GCAAGAGGGATACCGTTTAGCGATCCACCGGTCGCCACC-3’ 
 
WMK63: 3’ mutagenesis primer to delete stop codons (5’-TAATGAG-3’) from 
pEGFP-N1-HIV-2. Reverse complement of WMK62. Comprised of 39 homologous 
bases. Non-coding strand. 39 bases. 0.1mM stock. 
 
 5’-GGTGGCGACCGGTGGATCGCTAAACGGTATCCCTCTTGC-3’ 
 
WMK64: 5’ mutagenesis primer to delete stop codons (5’-TAATGA-3’) from 
pEGFP-N1-ARV2. ARV2 nef sequence ends with 5’-TGC-3’ and pEGFP-N1 
sequence starts with 5’-GAT-3’. Comprised of 40 homologous bases. 
Coding strand. 39 bases. 0.1mM stock. 
 
 5’-CCGGAGTACTACAAAGACTGCGATCCACCGGTCGCCACC-3’ 
 
WMK65: 3’ mutagenesis primer to delete stop codons (5’-TAATGAG-3’) from 
pEGFP-N1-ARV2. Reverse complement of WMK64. Comprised of 39 homologous 
bases. Non-coding strand. 39 bases. 0.1mM stock. 
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 5’-GGTGGCGACCGGTGGATCGCAGTCTTTGTAGTACTCCGG-3’ 
 
WMK66: 5’ mutagenesis primer to delete stop codons (5’-TAATGA-3’) from 
pEGFP-N1-LAI and pEGFP-N1-NL4-3. LAI/NL4-3 nef sequence ends with 5’-
TGC-3’ and pEGFP-N1 sequence starts with 5’-GAT-3’. Comprised of 39 
homologous bases. Coding strand. 39 bases. 0.1mM stock. 
 
 5’-CCGGAGTACTTCAAGAACTGCGATCCACCGGTCGCCACC-3’ 
 
WMK67: 3’ mutagenesis primer to delete stop codons (5’-TAATGAG-3’) from 
pEGFP-N1-LAI and pEGFP-N1-NL4-3. Reverse complement of WMK66. Comprised 
of 39 homologous bases. Non-coding strand. 39 bases. 0.1mM stock. 
 
 5’-GGTGGCGACCGGTGGATCGCAGTTCTTGAAGTACTCCGG-3’ 
 
WMK68: 5’ mutagenesis primer to delete stop codons (5’-TAATGA-3’) from 
pEGFP-N1-Cons. Consensus nef sequence ends with 5’-TGC-3’ and pEGFP-N1 
sequence starts with 5’-GAT-3’. Comprised of 39 homologous bases. 
Coding strand. 39 bases. 0.1mM stock. 
 
 5’-CCGGAGTACTACAAAGACTGCGATCCACCGGTCGCCACC-3’ 
 
WMK69: 3’ mutagenesis primer to delete stop codons (5’-TAATGAG-3’) from 
pEGFP-N1-Cons. Reverse complement of WMK68. Comprised of 39 homologous 
bases. Non-coding strand. 39 bases. 0.1mM stock. 
 
 5’-GGTGGCGACCGGTGGATCGCAGTCTTTGTAGTACTCCGG-3’ 
 
WMK70: 5’ mutagenesis primer to delete stop codons (5’-TAATGA-3’) from 
pEGFP-N1-ELI. ELI nef sequence ends with 5’-AAC-3’ and pEGFP-N1 
sequence starts with 5’-GAT-3’. Comprised of 43 homologous bases. 
Coding strand. 43 bases. 0.1mM stock. 
 
 5’-GATGCATCCGGAGTTCTACAAAAACGATCCACCGGTCGCCACC-3’ 
 
WMK71: 3’ mutagenesis primer to delete stop codons (5’-TAATGAG-3’) from 
pEGFP-N1-ELI. Reverse complement of WMK70. Comprised of 39 homologous 
bases. Non-coding strand. 39 bases. 0.1mM stock. 
 
 5’-GGTGGCGACCGGTGGATCGTTTTTGTAGAACTCCGGATGCATC-3’ 
 
WMK72: 5’ mutagenesis primer for pET32a-SS, pEGFP-N1-SIV to introduce 
D123G mutation. Substitution of residue 123 from D to G (D123G; 
GAT?GGC). Coding strand. 2 mismatched bases (AT?GC). 35 bases. 0.1mM 
stock. Tm =. 
 
 5’-GAAGGCATCATACCAGGCTGGCAGGATTACACCTC-3’ 
 
WMK73: 3’ mutagenesis primer for pET32a-SS, pEGFP-N1-SIV to introduce 
D123G mutation. Substitution of residue 123 from D to G (D123G; 
GAT?GGC). Non-coding strand. 2 mismatched bases (AT?GC). 35 bases. 
0.1mM stock. 
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 5’- GAGGTGTAATCCTGCCAGCCTGGTATGATGCCTTC-3’ 
 
WMK74: 5’ mutagenesis primer for pEGFP-ELI to introduce BamHI 
restriction digestion site (5’-GGATCC-3’) between N-terminal domain 
(M1-W57) and C-terminal domain (L58-N206). Coding strand. 37 bases. 5 
mismatched bases (5’-GGATCC-3’). 0.1mM stock. 
 
 5’-GCTGACTGTGCCTGGGGATCCCTAGAAGCACAAGAAG-3’ 
 
WMK75: 3’ mutagenesis primer for pEGFP-ELI to introduce BamHI 
restriction digestion site (5’-GGATCC-3’) between N-terminal domain 
(M1-W57) and C-terminal domain (L58-N206). Non-coding strand. 37 bases. 
5 mismatched bases (5’-GGATCC-3’). 0.1mM stock. 
 
 5’-CTTCTTGTGCTTCTAGGGATCCCCAGGCACAGTCAGC-3’ 
 
WMK76: 5’ mutagenesis primer for pEGFP-NL4-3 to introduce BamHI 
restriction digestion site (5’-GGATCC-3’) between N-terminal domain 
(M1-W57) and C-terminal domain (L58-C206). Coding strand. 37 bases. 5 
mismatched bases (5’-GGATCC-3’). 0.1mM stock. 
 
 5’-GCTGCTTGTGCCTGGGGATCCCTAGAAGCACAAGAGG-3’ 
 
WMK77: 3’ mutagenesis primer for pEGFP-NL4-3 to introduce BamHI 
restriction digestion site (5’-GGATCC-3’) between N-terminal domain 
(M1-W57) and C-terminal domain (L58-C206). Non-coding strand. 37 bases. 
5 mismatched bases (5’-GGATCC-3’). 0.1mM stock. 
 
 5’-CCTCTTGTGCTTCTAGGGATCCCCAGGCACAAGCAGC-3’ 
 
WMK78: 5’ mutagenesis primer for pEGFP-HIV-2 to introduce BamHI 
restriction digestion site (5’-GGATCC-3’) between N-terminal domain 
(M1-D88) and C-terminal domain (V89-S255). Coding strand. 41 bases. 5 
mismatched bases (5’-GGATCC-3’). 0.1mM stock. 
 
 5’-GCAACAAAATATGGATGATGGATCCGTAGATTCAGATGATG-3’ 
 
WMK79: 3’ mutagenesis primer for pEGFP-HIV-2 to introduce BamHI 
restriction digestion site (5’-GGATCC-3’) between N-terminal domain 
(M1-D88) and C-terminal domain (V89-S255). Non-coding strand. 41 bases. 
5 mismatched bases (5’-GGATCC-3’). 0.1mM stock. 
 
 5’-CATCATCTGAATCTACGGATCCATCATCCATATTTTGTTGC-3’ 
 
WMK80: 5’ mutagenesis primer for pEGFP-SIV to introduce BamHI 
restriction digestion site (5’-GGATCC-3’) between N-terminal domain 
(M1-D89) and C-terminal domain (V90-S263). Coding strand. 47 bases. 5 
mismatched bases (5’-GGATCC-3’). 0.1mM stock. 
 
 5’-CAGAAAACAAAATATGGATGATGGATCCATAGATGAGGAAGATGATG-3’ 
 
WMK81: 3’ mutagenesis primer for pEGFP-SIV to introduce BamHI 
restriction digestion site (5’-GGATCC-3’) between N-terminal domain 
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(M1-D89) and C-terminal domain (V90-S263). Coding strand. 47 bases. 5 
mismatched bases (5’-GGATCC-3’). 0.1mM stock. 
 
 5’-CATCATCTTCCTCATCTATGGATCCATCATCCATATTTTGTTTTCTG-3’ 
 
WMK82: 5’ mutagenesis primer for pEGFP-ELI/NL4-3 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between ELI N-terminal domain 
(M1-W57) and NL4-3 C-terminal domain (L58-C206). Coding strand. 31 
bases. 0.1mM stock. 
 
 5’-GCTGACTGTGCCTGGCTAGAAGCACAAGAGG-3’ 
 
WMK83: 3’ mutagenesis primer for pEGFP-ELI/NL4-3 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between ELI N-terminal domain 
(M1-W57) and NL4-3 C-terminal domain (L58-C206). Coding strand. 31 
bases. 0.1mM stock. 
 
 5’-CCTCTTGTGCTTCTAGCCAGGCACAGTCAGC-3’ 
 
WMK84: 5’ mutagenesis primer for pEGFP-ELI/HIV-2 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between ELI N-terminal domain 
(M1-W57) and HIV-2 C-terminal domain (V89-S255). Coding strand. 31 
bases. 0.1mM stock. 
 
 5’-GCTGACTGTGCCTGGGTAGATTCAGATGATG-3’ 
 
WMK85: 3’ mutagenesis primer for pEGFP-ELI/HIV-2 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between ELI N-terminal domain 
(M1-W57) and HIV-2 C-terminal domain (V89-S255). Coding strand. 31 
bases. 0.1mM stock. 
 
 5’-CATCATCTGAATCTACCCAGGCACAGTCAGC-3’ 
 
WMK86: 5’ mutagenesis primer for pEGFP-ELI/SIV to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between ELI N-terminal domain 
(M1-W57) and SIV C-terminal domain (V90-S263). Coding strand. 34 bases. 
0.1mM stock. 
 
 5’-GCTGACTGTGCCTGGATAGATGAGGAAGATGATG-3’ 
 
WMK87: 3’ mutagenesis primer for pEGFP-ELI/SIV to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between ELI N-terminal domain 
(M1-W57) and SIV C-terminal domain (V90-S263). Coding strand. 34 bases. 
0.1mM stock. 
 
 5’-CATCATCTTCCTCATCTATCCAGGCACAGTCAGC-3’ 
 
WMK88: 5’ mutagenesis primer for pEGFP-NL4-3/ELI to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between NL4-3 N-terminal 
domain (M1-W57) and ELI C-terminal domain (L58-N206). Coding strand. 34 
bases. 0.1mM stock. 
 
 5’-GCTGCTTGTGCCTGGCTAGAAGCACAAGAAG-3’ 
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WMK89: 3’ mutagenesis primer for pEGFP-NL4-3/ELI to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between NL4-3 N-terminal 
domain (M1-W57) and ELI C-terminal domain (L58-N206). Coding strand. 34 
bases. 0.1mM stock. 
 
 5’-CTTCTTGTGCTTCTAGCCAGGCACAAGCAGC-3’ 
 
WMK90: 5’ mutagenesis primer for pEGFP-NL4-3/HIV-2 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between NL4-3 N-terminal 
domain (M1-W57) and HIV-2 C-terminal domain (V89-S255). Coding strand. 
31 bases. 0.1mM stock. 
 
 5’-GCTGCTTGTGCCTGGGTAGATTCAGATGATG-3’ 
 
WMK91: 3’ mutagenesis primer for pEGFP-NL4-3/HIV-2 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between NL4-3 N-terminal 
domain (M1-W57) and HIV-2 C-terminal domain (V89-S255). Coding strand. 
31 bases. 0.1mM stock. 
 
 5’-CATCATCTGAATCTACCCAGGCACAAGCAGC-3’ 
 
WMK92: 5’ mutagenesis primer for pEGFP-NL4-3/SIV to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between NL4-3 N-terminal 
domain (M1-W57) and SIV C-terminal domain (V90-S263). Coding strand. 34 
bases. 0.1mM stock. 
 
 5’-GCTGCTTGTGCCTGGATAGATGAGGAAGATGATG-3’ 
 
WMK93: 3’ mutagenesis primer for pEGFP-NL4-3/SIV to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between NL4-3 N-terminal 
domain (M1-W57) and SIV C-terminal domain (V90-S263). Coding strand. 34 
bases. 0.1mM stock. 
 
 5’-CATCATCTTCCTCATCTATCCAGGCACAAGCAGC-3’ 
 
WMK94: 5’ mutagenesis primer for pEGFP-HIV-2/ELI to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between HIV-2 N-terminal 
domain (M1-D88) and ELI C-terminal domain (L58-N206). Coding strand. 35 
bases. 0.1mM stock. 
 
 5’-GCAACAAAATATGGATGATCTAGAAGCACAAGAAG-3’ 
 
WMK95: 3’ mutagenesis primer for pEGFP-HIV-2/ELI to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between HIV-2 N-terminal 
domain (M1-D88) and ELI C-terminal domain (L58-N206). Coding strand. 35 
bases. 0.1mM stock. 
 
 5’-CTTCTTGTGCTTCTAGATCATCCATATTTTGTTGC-3’ 
 
WMK96: 5’ mutagenesis primer for pEGFP-HIV-2/NL4-3 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between HIV-2 N-terminal 
  
159
domain (M1-D88) and NL4-3 C-terminal domain (L58-C206). Coding strand. 
35 bases. 0.1mM stock. 
 
 5’-GCAACAAAATATGGATGATCTAGAAGCACAAGAGG-3’ 
 
WMK97: 3’ mutagenesis primer for pEGFP-HIV-2/NL4-3 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between HIV-2 N-terminal 
domain (M1-D88) and NL4-3 C-terminal domain (L58-C206). Coding strand. 
35 bases. 0.1mM stock. 
 
 5’-CCTCTTGTGCTTCTAGATCATCCATATTTTGTTGC-3’ 
 
WMK98: 5’ mutagenesis primer for pEGFP-HIV-2/SIV to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between HIV-2 N-terminal 
domain (M1-D88) and SIV C-terminal domain (V90-S263). Coding strand. 38 
bases. 0.1mM stock. 
 
 5’-GCAACAAAATATGGATGATATAGATGAGGAAGATGATG-3’ 
 
WMK99: 3’ mutagenesis primer for pEGFP-HIV-2/SIV to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between HIV-2 N-terminal 
domain (M1-D88) and SIV C-terminal domain (V90-S263). Coding strand. 38 
bases. 0.1mM stock. 
 
 5’-CATCATCTTCCTCATCTATATCATCCATATTTTGTTGC-3’ 
 
WMK100: 5’ mutagenesis primer for pEGFP-SIV/ELI to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between SIV N-terminal domain 
(M1-D89) and ELI C-terminal domain (L58-N206). Coding strand. 38 bases. 
0.1mM stock. 
 
 5’-CAGAAAACAAAATATGGATGATCTAGAAGCACAAGAAG-3’ 
 
WMK101: 3’ mutagenesis primer for pEGFP-SIV/ELI to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between SIV N-terminal domain 
(M1-D89) and ELI C-terminal domain (L58-N206). Coding strand. 38 bases. 
0.1mM stock. 
 
 5’-CTTCTTGTGCTTCTAGATCATCCATATTTTGTTTTCTG-3’ 
 
WMK102: 5’ mutagenesis primer for pEGFP-SIV/NL4-3 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between SIV N-terminal domain 
(M1-D89) and NL4-3 C-terminal domain (L58-C206). Coding strand. 38 
bases. 0.1mM stock. 
 
 5’-CAGAAAACAAAATATGGATGATCTAGAAGCACAAGAGG-3’ 
 
WMK103: 3’ mutagenesis primer for pEGFP-SIV/NL4-3 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between SIV N-terminal domain 
(M1-D89) and NL4-3 C-terminal domain (L58-C206). Coding strand. 38 
bases. 0.1mM stock. 
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 5’-CCTCTTGTGCTTCTAGATCATCCATATTTTGTTTTCTG-3’ 
 
WMK104: 5’ mutagenesis primer for pEGFP-SIV/HIV-2 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between SIV N-terminal domain 
(M1-D89) and HIV-2 C-terminal domain (V89-S255). Coding strand. 38 
bases. 0.1mM stock. 
 
 5’-CAGAAAACAAAATATGGATGATGTAGATTCAGATGATG-3’ 
 
WMK105: 3’ mutagenesis primer for pEGFP-SIV/HIV-2 to remove BamHI 
restriction digestion site (5’-GGATCC-3’) between SIV N-terminal domain 
(M1-D89) and HIV-2 C-terminal domain (V89-S255). Coding strand. 38 
bases. 0.1mM stock. 
 
 5’-CATCATCTGAATCTACATCATCCATATTTTGTTTTCTG-3’ 
 
WMK106: 5’ mutagenesis primer for pET32a-HL to eliminate BamHI 
restriction digestion site (5’-GGATCC-3’) by silent mutation. Coding 
strand. 29 bases. 1 mismatched base (A?C). 0.1mM stock. 
 
 5’-GTGGCAGCAGTGGCTCCAAGAAGCGTTCC-3’ 
 
WMK107: 3’ mutagenesis primer for pET32a-HL to eliminate BamHI 
restriction digestion site (5’-GGATCC-3’) by silent mutation (5’-
GGCTCC-3’). Coding strand. 29 bases. 1 mismatched base (A?C). 0.1mM 
stock. 
 
 5’-GGAACGCTTCTTGGAGCCACTGCTGCCAC-3’ 
 
WMK108: 5’ subcloning /mutatgenesis primer extracting the S4-S255 HIV-2 
Nef (ST) coding region from pET32a-HL. Replaces WMK50. Comprised of 19 
non homologous bases (including silent mutation A?C) and 26 homologous 
bases (starts with AGT; S4). Contains 5’ EcoRI restriction site (5’-
GAATTC-3’) for cloning into pEFGP-N1. Contains M1-A3 N-terminal 
residues not present in the pET32a-HL expression vector. Coding strand. 
44 bases. 0.1mM stock. 
 
 5’-CTGGAATTCATGGGCGCCAGTGGCTCCAAGAAGCGTTCCGAGCC-3’ 
 
WMK109: 5’ mutagenesis primer for pEGFP-ELI to introduce BamHI 
restriction digestion site (5’-GGATCC-3’) between N-terminal domain 
(M1-W57) and C-terminal domain (L58-N206). Repeat of WMK74, with extra 
bases on each end. Coding strand. 48 bases. 5 mismatched bases (5’-
GGATCC-3’). 0.1mM stock. 
 
 5’-CTAATGCTGACTGTGCCTGGGGATCCCTAGAAGCACAAGAAGAGAGCG-3’ 
 
WMK110: 3’ mutagenesis primer for pEGFP-ELI to introduce BamHI 
restriction digestion site (5’-GGATCC-3’) between N-terminal domain 
(M1-W57) and C-terminal domain (L58-N206). Repeat of WMK75, with extra 
bases on each end. Non-coding strand. 48 bases. 5 mismatched bases (5’-
GGATCC-3’). 0.1mM stock. 
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 5’-CGCTCTCTTCTTGTGCTTCTAGGGATCCCCAGGCACAGTCAGCATTAG-3’ 
 
WMK111: 3’ sequencing primer for pEGFP-N1. Non-coding strand. In eGFP 
region. 22 bases. 0.1mM stock. 
 
 5’-GTTTACGTCGCCGTCCAGCTCG-3’ 
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